ZA200405829B - Aldosterone antagonist and non-steroidal anti-inflammatory agent combination therapy to prevent or treat cardiovascular disorders. - Google Patents
Aldosterone antagonist and non-steroidal anti-inflammatory agent combination therapy to prevent or treat cardiovascular disorders. Download PDFInfo
- Publication number
- ZA200405829B ZA200405829B ZA200405829A ZA200405829A ZA200405829B ZA 200405829 B ZA200405829 B ZA 200405829B ZA 200405829 A ZA200405829 A ZA 200405829A ZA 200405829 A ZA200405829 A ZA 200405829A ZA 200405829 B ZA200405829 B ZA 200405829B
- Authority
- ZA
- South Africa
- Prior art keywords
- composition
- treatment
- prevention
- substance
- nsaid
- Prior art date
Links
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 title claims description 108
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 title claims description 102
- 208000024172 Cardiovascular disease Diseases 0.000 title claims description 45
- 239000002170 aldosterone antagonist Substances 0.000 title description 45
- 229940083712 aldosterone antagonist Drugs 0.000 title description 44
- 238000002648 combination therapy Methods 0.000 title description 13
- 230000014509 gene expression Effects 0.000 claims description 161
- 238000000034 method Methods 0.000 claims description 150
- 238000011282 treatment Methods 0.000 claims description 148
- -1 tenoprofen Chemical compound 0.000 claims description 145
- JUKPWJGBANNWMW-VWBFHTRKSA-N eplerenone Chemical compound C([C@@H]1[C@]2(C)C[C@H]3O[C@]33[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)C(=O)OC)C[C@@]21CCC(=O)O1 JUKPWJGBANNWMW-VWBFHTRKSA-N 0.000 claims description 140
- 229960001208 eplerenone Drugs 0.000 claims description 140
- 239000000203 mixture Substances 0.000 claims description 79
- 230000002265 prevention Effects 0.000 claims description 76
- 102000003979 Mineralocorticoid Receptors Human genes 0.000 claims description 74
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 claims description 74
- 150000003254 radicals Chemical class 0.000 claims description 74
- 239000000126 substance Substances 0.000 claims description 73
- 102000004264 Osteopontin Human genes 0.000 claims description 70
- 108010081689 Osteopontin Proteins 0.000 claims description 70
- 150000001875 compounds Chemical class 0.000 claims description 70
- 229940044551 receptor antagonist Drugs 0.000 claims description 69
- 239000002464 receptor antagonist Substances 0.000 claims description 69
- 206010061218 Inflammation Diseases 0.000 claims description 68
- 230000004054 inflammatory process Effects 0.000 claims description 65
- 108010037462 Cyclooxygenase 2 Proteins 0.000 claims description 56
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims description 46
- 210000002216 heart Anatomy 0.000 claims description 46
- 230000000694 effects Effects 0.000 claims description 42
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims description 41
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 claims description 40
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 38
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 38
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 claims description 36
- 102000008186 Collagen Human genes 0.000 claims description 34
- 108010035532 Collagen Proteins 0.000 claims description 34
- 229920001436 collagen Polymers 0.000 claims description 34
- MITFXPHMIHQXPI-UHFFFAOYSA-N Oraflex Chemical compound N=1C2=CC(C(C(O)=O)C)=CC=C2OC=1C1=CC=C(Cl)C=C1 MITFXPHMIHQXPI-UHFFFAOYSA-N 0.000 claims description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 26
- 239000008194 pharmaceutical composition Substances 0.000 claims description 26
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims description 25
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 claims description 25
- 230000002792 vascular Effects 0.000 claims description 25
- 210000000056 organ Anatomy 0.000 claims description 22
- 206010020772 Hypertension Diseases 0.000 claims description 21
- 208000035475 disorder Diseases 0.000 claims description 21
- 229960001259 diclofenac Drugs 0.000 claims description 20
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims description 20
- 229960001680 ibuprofen Drugs 0.000 claims description 20
- 229960002895 phenylbutazone Drugs 0.000 claims description 20
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 claims description 20
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims description 20
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 19
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 claims description 19
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims description 19
- 229960000905 indomethacin Drugs 0.000 claims description 19
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims description 19
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 claims description 19
- 229960002009 naproxen Drugs 0.000 claims description 19
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 19
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 claims description 19
- 229960005489 paracetamol Drugs 0.000 claims description 19
- 229960002702 piroxicam Drugs 0.000 claims description 19
- 229960001017 tolmetin Drugs 0.000 claims description 19
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 claims description 19
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 18
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 18
- 229960000991 ketoprofen Drugs 0.000 claims description 18
- 229960004752 ketorolac Drugs 0.000 claims description 18
- 210000003734 kidney Anatomy 0.000 claims description 18
- 229940013798 meclofenamate Drugs 0.000 claims description 18
- 229960004270 nabumetone Drugs 0.000 claims description 18
- 229960002739 oxaprozin Drugs 0.000 claims description 18
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 claims description 18
- 229960000894 sulindac Drugs 0.000 claims description 18
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 claims description 17
- 208000010125 myocardial infarction Diseases 0.000 claims description 17
- 230000003637 steroidlike Effects 0.000 claims description 17
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 claims description 16
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical class [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 16
- 229960001419 fenoprofen Drugs 0.000 claims description 16
- 229960002390 flurbiprofen Drugs 0.000 claims description 16
- 229960003464 mefenamic acid Drugs 0.000 claims description 16
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 claims description 16
- LXIKEPCNDFVJKC-QXMHVHEDSA-N tenidap Chemical compound C12=CC(Cl)=CC=C2N(C(=O)N)C(=O)\C1=C(/O)C1=CC=CS1 LXIKEPCNDFVJKC-QXMHVHEDSA-N 0.000 claims description 16
- MDKGKXOCJGEUJW-VIFPVBQESA-N (2s)-2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-VIFPVBQESA-N 0.000 claims description 15
- 229960003184 carprofen Drugs 0.000 claims description 15
- IVUMCTKHWDRRMH-UHFFFAOYSA-N carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 claims description 15
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 claims description 15
- 229960000616 diflunisal Drugs 0.000 claims description 15
- 229960005293 etodolac Drugs 0.000 claims description 15
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 claims description 15
- 229960000649 oxyphenbutazone Drugs 0.000 claims description 15
- HFHZKZSRXITVMK-UHFFFAOYSA-N oxyphenbutazone Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=C(O)C=C1 HFHZKZSRXITVMK-UHFFFAOYSA-N 0.000 claims description 15
- 229960004492 suprofen Drugs 0.000 claims description 15
- 229960003676 tenidap Drugs 0.000 claims description 15
- ZXVNMYWKKDOREA-UHFFFAOYSA-N zomepirac Chemical compound C1=C(CC(O)=O)N(C)C(C(=O)C=2C=CC(Cl)=CC=2)=C1C ZXVNMYWKKDOREA-UHFFFAOYSA-N 0.000 claims description 15
- 229960003414 zomepirac Drugs 0.000 claims description 15
- 229960005430 benoxaprofen Drugs 0.000 claims description 14
- 230000033228 biological regulation Effects 0.000 claims description 14
- AGWFKXDTYITCSP-NHGLSFBUSA-N (8s,9s,10r,13r,14s,17r)-17-(2-carboxyethyl)-10,13-dimethyl-2,3,6,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene-7-carboxylic acid Chemical compound C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)CCC(O)=O)[C@@H]4[C@@H]3C(C(O)=O)CC2=C1 AGWFKXDTYITCSP-NHGLSFBUSA-N 0.000 claims description 12
- 239000004593 Epoxy Substances 0.000 claims description 12
- 208000006011 Stroke Diseases 0.000 claims description 12
- 201000001320 Atherosclerosis Diseases 0.000 claims description 11
- 102000002045 Endothelin Human genes 0.000 claims description 10
- 108050009340 Endothelin Proteins 0.000 claims description 10
- 206010019280 Heart failures Diseases 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- HKYYMVLLLCHGTL-UNUXFHLRSA-N 3-[(8s,9s,10r,13r,14s,17r)-10,13-dimethyl-2,3,8,9,11,12,14,15,16,17-decahydro-1h-cyclopenta[a]phenanthren-17-yl]propanoic acid Chemical compound C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)CCC(O)=O)[C@@H]4[C@@H]3C=CC2=C1 HKYYMVLLLCHGTL-UNUXFHLRSA-N 0.000 claims description 9
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 150000002148 esters Chemical class 0.000 claims description 9
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical group C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 claims description 9
- 208000004434 Calcinosis Diseases 0.000 claims description 8
- 102000000589 Interleukin-1 Human genes 0.000 claims description 8
- 108010002352 Interleukin-1 Proteins 0.000 claims description 8
- 102000004889 Interleukin-6 Human genes 0.000 claims description 8
- 108090001005 Interleukin-6 Proteins 0.000 claims description 8
- 210000004556 brain Anatomy 0.000 claims description 8
- 230000002308 calcification Effects 0.000 claims description 8
- 208000029078 coronary artery disease Diseases 0.000 claims description 8
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 claims description 8
- 229960002256 spironolactone Drugs 0.000 claims description 8
- 238000002560 therapeutic procedure Methods 0.000 claims description 8
- 206010002329 Aneurysm Diseases 0.000 claims description 7
- 206010002383 Angina Pectoris Diseases 0.000 claims description 7
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 7
- 102100032912 CD44 antigen Human genes 0.000 claims description 7
- 208000005189 Embolism Diseases 0.000 claims description 7
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 7
- 208000011200 Kawasaki disease Diseases 0.000 claims description 7
- 208000007536 Thrombosis Diseases 0.000 claims description 7
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 7
- 102100040247 Tumor necrosis factor Human genes 0.000 claims description 7
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 7
- 230000003247 decreasing effect Effects 0.000 claims description 7
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 claims description 7
- 102000006495 integrins Human genes 0.000 claims description 7
- 108010044426 integrins Proteins 0.000 claims description 7
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims description 7
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 claims description 7
- 108010007843 NADH oxidase Proteins 0.000 claims description 6
- 108010002998 NADPH Oxidases Proteins 0.000 claims description 6
- 102000004722 NADPH Oxidases Human genes 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 108010049003 Fibrinogen Proteins 0.000 claims description 5
- 102000008946 Fibrinogen Human genes 0.000 claims description 5
- 239000005557 antagonist Substances 0.000 claims description 5
- 229940012952 fibrinogen Drugs 0.000 claims description 5
- 150000004702 methyl esters Chemical class 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 108010029697 CD40 Ligand Proteins 0.000 claims description 4
- 101150013553 CD40 gene Proteins 0.000 claims description 4
- 102100032937 CD40 ligand Human genes 0.000 claims description 4
- 102000003814 Interleukin-10 Human genes 0.000 claims description 4
- 108090000174 Interleukin-10 Proteins 0.000 claims description 4
- 206010035148 Plague Diseases 0.000 claims description 4
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 4
- 241000607479 Yersinia pestis Species 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 102000013462 Interleukin-12 Human genes 0.000 claims description 3
- 108010065805 Interleukin-12 Proteins 0.000 claims description 3
- 102000004987 Troponin T Human genes 0.000 claims description 3
- 108090001108 Troponin T Proteins 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 125000004494 ethyl ester group Chemical group 0.000 claims description 3
- 230000001105 regulatory effect Effects 0.000 claims description 3
- PORJGKBQQFPVED-UNUXFHLRSA-N 3-[(8s,9s,10r,13r,14s,17r)-10,13-dimethyl-8,9,11,12,14,15,16,17-octahydro-3h-cyclopenta[a]phenanthren-17-yl]propanoic acid Chemical compound C1C=C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)CCC(O)=O)[C@@H]4[C@@H]3C=CC2=C1 PORJGKBQQFPVED-UNUXFHLRSA-N 0.000 claims description 2
- 108010058864 Phospholipases A2 Proteins 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 claims 24
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 claims 16
- 102100033571 Tissue-type plasminogen activator Human genes 0.000 claims 12
- 108050006955 Tissue-type plasminogen activator Proteins 0.000 claims 12
- 108050000824 Angiotensin II receptor Proteins 0.000 claims 6
- 102000008873 Angiotensin II receptor Human genes 0.000 claims 6
- 102000012335 Plasminogen Activator Inhibitor 1 Human genes 0.000 claims 6
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 claims 6
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 claims 5
- 102100031051 Cysteine and glycine-rich protein 1 Human genes 0.000 claims 3
- 101000944608 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) Chaperonin GroEL 2 Proteins 0.000 claims 3
- 108091006374 cAMP receptor proteins Proteins 0.000 claims 3
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 claims 2
- 101150021185 FGF gene Proteins 0.000 claims 2
- 102000015439 Phospholipases Human genes 0.000 claims 2
- 108010064785 Phospholipases Proteins 0.000 claims 2
- 102100021324 5-azacytidine-induced protein 2 Human genes 0.000 claims 1
- 101100001475 Aeromonas hydrophila subsp. hydrophila (strain ATCC 7966 / DSM 30187 / BCRC 13018 / CCUG 14551 / JCM 1027 / KCTC 2358 / NCIMB 9240 / NCTC 8049) alr-1 gene Proteins 0.000 claims 1
- 102100037611 Lysophospholipase Human genes 0.000 claims 1
- 108050006091 Ornithine decarboxylase antizyme 2 Proteins 0.000 claims 1
- 102000004316 Oxidoreductases Human genes 0.000 claims 1
- 108090000854 Oxidoreductases Proteins 0.000 claims 1
- 108090001027 Troponin Proteins 0.000 claims 1
- 102000004903 Troponin Human genes 0.000 claims 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 claims 1
- 150000001735 carboxylic acids Chemical class 0.000 claims 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 166
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 162
- 229960002478 aldosterone Drugs 0.000 description 162
- 235000002639 sodium chloride Nutrition 0.000 description 155
- 150000003839 salts Chemical class 0.000 description 144
- 241000700159 Rattus Species 0.000 description 100
- 108020004999 messenger RNA Proteins 0.000 description 66
- 241001465754 Metazoa Species 0.000 description 63
- 239000003981 vehicle Substances 0.000 description 48
- 239000000523 sample Substances 0.000 description 39
- 102000010907 Cyclooxygenase 2 Human genes 0.000 description 32
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 32
- 210000001519 tissue Anatomy 0.000 description 31
- 125000004432 carbon atom Chemical group C* 0.000 description 28
- 230000036772 blood pressure Effects 0.000 description 25
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 23
- 230000002354 daily effect Effects 0.000 description 22
- 230000002107 myocardial effect Effects 0.000 description 21
- 239000000047 product Substances 0.000 description 21
- 125000000217 alkyl group Chemical group 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 18
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 18
- 238000001802 infusion Methods 0.000 description 18
- 230000002757 inflammatory effect Effects 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 17
- 239000011734 sodium Substances 0.000 description 17
- 230000002485 urinary effect Effects 0.000 description 17
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 16
- 230000037396 body weight Effects 0.000 description 16
- 206010028851 Necrosis Diseases 0.000 description 15
- 239000000872 buffer Substances 0.000 description 15
- 230000017074 necrotic cell death Effects 0.000 description 15
- 102400000345 Angiotensin-2 Human genes 0.000 description 14
- 101800000733 Angiotensin-2 Proteins 0.000 description 14
- 102000015427 Angiotensins Human genes 0.000 description 14
- 108010064733 Angiotensins Proteins 0.000 description 14
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 14
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 14
- 229950006323 angiotensin ii Drugs 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 14
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 14
- 239000003826 tablet Substances 0.000 description 14
- 229960002591 hydroxyproline Drugs 0.000 description 13
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 13
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- 235000019441 ethanol Nutrition 0.000 description 12
- 208000037891 myocardial injury Diseases 0.000 description 12
- 230000000770 proinflammatory effect Effects 0.000 description 12
- 239000011780 sodium chloride Substances 0.000 description 12
- 210000002303 tibia Anatomy 0.000 description 12
- 102000012422 Collagen Type I Human genes 0.000 description 11
- 108010022452 Collagen Type I Proteins 0.000 description 11
- 102000001493 Cyclophilins Human genes 0.000 description 11
- 108010068682 Cyclophilins Proteins 0.000 description 11
- 239000002253 acid Substances 0.000 description 11
- 238000010186 staining Methods 0.000 description 11
- 238000007619 statistical method Methods 0.000 description 11
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 10
- 208000035868 Vascular inflammations Diseases 0.000 description 10
- 125000003118 aryl group Chemical group 0.000 description 10
- 238000003556 assay Methods 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 230000006378 damage Effects 0.000 description 10
- 230000007423 decrease Effects 0.000 description 10
- 125000005843 halogen group Chemical group 0.000 description 10
- 230000003902 lesion Effects 0.000 description 10
- 238000005259 measurement Methods 0.000 description 10
- 125000004430 oxygen atom Chemical group O* 0.000 description 10
- 230000001575 pathological effect Effects 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- 229910052708 sodium Inorganic materials 0.000 description 10
- 230000035488 systolic blood pressure Effects 0.000 description 10
- 210000004351 coronary vessel Anatomy 0.000 description 9
- 235000005911 diet Nutrition 0.000 description 9
- 238000011534 incubation Methods 0.000 description 9
- 230000007170 pathology Effects 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 125000004434 sulfur atom Chemical group 0.000 description 9
- 238000001356 surgical procedure Methods 0.000 description 9
- 230000003827 upregulation Effects 0.000 description 9
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 8
- 108020001621 Natriuretic Peptide Proteins 0.000 description 8
- 102000004571 Natriuretic peptide Human genes 0.000 description 8
- 125000003545 alkoxy group Chemical group 0.000 description 8
- 230000001631 hypertensive effect Effects 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- 210000005240 left ventricle Anatomy 0.000 description 8
- 210000004165 myocardium Anatomy 0.000 description 8
- 239000000692 natriuretic peptide Substances 0.000 description 8
- 125000004433 nitrogen atom Chemical group N* 0.000 description 8
- 150000003180 prostaglandins Chemical class 0.000 description 8
- 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 description 7
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 210000000702 aorta abdominal Anatomy 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 125000001589 carboacyl group Chemical group 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 239000000975 dye Substances 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 7
- 239000011591 potassium Substances 0.000 description 7
- 229910052700 potassium Inorganic materials 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 230000002441 reversible effect Effects 0.000 description 7
- 229910052717 sulfur Inorganic materials 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 206010028594 Myocardial fibrosis Diseases 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 108090000783 Renin Proteins 0.000 description 6
- 102100028255 Renin Human genes 0.000 description 6
- 210000004413 cardiac myocyte Anatomy 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 230000037213 diet Effects 0.000 description 6
- 230000002526 effect on cardiovascular system Effects 0.000 description 6
- 125000000623 heterocyclic group Chemical group 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 239000001103 potassium chloride Substances 0.000 description 6
- 235000011164 potassium chloride Nutrition 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 5
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 description 5
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 description 5
- 101710091439 Major capsid protein 1 Proteins 0.000 description 5
- YIQKLZYTHXTDDT-UHFFFAOYSA-H Sirius red F3B Chemical compound C1=CC(=CC=C1N=NC2=CC(=C(C=C2)N=NC3=C(C=C4C=C(C=CC4=C3[O-])NC(=O)NC5=CC6=CC(=C(C(=C6C=C5)[O-])N=NC7=C(C=C(C=C7)N=NC8=CC=C(C=C8)S(=O)(=O)[O-])S(=O)(=O)[O-])S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+] YIQKLZYTHXTDDT-UHFFFAOYSA-H 0.000 description 5
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 5
- 210000000709 aorta Anatomy 0.000 description 5
- 125000003710 aryl alkyl group Chemical group 0.000 description 5
- 150000005840 aryl radicals Chemical class 0.000 description 5
- 230000001746 atrial effect Effects 0.000 description 5
- 230000002238 attenuated effect Effects 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 230000035622 drinking Effects 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 229940100601 interleukin-6 Drugs 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 210000001616 monocyte Anatomy 0.000 description 5
- 210000002254 renal artery Anatomy 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 4
- 108010074051 C-Reactive Protein Proteins 0.000 description 4
- 102100032752 C-reactive protein Human genes 0.000 description 4
- 102000001187 Collagen Type III Human genes 0.000 description 4
- 108010069502 Collagen Type III Proteins 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 4
- 229940124639 Selective inhibitor Drugs 0.000 description 4
- 208000024248 Vascular System injury Diseases 0.000 description 4
- 208000012339 Vascular injury Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 125000003282 alkyl amino group Chemical group 0.000 description 4
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 210000001367 artery Anatomy 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 125000004181 carboxyalkyl group Chemical group 0.000 description 4
- 229940096422 collagen type i Drugs 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 239000002934 diuretic Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000029142 excretion Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000028709 inflammatory response Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000001338 necrotic effect Effects 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- 238000011321 prophylaxis Methods 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 210000005241 right ventricle Anatomy 0.000 description 4
- 238000011699 spontaneously hypertensive rat Methods 0.000 description 4
- 150000003431 steroids Chemical class 0.000 description 4
- 230000000451 tissue damage Effects 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 101150071146 COX2 gene Proteins 0.000 description 3
- 101100114534 Caenorhabditis elegans ctc-2 gene Proteins 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 3
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- 206010027525 Microalbuminuria Diseases 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 101150000187 PTGS2 gene Proteins 0.000 description 3
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 3
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Natural products CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 3
- 125000003435 aroyl group Chemical group 0.000 description 3
- 230000004872 arterial blood pressure Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 125000001246 bromo group Chemical group Br* 0.000 description 3
- 125000003917 carbamoyl group Chemical class [H]N([H])C(*)=O 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000035487 diastolic blood pressure Effects 0.000 description 3
- 230000000378 dietary effect Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 230000001882 diuretic effect Effects 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- METQSPRSQINEEU-HXCATZOESA-N drospirenone Chemical compound C([C@]12[C@H]3C[C@H]3[C@H]3[C@H]4[C@@H]([C@]5(CCC(=O)C=C5[C@@H]5C[C@@H]54)C)CC[C@@]31C)CC(=O)O2 METQSPRSQINEEU-HXCATZOESA-N 0.000 description 3
- 238000002651 drug therapy Methods 0.000 description 3
- 239000003792 electrolyte Substances 0.000 description 3
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 230000004761 fibrosis Effects 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- 125000001188 haloalkyl group Chemical group 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 125000001072 heteroaryl group Chemical group 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 3
- 238000010191 image analysis Methods 0.000 description 3
- 238000003364 immunohistochemistry Methods 0.000 description 3
- 238000012744 immunostaining Methods 0.000 description 3
- 238000007901 in situ hybridization Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 210000005165 macula densa Anatomy 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 229910052753 mercury Inorganic materials 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 230000001452 natriuretic effect Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 230000008816 organ damage Effects 0.000 description 3
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 3
- 208000033808 peripheral neuropathy Diseases 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 230000012495 positive regulation of renal sodium excretion Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 201000001474 proteinuria Diseases 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 238000013222 sprague-dawley male rat Methods 0.000 description 3
- 239000008399 tap water Substances 0.000 description 3
- 235000020679 tap water Nutrition 0.000 description 3
- WGTODYJZXSJIAG-UHFFFAOYSA-N tetramethylrhodamine chloride Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C(O)=O WGTODYJZXSJIAG-UHFFFAOYSA-N 0.000 description 3
- 229940099456 transforming growth factor beta 1 Drugs 0.000 description 3
- 230000002861 ventricular Effects 0.000 description 3
- 239000008096 xylene Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- TYRGTHQUZVMKOF-UHFFFAOYSA-N 16,17-dihydro-15h-cyclopenta[a]phenanthrene Chemical group C1=CC=C2C3=CC=C4CCCC4=C3C=CC2=C1 TYRGTHQUZVMKOF-UHFFFAOYSA-N 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 2
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 2
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 2
- 102100031478 C-type natriuretic peptide Human genes 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000022306 Cerebral injury Diseases 0.000 description 2
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 241000288140 Gruiformes Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000635938 Homo sapiens Transforming growth factor beta-1 proprotein Proteins 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- 241000353097 Molva molva Species 0.000 description 2
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 101000605131 Rattus norvegicus Prostaglandin G/H synthase 2 Proteins 0.000 description 2
- 208000037656 Respiratory Sounds Diseases 0.000 description 2
- 208000017442 Retinal disease Diseases 0.000 description 2
- 206010038923 Retinopathy Diseases 0.000 description 2
- 208000000924 Right ventricular hypertrophy Diseases 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
- 102100030742 Transforming growth factor beta-1 proprotein Human genes 0.000 description 2
- 210000003815 abdominal wall Anatomy 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- FXAGBTBXSJBNMD-UHFFFAOYSA-N acetic acid;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound CC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O FXAGBTBXSJBNMD-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 125000000278 alkyl amino alkyl group Chemical group 0.000 description 2
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 125000004103 aminoalkyl group Chemical group 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 230000003276 anti-hypertensive effect Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- 125000001769 aryl amino group Chemical group 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- CREXVNNSNOKDHW-UHFFFAOYSA-N azaniumylideneazanide Chemical group N[N] CREXVNNSNOKDHW-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
- 238000012925 biological evaluation Methods 0.000 description 2
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 2
- 229960000830 captopril Drugs 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 125000004982 dihaloalkyl group Chemical group 0.000 description 2
- METQSPRSQINEEU-UHFFFAOYSA-N dihydrospirorenone Natural products CC12CCC(C3(CCC(=O)C=C3C3CC33)C)C3C1C1CC1C21CCC(=O)O1 METQSPRSQINEEU-UHFFFAOYSA-N 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 229960004845 drospirenone Drugs 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000024924 glomerular filtration Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000004438 haloalkoxy group Chemical group 0.000 description 2
- 210000005003 heart tissue Anatomy 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 238000012766 histopathologic analysis Methods 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 238000013299 hypertensive rat model Methods 0.000 description 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
- 230000006749 inflammatory damage Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 2
- 150000002596 lactones Chemical group 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- SBDNJUWAMKYJOX-UHFFFAOYSA-M meclofenamic acid(1-) Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C([O-])=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-M 0.000 description 2
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000008722 morphological abnormality Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 210000003200 peritoneal cavity Anatomy 0.000 description 2
- 125000006684 polyhaloalkyl group Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 2
- 206010037833 rales Diseases 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000008085 renal dysfunction Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 125000001113 thiadiazolyl group Chemical group 0.000 description 2
- 229960000187 tissue plasminogen activator Drugs 0.000 description 2
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- WHBMMWSBFZVSSR-GSVOUGTGSA-M (R)-3-hydroxybutyrate Chemical compound C[C@@H](O)CC([O-])=O WHBMMWSBFZVSSR-GSVOUGTGSA-M 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- QXQAPNSHUJORMC-UHFFFAOYSA-N 1-chloro-4-propylbenzene Chemical compound CCCC1=CC=C(Cl)C=C1 QXQAPNSHUJORMC-UHFFFAOYSA-N 0.000 description 1
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IELVZKKFWNCUAQ-UHFFFAOYSA-N 1h-pyrrolizine-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)C=CN21 IELVZKKFWNCUAQ-UHFFFAOYSA-N 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- OXBLVCZKDOZZOJ-UHFFFAOYSA-N 2,3-Dihydrothiophene Chemical compound C1CC=CS1 OXBLVCZKDOZZOJ-UHFFFAOYSA-N 0.000 description 1
- OYJGEOAXBALSMM-UHFFFAOYSA-N 2,3-dihydro-1,3-thiazole Chemical compound C1NC=CS1 OYJGEOAXBALSMM-UHFFFAOYSA-N 0.000 description 1
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 1
- DGPBVJWCIDNDPN-UHFFFAOYSA-N 2-(dimethylamino)benzaldehyde Chemical compound CN(C)C1=CC=CC=C1C=O DGPBVJWCIDNDPN-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- XOVUGONFOXECQL-UHFFFAOYSA-N 3-(1,3-oxazol-2-yl)propanoic acid Chemical compound OC(=O)CCC1=NC=CO1 XOVUGONFOXECQL-UHFFFAOYSA-N 0.000 description 1
- FQRHOOHLUYHMGG-BTJKTKAUSA-N 3-(2-acetylphenothiazin-10-yl)propyl-dimethylazanium;(z)-4-hydroxy-4-oxobut-2-enoate Chemical compound OC(=O)\C=C/C(O)=O.C1=C(C(C)=O)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 FQRHOOHLUYHMGG-BTJKTKAUSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- BGNGWHSBYQYVRX-UHFFFAOYSA-N 4-(dimethylamino)benzaldehyde Chemical compound CN(C)C1=CC=C(C=O)C=C1 BGNGWHSBYQYVRX-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 101150037123 APOE gene Proteins 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- 102100040214 Apolipoprotein(a) Human genes 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 101800001288 Atrial natriuretic factor Proteins 0.000 description 1
- 102400001282 Atrial natriuretic peptide Human genes 0.000 description 1
- 101800001890 Atrial natriuretic peptide Proteins 0.000 description 1
- 102100039339 Atrial natriuretic peptide receptor 1 Human genes 0.000 description 1
- 101710102163 Atrial natriuretic peptide receptor 1 Proteins 0.000 description 1
- 206010064539 Autoimmune myocarditis Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 101800000060 C-type natriuretic peptide Proteins 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 108010075016 Ceruloplasmin Proteins 0.000 description 1
- 108010078239 Chemokine CX3CL1 Proteins 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 101100216294 Danio rerio apoeb gene Proteins 0.000 description 1
- 206010011906 Death Diseases 0.000 description 1
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
- 206010052337 Diastolic dysfunction Diseases 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 102000013818 Fractalkine Human genes 0.000 description 1
- DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101000780028 Homo sapiens Natriuretic peptides A Proteins 0.000 description 1
- 208000019025 Hypokalemia Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108010033266 Lipoprotein(a) Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- NZXKDOXHBHYTKP-UHFFFAOYSA-N Metohexital Chemical compound CCC#CC(C)C1(CC=C)C(=O)NC(=O)N(C)C1=O NZXKDOXHBHYTKP-UHFFFAOYSA-N 0.000 description 1
- 101100518501 Mus musculus Spp1 gene Proteins 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 1
- 102100034296 Natriuretic peptides A Human genes 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 240000007673 Origanum vulgare Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- SGUKUZOVHSFKPH-UHFFFAOYSA-N PGG2 Natural products C1C2OOC1C(C=CC(OO)CCCCC)C2CC=CCCCC(O)=O SGUKUZOVHSFKPH-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102100026918 Phospholipase A2 Human genes 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 101001135788 Pinus taeda (+)-alpha-pinene synthase, chloroplastic Proteins 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 206010037368 Pulmonary congestion Diseases 0.000 description 1
- 108020004518 RNA Probes Proteins 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 101001121466 Rattus norvegicus Osteopontin Proteins 0.000 description 1
- 101000843521 Rattus norvegicus Oxygen-dependent coproporphyrinogen-III oxidase, mitochondrial Proteins 0.000 description 1
- 101000703459 Rattus norvegicus Sphingosine-1-phosphate phosphatase 1 Proteins 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 208000027032 Renal vascular disease Diseases 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Natural products OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
- 206010040030 Sensory loss Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 101710136739 Teichoic acid poly(glycerol phosphate) polymerase Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 241000710779 Trina Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000013394 Troponin I Human genes 0.000 description 1
- 108010065729 Troponin I Proteins 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 102000006943 Uracil-DNA Glycosidase Human genes 0.000 description 1
- 108010072685 Uracil-DNA Glycosidase Proteins 0.000 description 1
- 208000005475 Vascular calcification Diseases 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 210000003489 abdominal muscle Anatomy 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 229960001946 acepromazine maleate Drugs 0.000 description 1
- LUSZLZVCFYQKQC-UHFFFAOYSA-N acetic acid;2-hydroxypropane-1,2,3-tricarboxylic acid;propan-2-ol Chemical compound CC(C)O.CC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O LUSZLZVCFYQKQC-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940092229 aldactone Drugs 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- 150000001325 aldosterones Chemical group 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 description 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 125000005097 aminocarbonylalkyl group Chemical group 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 125000001691 aryl alkyl amino group Chemical group 0.000 description 1
- 125000004659 aryl alkyl thio group Chemical group 0.000 description 1
- 125000005129 aryl carbonyl group Chemical group 0.000 description 1
- 125000005160 aryl oxy alkyl group Chemical group 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229940064804 betadine Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229940096423 bovine collagen type i Drugs 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- SIEYLFHKZGLBNX-UHFFFAOYSA-N bupivacaine hydrochloride (anhydrous) Chemical compound [Cl-].CCCC[NH+]1CCCCC1C(=O)NC1=C(C)C=CC=C1C SIEYLFHKZGLBNX-UHFFFAOYSA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 230000009787 cardiac fibrosis Effects 0.000 description 1
- 230000009084 cardiovascular function Effects 0.000 description 1
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000058 cyclopentadienyl group Chemical group C1(=CC=CC1)* 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 231100000856 decreased creatinine clearance Toxicity 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 125000006003 dichloroethyl group Chemical group 0.000 description 1
- 125000004774 dichlorofluoromethyl group Chemical group FC(Cl)(Cl)* 0.000 description 1
- 125000004772 dichloromethyl group Chemical group [H]C(Cl)(Cl)* 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- ZSWFCLXCOIISFI-UHFFFAOYSA-N endo-cyclopentadiene Natural products C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 125000004672 ethylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000005048 flame photometry Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 201000000079 gynecomastia Diseases 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 125000006343 heptafluoro propyl group Chemical group 0.000 description 1
- 125000004475 heteroaralkyl group Chemical group 0.000 description 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 1
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005935 hexyloxycarbonyl group Chemical group 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 125000001145 hydrido group Chemical group *[H] 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical compound O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 description 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 description 1
- 210000003090 iliac artery Anatomy 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 230000019948 ion homeostasis Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- VCMGMSHEPQENPE-UHFFFAOYSA-N ketamine hydrochloride Chemical compound [Cl-].C=1C=CC=C(Cl)C=1C1([NH2+]C)CCCCC1=O VCMGMSHEPQENPE-UHFFFAOYSA-N 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000003295 lusitropic effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 235000012245 magnesium oxide Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229940106885 marcaine Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960002683 methohexital Drugs 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical group [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 description 1
- OJURWUUOVGOHJZ-UHFFFAOYSA-N methyl 2-[(2-acetyloxyphenyl)methyl-[2-[(2-acetyloxyphenyl)methyl-(2-methoxy-2-oxoethyl)amino]ethyl]amino]acetate Chemical compound C=1C=CC=C(OC(C)=O)C=1CN(CC(=O)OC)CCN(CC(=O)OC)CC1=CC=CC=C1OC(C)=O OJURWUUOVGOHJZ-UHFFFAOYSA-N 0.000 description 1
- 125000006533 methyl amino methyl group Chemical group [H]N(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 239000012120 mounting media Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000003680 myocardial damage Effects 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001038 naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000013059 nephrectomy Methods 0.000 description 1
- 201000009925 nephrosclerosis Diseases 0.000 description 1
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 229910052760 oxygen Chemical group 0.000 description 1
- 239000001301 oxygen Chemical group 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000004786 perivascular cell Anatomy 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical class OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000030786 positive chemotaxis Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 208000024896 potassium deficiency disease Diseases 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000009117 preventive therapy Methods 0.000 description 1
- 230000007112 pro inflammatory response Effects 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- SGUKUZOVHSFKPH-YNNPMVKQSA-N prostaglandin G2 Chemical compound C1[C@@H]2OO[C@H]1[C@H](/C=C/[C@@H](OO)CCCCC)[C@H]2C\C=C/CCCC(O)=O SGUKUZOVHSFKPH-YNNPMVKQSA-N 0.000 description 1
- YIBNHAJFJUQSRA-YNNPMVKQSA-N prostaglandin H2 Chemical compound C1[C@@H]2OO[C@H]1[C@H](/C=C/[C@@H](O)CCCCC)[C@H]2C\C=C/CCCC(O)=O YIBNHAJFJUQSRA-YNNPMVKQSA-N 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000003331 prothrombotic effect Effects 0.000 description 1
- 210000002097 psoas muscle Anatomy 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011897 real-time detection Methods 0.000 description 1
- 208000012802 recumbency Diseases 0.000 description 1
- 208000015670 renal artery disease Diseases 0.000 description 1
- 230000008327 renal blood flow Effects 0.000 description 1
- 210000002796 renal vein Anatomy 0.000 description 1
- 239000002461 renin inhibitor Substances 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 235000021023 sodium intake Nutrition 0.000 description 1
- NVMNEWNGLGACBB-UHFFFAOYSA-N sodium;1,2-diaza-4-azanidacyclopenta-2,5-diene Chemical compound [Na+].C=1N=C[N-]N=1 NVMNEWNGLGACBB-UHFFFAOYSA-N 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000005301 thienylmethyl group Chemical group [H]C1=C([H])C([H])=C(S1)C([H])([H])* 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 210000003371 toe Anatomy 0.000 description 1
- PMMYEEVYMWASQN-IMJSIDKUSA-N trans-4-Hydroxy-L-proline Natural products O[C@@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-IMJSIDKUSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-N trans-cinnamic acid Chemical compound OC(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 238000009966 trimming Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 210000004231 tunica media Anatomy 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 230000036325 urinary excretion Effects 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000004869 vascular alteration Effects 0.000 description 1
- 208000011733 vascular alteration Diseases 0.000 description 1
- 230000003966 vascular damage Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 206010047470 viral myocarditis Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 230000007279 water homeostasis Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
ALDOSTERONE ANTAGONIST AND NON-STEROIDAL ANTI-
INFLAMMATORY AGENT COMBINATION THERAPY TO PREVENT OR
TREAT CARDIOVASCULAR DISORDERS
Field of the Invention [] This invention is in the field of preventing or treating cardiovascular disorders. More specifically, this invention relates to the use of aldosterone antagonist and non-steroidal anti-inflammatory drug (NSAID) combination therapy in preventing or treating cardiovascular disease including atherosclerosis.
Prostaglandins play a major role in the inflammation process and the inhibition of prostaglandin production, especially production of PGG2, PGH2 and
PGE2, has been a common target of anti-inflammatory drug discovery. However, common non-steroidal anti- inflammatory drugs (NSAIDs) that are active in reducing the prostaglandin-induced pain and swelling associated with the inflammation process are also active in affecting other prostaglandin-regulated processes not associated with the inflammation process. Thus, use of high doses of most common NSAID’s can produce severe side effects, including life threatening ulcers, that limit their therapeutic potential. An alternative to
NSAID’s is the use of corticosteroids, which also produce severe adverse effects, especially when long : term therapy is involved. pe NSAIDs have been found to prevent the production of prostaglandins by inhibiting enzymes in the human - arachidonic acid/prostaglandin pathway, including the enzyme cyclooxygenase (COX). Recently an inducible enzyme associated with inflammation (named
"cyclooxygenase-2 (COX-2)" or "prostaglandin G/H . synthase II") was discovered. } « Several studies have suggested that inflammation plays a role in cardiovascular diseases. For example,
Ridker et al. (New Eng. J. Med., 336, 973-9 (1897)) describes a possible role of inflammation in cardiovascular disease. J. Boyle (J. Path., 181, 93-9 (1997)) describes the association of plague rupture and atherosclerotic inflammation.
In the treatment or prevention of cardiovascular disorders, present drug therapies are not always effective or well tolerated by the subjects undergoing therapy. Accordingly new drug therapies are necessary to fill this need. The present invention is therefore : directed to a novel drug therapy employing a combination of an aldosterone antagonist and NSAID to treat or prevent cardiovascular disorders. More specifically, : 20 this invention relates to the use of aldosterone antagonist and NSAID combination therapy in preventing or treating cardiovascular disorders.
Fig. 1 shows changes in systolic blood pressure in angiotensin ITI infused rat study.
Fig. 2 shows prevention by eplerenone (epoxymexrenone) of vascular inflammation in the heart of angiotensin II infused rats.
Fig. 3 shows lack of cyclooxygenase-2 (COX-2) ) expression in the heart of a vehicle infused rat.
Fig. 4 shows induction of COX-2 expression in heart of Ang IT infused rat.
Fig. 5 shows prevention by eplerenone of induction : of COX-2 expression in heart of Ang II infused rat.
Fig. 6 shows lack of osteopontin expression in the “ heart of a vehicle infused rat.
Fig. 7 shows prevention by eplerenone of induction of osteopontin expression in heart of aldosterone infused rat.
Fig. 8 shows prevention by eplerenone of osteopontin upregulation in myocardium of aldosterone infused rats.
Fig. 9 shows prevention by eplerenone of COoX-2 upregulation in myocardium of aldosterone infused rats.
Fig. 10 shows prevention by eplerenone of myocardial injury in aldosterone infused rats.
Fig. 11 shows upregulated co-expression of COX-2 and osteopontin in coronary artery media of aldosterone infused rat.
Fig. 12 shows some of the mechanisms for aldosterone-induced vascular inflammation and injury.
Fig. 13 shows inhibition of increased urinary protein excretion by eplerenone treatment in angiotensin
II infused, captopril treated stroke prone spontaneously hypertensive rats.
Fig. 14 shows reduction in histopathological scores for renal injury with eplerenone treatment in angiotensin II infused, captopril treated stroke prone spontaneously hypertensive rats.
Fig. 15 shows increased survival and reduced . cerebral injury with eplerenone treatment in stroke- - 30 prone spontaneously hypertensive rats. “ Fig. 16 shows decrease in cerebral injury with eplerenone treatment in stroke-prone spontaneously hypertensive rats.
Fig. 17 shows inhibition of early time-course - expression of myocardial COX-2 in aldosterone-infused, hypertensive rats treated with eplerenone. “ Fig. 18 shows inhibition of early time-course expression of myocardial osteopontin in aldosterone- infused, hypertensive rats treated with eplerencne.
Fig. 19 shows inhibition of early time-course expression of myocardial MCP-1 in aldosterone-infused, hypertensive rats treated with eplerenone.
Fig. 20 shows inhibition of early time-course expression of myocardial ICAM-1 and VCAM-1 in aldosterone-infused, hypertensive rats treated with eplerenone.
Fig. 21 shows systolic blood pressure elevation with aldosterone infusion, and depression of this elevation with aldosterone infusion and eplerenone treatment. ’
Fig. 22 shows myocardial histopathology scores at 28 days for control rats, for rats infused with aldosterone, and for rats infused with aldosterone and treated with eplerenone, and the ratio of heart weight to body weight for rats infused with aldosterone, and for rats infused with aldosterone and treated with eplerenone.
Fig. 23 shows 28 day circulating osteopontin levels for control rats, for rats infused with aldosterone, and for rats infused with aldosterone and treated with - eplerenone.
Fig. 24 shows the relative mRNA expression at 28 “ 30 days for inflammatory cytokines in control rats, in rats infused with aldosterone, and in rats infused with aldosterone and treated with eplerenone.
- Detailed Description of the Invention 9 The present invention provides a method for 5 preventing or treating cardiovascular disorders in a subject in need thereof. The method comprises treating the subject with a therapeutically effective amount of an aldosterone receptor antagonist (including, but not limited to, derivatives or pharmaceutically-acceptable salts thereof) in combination with a NSAID (including, but not limited to, derivatives or pharmaceutically- acceptable salts thereof).
The method above would be useful for, but not limited to, preventing or treating inflammation-related disorders in a subject, including but not limited to inflammation-related disorders of the heart, kidney and brain, particularly vascular inflammation-related disorders. The method would be useful for prevention ox treatment of hypertension, heart failure, heart failure folloing myocardial infarction, congestive heart failure, coronary artery disease, aneurysm, arteriosclerosis, atherosclerosis including cardiac transplant atherosclerosis, myocardial infarction, embolism, stroke, thrombosis, including venous thrombosis, angina including unstable angina, calcification (such as vascular calcification and valvar p calcification), Kawasaki disease and inflammation (such as coronary plaque inflammation, bacterial-induced - 30 inflammation including Chlamydia-induced inflammation and viral induced inflammation).
The method is useful for, but not limited to, ~ treating or preventing inflammation-related disorders by altering the expression of one or more expression ‘ products that directly or indirectly regulate inflammation. Inflammation-related disorders, particularly inflammation-related cardiovascular disorders, may be mediated, in whole or in part, by one or more expression products, which may undergo increased or decreased expression. Said expression products may include but are not limited to organic molecules, proteins, DNA-based or RNA-based molecules, and networks or aggregates of such products, acting together or alone, to directly or indirectly produce an effect.
Changes in patterns of expression of said expression products may occur sequentially or simultaneously, involving two or more expression products. These expression products may have direct or indirect affects on the tissues or organs of the subject, inducing or amplifying a pathological effect induced by other molecules or expression products. These expression products may produce pro-inflammatory effects by increased expression or decreased expression, depending on their function as pro-inflammatory or anti- inflammatory expression products, respectively.
The method is particularly useful for treating or : preventing conditions by moderating the upregulation of a pro-inflammatory components found in affected tissues, including cyclooxygenase and osteopontin, while also inhibiting the activity of cyclooxygenase in the kidney, particularly the macula densa where aldosterone antagonism can induce expression of cyclooxygenase.
While the use of an aldosterone antagonist leads to a reduction in cyclooxygenase expression induced by an w inflammation-related disorder, it may not completely prevent cyclooxygenase activity. The co-action of “ adding an NSAID that inhibits cyclooxygenase activity will also lead to a reduction in inflammation of the affected tissue or organ. The use of an aldosterone antagonist can induce upregulation of cyclooxygenase in the macula densa and cortical thick ascending limb (CTAL) of Henle’s loop in the kidney. In the kidney, prostaglandins, the product of cyclooxygenase, are involved in the regulation of renal hemodynamics and salt/water homeostasis. As a result the non- inflammatory aldosterone antagonist induction of cyclooxygenase in the macula densa and CTAL region of the kidney can lead to pathological effects such as increased blood pressure and retention of salt and water. Accordingly, co-administration of a NSAID that inhibits cyclooxygenase, with an aldosterone antagonist, will slow, stop, or reverse the progression of the pathological renal response to the aldosterone antagonist induction of cyclooxygenase in the kidney.
In the method above, cardiovascular disorder includes, but is not limited to, those disorders which are known to have an inflammation component and those that may be mediated by aldosterone or cyclooxygenase or both. The method above also includes treatment of patients with an aldosterone antagonist and NSAID p combination requiring moderation of the upregulated expression of cyclooxygenase or osteopontin. In . tissues, including but not limited to the kidney, heart, and brain, cyclooxygenase may be induced resulting in upregulated expression of this pro-inflammatory enzyme, which can cause mild to severe tissue and organ damage.
In the method above, administration of an aldosterone - antagonist and NSAID combination is used to moderate the upregulated expression of cyclooxygenase. The method “ above would also be useful for preventing or treating conditions which may arise in tissues, including but not limited to the kidney, heart, and brain, wherein the upregulated expression of the pro-inflammatory protein osteopontin, may be induced, resulting in mild to severe tissue and organ damage. In the method above, administration of an aldosterone antagonist and NSAID combination is used to moderate the upregulated expression of osteopontin.
In another embodiment, the present invention would be useful in preventing or treating conditions in tissues and organs, including but not limited to the kidney, heart and brain, wherein the upregulated expression of any one of the pro-inflammatory expression products MCP-1, IL-1, IL-6, VCAM-1 and ICAM-1 may occur, resulting in mild to severe tissue and organ damage. In the method above, administration of an aldosterone antagonist and NSAID combination is used to moderate the upregulated expression of any one of MCP-1, IL-1, IL-6,
VCAM-1 and ICAM-1.
Non-limiting examples of expression products, whose expression can be moderated to reduce inflammation- . related cardiovascular disease by treatment with an aldosterone antagonist and NSAID combination, are shown - 30 in Figure 24. Non-limiting examples of pro-inflammatory expression products that may be upregulated include one or more of the following: (a) receptors for angiotensin II and endothelin,
(b) monocyte activating molecules avR3 (adhesion, . proliferation, migration) and CD44 (migration), (c) mediators of vascular inflammation interferon-vy u (Inf-v), interleukin-1 (IL-1) and tumor necrosis factor-a (TNF-a), (d) NADH/NADPH oxidase to produce tissue damaging superoxide radicals, and (e) prothrombotic plasminogen activator inhibitor-1 (PAI-1) causing a decrease in active tissue plasminogen activator (t-PA).
In another embodiment of the present invention, non-limiting examples of expression products, whose expression can be moderated to reduce inflammation- related cardiovascular disease by treatment with an aldosterone antagonist and NSAID combination, include one or more of the following: acute phase reactants like C-reactive protein (CRP) , pleiotropic cytokines like interleukin-6 (IL-6),
IL-10, IL-12, soluble intracellular adhesion molecule-1 (sICAM-1), troponin T or I, heat shock protein 65 (HSP65), amyloid, phospholipase A2, fibrinogen, CD40/CD40L signaling pathway and adhesion mediators like collagen-binding integrins alf3l (mesenchymal cells) and a2Rl ’ (epithelial cells). ’ 30 In another embodiment of the present invention, one or more of the inflammation-related expression products can be moderated or altered by combination therapy of an aldosterone receptor antagonist and a NSAID, through an . : increase or decrease in expression of at least 10%. In another embodiment, said expression products can be ) moderated or altered by combination therapy of an aldosterone receptor antagonist and a NSAID, through an increase or decrease in expression of at least 25%. In another embodiment, said expression products can be moderated or altered by combination therapy of an aldosterone receptor antagonist and a NSAID, through an increase or decrease in expression of at least 50%. In. another embodiment, said expression products can be moderated or altered by combination therapy of an aldosterone receptor antagonist and a NSAID, through an increase or decrease in expression of at least 100%.
Inhibitors of the cyclooxygenase pathway in the metabolism of arachidonic acid used in the prevention of cardiovascular disorder may inhibit enzyme activity through a variety of mechanisms. By the way of example, the inhibitors used in the methods described herein may inhibit expression of the enzyme activity. Blocking expression of cyclooxygenase-2, at the site of inflammatory damage, using an aldosterone antagonist, is highly advantageous in that it minimizes the gastric side effects that can occur with non-selective NSAID'’s, especially where prolonged prophylactic treatment at a high dose of NSAID is expected. [4
Dosages and Treatment Regimen ’ 30 The amount of aldosterone receptor antagonist blocker that is administered and the dosage regimen for the methods of this invention depend on a variety of factors, including the age, weight, sex and medical condition of the subject, the severity of the pathogenic , effect, the route and frequency of administration, and the particular aldosterone blocker employed, and thus ; may vary widely. A daily dose administered to a subject of about 0.001 to 30 mg/kg body weight, preferably between about 0.005 and about 20 mg/kg body weight, more preferably between about 0.01 and about 15 mg/kg body weight, still more preferably between about 0.05 and about 10 mg/kg body weight, and most preferably between about 0.01 to 5 mg/kg body weight, may be appropriate.
The daily dose of aldosterone antagonist administered to a human subject typically will range from about 0.1 mg to about 2000 mg. In one embodiment of the present invention, the daily dose range is from about 0.1 mg to about 400 mg. In another embodiment of : the present invention, the daily dose range is from about 1 mg to about 200 mg. In a further embodiment of the present invention, the daily dose range is from about 1 mg to about 100 mg. In another embodiment of the present invention, the daily dose range is from about 10 mg to about 100 mg. In a further embodiment of the present invention, the daily dose range is from about 25 mg to about 100 mg. In another embodiment of the present invention, the daily dose is selected from the group consisting of 5 mg, 10 mg, 12.5 mg, 25 mg, 50 mg, 75 mg, and 100 mg. In a further embodiment of the ” present invention, the daily dose is selected from the group consisting of 25 mg, 50 mg, and 100 mg. A daily dose of aldosterone blocker that produces no substantial diuretic and/or anti-hypertensive effect in a subject is specifically embraced by the present method. The daily dose can be administered in one to four doses per day. . Dosing of the aldosterone blocker can be determined and adjusted based on measurement of blood pressure or ’ appropriate surrogate markers (such as natriuretic peptides, endothelins, and other surrogate markers discussed below). Blood pressure and/or surrogate : marker levels after administration of the aldosterone : blocker can be compared against the corresponding baseline levels prior to administration of the aldosterone blocker to determine efficacy of the present method and titrated as needed. ©Non-limiting examples of surrogate markers useful in the method are surrogate markers for renal and cardiovascular disease.
Prophylatic Dosing
It is beneficial to administer the aldosterone blocker prophylatically, prior to a diagnosis of said inflammation-related cardiovascular disorders, and to continue administration of the aldosterone blocker during the period of time the subject is susceptible to the inflammation-related cardiovascular disorders.
Individuals with no remarkable clinical presentation but that are nonetheless susceptible to pathologic effects therefore can be placed upon a prophylatic dose of an aldosterone blocking compound. Such prophylactic doses of the aldosterone blocker may, but need not, be lower than the doses used to treat the specific pathogenic 7 effect of interest.
Cardiovascular Pathology Dosing
Dosing to treat pathologies of cardiovascular function can be determined and adjusted based on measurement of blood concentrations of natriuretic ’ peptides. Natriuretic peptides are a group of structurally similar but genetically distinct peptides that have diverse actions in cardiovascular, renal, and endocrine homeostasis. Atrial natriuretic peptide (“ANP”) and brain natriuretic peptide (“BNP”) are of myocardial cell origin and C-type natriuretic peptide (“CNP”) is of endothelial origin. ANP and BNP bind to the natriuretic peptide-A receptor (“NPR-A”), which, via 3’, 5'-cyclic guanosine monophosphate (cGMP), mediates natriuresis, vasodilation, renin inhibition, antimitogenesis, and lusitropic properties. Elevated natriuretic peptide levels in the blood, particularly blood BNP levels, generally are observed in subjects under conditions of blood volume expansion and after vascular injury such as acute myocardial infarction and remain elevated for an extended period of time after the infarction. (Uusimaa et al.: Int. J. Cardiol 1999; 69: 5-14) .
A decrease in natriuretic peptide level relative to the baseline level measured prior to administration of the aldosterone blocker indicates a decrease in the pathologic effect of aldosterone and therefore provides a correlation with inhibition of the pathologic effect.
Blood levels of the desired natriuretic peptide level therefore can be compared against the . corresponding baseline level prior to administration of the aldosterone blocker to determine efficacy of the . present method in treating the patologic effect. Based upon such natriuretic peptide level measurements, dosing of the aldosterone blocker can be adjusted to reduce the cardiovascular pathologic effect.
Similarly, cardiac pathologies can also be . identified, and the appropriate dosing determined, based on circulating and urinary cGMP Levels. An increased ’ plasma level of cGMP parallels a fall in mean arterial pressure. Increased urinary excretion of cGMP is correlated with the natriuresis.
Cardiac pathologies also can be identified by a reduced ejection fraction or the presence of myocardial infarction or heart failure or left ventricular hypertrophy. Left ventricular hypertrophy can be identified by echo-cardiogram or magnetic resonance imaging and used to monitor the progress of the treatment and appropriateness of the dosing.
In another embodiment of the invention, therefore, the methods of the present invention can be used to reduce natriuretic peptide levels, particularly BNP levels, thereby also treating related cardiovascular : pathologies.
Renal Pathology Dosing
Dosing to treat pathologies of renal function can be determined and adjusted based on measurement of proteinuria, microalbuminuria, decreased glomerular filtration rate (GFR), or decreased creatinine clearance. Proteinuria is identified by the presence of greater than 0.3 g of urinary protein in a 24 hour urine collection. Microalbuminuria is identified by an ’ increase in immunoassayable urinary albumin. Based upon such measurements, dosing of the aldosterone blocker can be adjusted to reduce the renal pathologic effect.
Neuropathy Pathology Dosing . Neuropathy, especially peripheral neuropathy, can be identified by and dosing adjustments based on, ' neurologic exam of sensory deficit or sensory motor ability.
Retinopathy Pathology Dosing
Retinopathy can be identified by, and dosing adjustments based on, ophthalmologic exam.
Inflammation Markers
Certain markers may be indicative of or responsible for inflammation, or pre-inflammatory conditions.
Measurement of these markers may be useful in determination of an appropriate dosage of aldosterone blocker to be administered, or determination of an efficatious dose of an aldosterone blocker after administration. Non-limiting examples of such markers are: osteopontin; acute phase reactants such as C reactive protein (CRP), fibrinogen, Factor VIII, serum copper (carrier protein ceruloplasmin), serum iron (carrier protein ferritin), Plasminogen activator
Inhibitor-1 (PAI-1) and lipoprotein(a); natriuretic peptides; endothelins; VCAM-1; ICAM-1; IL-18; TNF-o; IL- 6; COX-2; fractalkine; MCP-1; and triglyceride. ’ NSAIDs useful in the present invention include compounds listed in Table 1 (including derivatives of ’ these compounds). Each published document listed in
Table 1 describes selected aspects of the NSAID, such as the chemical preparation or the biological properties of such compound. The content of each of these documents . is incorporated herein by reference.
Table 1: NSAIDs
COMPOUND NAME CHEMICAL
NAME /CAS [acetaminophen | lus3tsses [bemoxaprofen | |Ussomms |. [caprofen | __— |US3go6lds |] [diffunisal | |FRis522570 tetrahydropyrano[3,4- blindole-1-acetic acid /41340- 25-4 flurbiprofen (alphaR)-2-fluoro-alpha- EP 103265 el acid/ 5104-49-4 ~~ = ibuprofen alpha-methyl-4-(2- GB 1538636
EEE TT acid 2-methoxyphenyl ester/ 66332-77-2 methylbenzeneacetic acid/ 22071-15-4 1H-pyrrolizine-1-carboxylic acid/ 74103-06-3 [mecloferampate | | 0000 mefenamicacid | |uUs3z94813 butanone/ 42924-53-8 oxazolepropanoic acid / 21256-18-8 [oxyphembutazone | ~~ |US348021 (phenylbutazone | ~~ |US3265577 ’ piroxicam 3-phenyl-propenoic acid, 2- EP 79639 methyl-3-[(2-pyridinylamino)-
EET
: benzothiazin-4-y! ester, S,S- dioxide/ 36322-90-4 [Suprofes | [US403s3%6 {(hydroxy-2-thienylmethylene)-
Te carboxamide /120210-48-2
Tolmetin [26171233 |US3752826
Coomepac [Tussi [Aspithn | — 1
In one embodiment, the NSAID is selected from the group consisting of acetaminophen, benoxaprofen, carprofen, diclofenac, diflunisal, etodolac, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamate, mefenamic acid, nabumetone, naproxen, oxaprozin, oxyphenbutazone, phenylbutazone, piroxicam, sulindac, suprofen, tenidap, tolmetin, zomepirac, and aspirin.
In another embodiment, the NSAID is selected from the group consisting of acetaminophen, benoxaprofen, carprofen, diclofenac, diflunisal, etodolac, fenoprofen, : and flurbiprofen.
In another embodiment, the NSAID is selected from the group consisting of ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamate, mefenamic acid, nabumetone, naproxen, and oxaprozin.
In another embodiment, the NSAID is selected from the group consisting of oxyphenbutazone, phenylbutazone, piroxicam, sulindac, suprofen, tenidap, tolmetin, zomepirac, and aspirin.
The term “NSAID” includes any compounds (such as ‘ derivatives and pharmaceutically acceptable salts), which are structurally related to a NSAID and which ’ possess the substantially equivalent biologic activity.
By way of example, such compounds may include, but are not limited to, prodrugs thereof.
: The term “aldosterone receptor antagonist” or “aldosterone antagonist” denotes a compound capable of - binding to an aldosterone receptor, as a competitive 5° inhibitor of the action of aldosterone itself at the receptor site, so as to modulate the receptor-mediated activity of aldosterone.
Aldosterone Antagonists
The aldosterone antagonists used in the methods of the present invention generally are spirolactone- type steroidal compounds. The term “spirolactone- type” is intended to characterize a structure comprising a lactone moiety attached to a steroid nucleus, typically at the steroid “D” ring, through a spiro bond configuration. A subclass of spirolactone- type aldosterone antagonist compounds consists of epoxy-steroidal aldosterone antagonist compounds such as eplerenone. Another subclass of spirolactone-type antagonist compounds consists of non-epoxy-steroidal aldosterone antagonist compounds such as spironolactone.
The epoxy-steroidal aldosterone antagonist compounds used in the method of the present invention generally have a steroidal nucleus substituted with an epoxy-type moiety. The term “epoxy-type” moiety is intended to embrace any moiety characterized in having o> an oxygen atom as a bridge between two carbon atoms, examples of which include the following moieties:
8} O 0 epoxyethyl 1,3-epoxypropyl 1,2-epoxypropyl
The term “steroidal”, as used in the phrase “epoxy-steroidal”, denotes a nucleus provided by a cyclopenteno-phenanthrene moiety, having the conventional “A”, “B”, “C” and “D” rings. The epoxy- type moiety may be attached to the cyclopentenophenanthrene nucleus at any attachable or substitutable positions, that is, fused to one of the rings of the steroidal nucleus or the moiety may be substituted on a ring member of the ring system. The phrase “epoxy-steroidal” is intended to embrace a steroidal nucleus having one or a plurality of epoxy- type moieties attached thereto.
Epoxy-steroidal aldosterone antagonists suitable for use in the present methods include a family of compounds having an epoxy moiety fused to the “C” ring of the steroidal nucleus. Especially preferred are 20- spiroxane compounds characterized by the presence of a 9
O,llx-substituted epoxy moiety. Compounds 1 through 11, Table 1 below, are illustrative 90, 1l0-epoxy- steroidal compounds that may be used in the present methods. These epoxy steroids may be prepared by procedures described in Grob et al., U.S. Patent No. 4,559,332. Additional processes for the preparation of » 25 9,ll-epoxy steroidal compounds and their salts are disclosed in Ng et al., W097/21720 and Ng et al., . WO98/25948.
TABLE 2: Aldosterone Receptor Antagonist
: Compound # Structure and Name 0] { 0 1 S oJ Fo
S R L
RH
OMe 0 rr
O
Pregn-4-ene-7,21-dicarboxylic acid, 9,1ll1l-epoxy- 17-hydroxy-3-oxo-,y-lactone, methyl ester, (7a0,110,17PB) -
OMe
Me | OH
Oo 2 .- 0]
S > 1 [3 0 w
Oo
Pregn-4-ene-7,21-dicarboxylic acid, 9,1ll-epoxy- 17-hydroxy-3-oxo-,dimethyl ester, (7a,11la,17f) -
Me 3 5 Re) c © ]0 o” To “.
IN
. 0) 3'H-cyclopropal6, 7] pregna-4, 6-diene-21-carboxylic : acid, 9,1ll-epoxy-6,7-dihydro-17-hydroxy-3-oxo-, y-lactone, (68, 7p, lla, 17B)-
Me OH COH 4 .-
Je . J xt
S 1
RY
. OPr-i o) a
O
Pregn-4-ene-7,21l-dicarboxylic acid, 9,1ll-epoxy-17-~ hydroxy-3-oxo-,7- (l-methylethyl) ester, monopotassium salt, (7a,1la,17B) -
Me OH CO,H 5 . oI’
CRA.
H
. OMe 0 a .
Oo : Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17- hydroxy-3-oxo-, 7-methylethyl) ester, monopotassium salt, (7a,11la,17B) -
Me 6 Re
Me I cog 0” To
S A
S B sty H . 0 3'H-cyclopropal6, 7] pregna-1,4,6-triene-21-carboxylic acid, 9,11-epoxy-6,7-dihydro-17-hydroxy-3-oxo-, y-lactone (6B, 78,11a) - :
Meo 2 7 RC S R OMe
M e Soh
SN :
S * stg H 0] 3'H-cyclopropa [6, 7] pregna-4, 6-diene-21-carboxylic acid, 9,1ll-epoxy-6,7-dihydro-17-hydroxy-3-oxo-, methyl ester, (6B,78,11a,17B)-
Me HO
CO,H
R.-
Me
Sod 8 R S *
S .
S H H . KF oO 3'H-cyclopropal6,7]pregna-4,6-diene-21-carboxylic acid, 9,1ll-epoxy-6,7-dihydro-17-hydroxy-3-oxo-, monopotassium salt, (6B,7p,11a,17p)-
Me
R- 9 M ~ S ZN [ Ke) S (@] 0
S * . S it
S' § H - 0 3'H-cyclopropa [6,7] pregna-1,4,6-triene-21l-carboxylic acid, 9,1ll-epoxy-6,7-dihydro-17-hydroxy-3-0xo-,y- lactone (6pB,7B8,11a,178)- [ < 0
SR or Me
S £3 1
OL
H
: rr 0)
Pregn-4-ene-7,21l-dicarboxylic acid, 9,1l-epoXy- 17-hydroxy-3-oxo-,y-lactone, ethyl ester, (70,110,17B)-
LO
11 S —R oz’ R H Me
Rg
Mel 0 opr 0}
Pregn-4-ene-7,21-dicarboxylic acid, 9,ll-epoxy- 17-hydroxy-3-oxo-,y-lactone, l-methylethyl . ester (7a,llo,17B)-
Of particular interest is the compound eplerenone (also known as: epoxymexrenone and CGP 30 083) which is compound 1 as shown above. The chemical name for eplerenone is pregn-4-ene-7,2l-dicarboxylic acid, 9,11- ) 5 epoxy-17-hydroxy-3-oxo, y-lactone, methyl ester, (7a, lla, 17a)-. This chemical name corresponds to the CAS registry name for eplerenone (the CAS registry number : for eplerenone is 107724-20-9). U.S. Patent No. 4,559,332 identifies eplerenone by the alternative name of 9u,lla-epoxy-Ta-methoxycarbonyl-20-spirox-4-ene-3,21- dione. Such “spiroxane” nomenclature is further described, for example, at column 2, line 16 through column 4, line 48 of U.S. Patent No. 4,559,332.
Eplerenone is an aldosterone receptor antagonist and has a higher specificity for aldosterone receptors than does, for example, spironolactone. Selection of eplerenone as the aldosterone antagonist in the present method would be beneficial to reduce certain side- : effects such as gynecomastia that occur with use of aldosterone antagonists having less specificity.
Non-epoxy-steroidal aldosterone antagonists suitable for use in the present methods include a family of spirolactone-type compounds defined by Formula I:
T° “.. 0
Pe
Cis
Cr cs’ M . wherein ~~ Cev™ c; is ~ ig or 4 ~ * SCOR wherein R is lower alkyl of up to 5 carbon atoms, and wherein TCqsv cn is ~_/ ~~ or Tg .
H, H,
Lower alkyl residues include branched and unbranched groups, preferably methyl, ethyl and n- propyl.
Specific compounds of interest within Formula I are the following: : 7Ja-acetylthio-3-oxo-4,15-androstadiene- [17 (B-1") - spiro-5']perhydrofuran-2’-one; 3-0x0-70-propionylthio-4,15-androstadiene- [17 ( (B- 1’)-spiro-5'}perhydrofuran-2’-one; 6B, 7p-methylene-3-oxo4, 15-androstadiene- [17 ((B-1") - spiro-5']perhydrofuran-2’'-one; 150, 16a-methylene-3-oxo-4, 7o-propionylthio-4- androstene [17 (B-1’) -spiro-5']perhydrofuran-2’-one; 6B, 78, 15a, 160c-dimethylene-3-oxo-4-androstene [17 (B- 1’) -spiro-5'] -perhydrofuran-2’'-one;
Jo-acetylthio-15B,16Bf-Methylene-3-oxo-4-androstene- [17 (B-1") -spiro-5']perhydrofuran-2’-one; 15B, 16p-methylene-3-oxo-7B-propionylthio-4- androstene- [17 (B-1’)-spiro-5']perhydrofuran-2’-one; and 6B, 7B,15B,16Bp-dimethylene-3-oxo-4-androstene- [17 (B- 17) -spiro-5']lperhydrofuran-2'-one.
Methods to make compounds of Formula I are described in U.S. Patent No. 4,129,564 to Wiechart et . al. issued on 12 December 1978. . 5 Another family of non-epoxy-steroidal compounds of interest is defined by Formula II: lo}
I» gs ( Y ~ (Im) 0 “1 sre wherein R' is Ciz-alkyl or Ci.3 acyl and R? igs H or Ci-i- alkyl.
Specific compounds of interest within Formula II are the following: la-acetylthio-15p, 16B-methylene-7a-methylthio-3- : oxo-l70-pregn-4-ene-21,17-carbolactone; and 15B,16B-methylene-1a, 70-dimethylthio-3-oxo-17a- pregn-4-ene-21,17-carbolactone.
Methods to make the compounds of Formula II are described in U.S. Patent No. 4,789,668 to Nickisch et al. which issued 6 December 1988.
Yet another family of non-epoxy-steroidal compounds of interest is defined by a structure of Formula III:
[0]
Q 7] 0, cn, JHC ’ or cy, BCX 1) . / o -----SOCR © y wherein R is lower alkyl, with preferred lower alkyl groups being methyl, ethyl, propyl and butyl. Specific compounds of interest include: 3B,21-dihydroxy-170-pregna-5,15-diene-17-carboxylic acid y-lactone; 3B,21~-dihydroxy-170-pregna-5,15-diene-17-carboxylic acid y-lactone 3-acetate; 3B, 21-dihydroxy-17a-pregn-5-ene-17-carboxylic acid vy-lactone; 3B, 21-dihydroxy-170-pregn-5-ene-17-carboxylic acid v-lactone 3-acetate; 21-hydroxy-3-oxo-170-pregn-4-ene-17-carboxylic acid
Y-lactone; 21-hydroxy-3-oxo-170-pregna-4,6-diene-17-carboxylic acid y-lactone; 21-hydroxy-3-oxo-170-pregna-1,4-diene-17-carboxylic acid y-lactone; 70-acylthio-21-hydroxy-3-0oxo-170-pregn-4-ene-17- carboxylic acid ylactone; and 70-acetylthio-21-hydroxy-3-oxo-170-pregn-4-ene-17- . carboxylic acid y-lactone.
Methods to make the compounds of Formula III are described in U.S. Patent No. 3,257,390 to Patchett which } issued 21 June 1966. ¢ 5 Still another family of non-epoxy-steroidal compounds of interest is represented by Formula IV:
LT
. lo}
J av)
R
£! 0 / E" wherein E’ is selected from the group consisting of ethylene, vinylene and (lower alkanoyl)thioethylene radicals, E” is selected from the group consisting of ethylene, vinylene, (lower alkanoyl)thiocethylene and (Lower alkanoyl)thiopropylene radicals; R is a methyl radical except when E’ and E” are ethylene and (lower alkanoyl) thioethylene radicals, respectively, in which case R is selected from the group consisting of hydrogen and methyl radicals; and the selection of E/ and E” is such that at least one (lower alkanoyl)thio radical is present.
A preferred family of non-epoxy-steroidal compounds within Formula IV is represented by Formula V: } 1 1 0 o CHs HG lower allyl) — Vv) 0
A more preferred compound of Formula V is l-acetylthio-17a- (2-carboxyethyl) -17p-hydroxy-androst-4- en-3-one lactone.
Another preferred family of non-epoxy-steroidal compounds within Formula IV is represented by Formula
VI:
T° , 0 *
CH; AH (VD) 0) o a. lower alkyl
More preferred compounds within Formula VI include the following: . 15 70-acetylthio-170- (2-carboxyethyl) -17B-hydroxy~ } androst-4-en-3-one lactone; 7B-acetylthio-17a- (2-carboxyethyl) -17B3-hydroxy- androst-4-en-3-one lactone;
1x, 7a-diacetylthio-170- (2-carboxyethyl) -173- hydroxy-androsta-4,6-dien-3-one lactone; : : 7a-acetylthio-17a- (2-carboxyethyl) -17B-hydroxy- androsta-1,4-dien-3-one lactone; ’ 5 70-acetylthio-170- (2-carboxyethyl) -17B-hydroxy-19- norandrost-4-en-3-one lactone; and 7a-acetylthio-17a- (2-carboxyethyl) -17B-hydroxy-6&- . methylandrost-4-en-3-one lactone;
In Formulae IV-VI, the term “alkyl” is intended to embrace linear and branched alkyl radicals containing one to about eight carbons. The term “(lower alkanoyl) thio” embraces radicals of the formula lower 0 alkyl —h—s i
Of particular interest is the compound spironolactone having the following structure and formal name :
Q oD © "SCOCH; wspironolactone”: 17-hydroxy-70-mercapto-3-oxo-174- . pregn-4-ene-21l-carboxylic acid y-lactone acetate. . Methods to make compounds of Formulae IV-VI are described in U.S. Patent No. 3,013,012 to Cella et al. which issued 12 December 1961. Spironolactone is sold by G.D. Searle & Co., Skokie, Illinois, under the trademark “ALDACTONE”, in tablet dosage form at doses of 25 mg, 50 mg and 100 mg per tablet.
Another family of steroidal aldosterone antagonists . 5 is exemplified by drospirenone, [6R- (6alpha, 7alpha, 8beta, 9alpha, 10beta, 13beta, 14alpha, 15alph a,l6alpha, 17beta)]- 1,3',4',6,7,8,9,10,11,12,13,14,15,16,20,21-hex adecahydro-10, 13-dimethylspiro[17H- dicyclopropal6,7:15,16]cyclopenta [a] phenanthrene- 17,2" (5'H) -furan] -3,5' (2H) -dione, CAS registration number 67392-87-4. Methods to make and use drospirenone are described in patent GB 1550568 1979, priority DE 2652761 1976.
The term “treatment” or “treating” includes the : administration, to a person in need, of an amount of an aldosterone antagonist and NSAID combination that will : 20 inhibit or reverse development of a pathological cardiovascular condition.
The term "prevention" or “preventing” includes either preventing the onset of clinically evident cardiovascular disorders altogether or preventing the onset of a preclinically evident stage of cardiovascular disorder in individuals. This includes prophylactic treatment of those at risk of developing a cardiovascular disorder. * 30
The phrase "therapeutically-effective" is intended : to qualify the amount of the two agents given in combination which will achieve the goal of improvement in disorder severity and the frequency of incidence, while avoiding adverse side effects.
The term "subject" for purposes of treatment includes any human or animal subject (preferably mammalian and including, but not limited to, domesticated animals such as those from the bovine, porcine, ovine or equine families, and companion animals such as those from the canine and feline family), susceptible to or suffering from a cardiovascular disorders, and preferably is a human subject. The subject, for example, may be at risk due to diet, exposure to bacterial or viral infection, having common markers present, being genetically predisposed to the cardiovascular disorders, and the like.
The terms “aldosterone antagonist” and “aldosterone receptor antagonist” include a compound that inhibits the binding of aldosterone to mineralocorticoid receptors thereby blocking the biological effects of aldosterone.
The terms “non-steroidal anti-inflammatory drug” or : “NSAID” include a compound whose structure lacks a steroid ring and prevents, reduces or inhibits an inflammatory response in a tissue or organ.
The term “pro-inflammmatory” characterizes molecules produced in the body to induce, activate or enhance an inflammatory response in a tissue or organ. . 30 The term "hydrido" denotes a single hydrogen atom (H). This hydrido radical may be attached, for example, . to an oxygen atom to form a hydroxyl radical or two hydrido radicals may be attached to a carbon atom to form a methylene (-CHz-) radical. Where used, either alone or within other terms such as "haloalkyl",
"alkylsulfonyl", "alkoxyalkyl" and "hydroxyalkyl", the term "alkyl" embraces linear or branched radicals having one to about twenty carbon atoms or, preferably, one to about twelve carbon atoms. More preferred alkyl radicals . 5 are "lower alkyl" radicals having one to about ten carbon atoms. Most preferred are lower alkyl radicals having one to about six carbon atoms. Examples of such radicals include methyl, ethyl, n-propyl, isopropyl, n- butyl, isobutyl, sec-butyl, tert-butyl, pentyl, iso- amyl, hexyl and the like. The term "alkenyl" embraces linear or branched radicals having at least one carbon- carbon double bond of two to about twenty carbon atoms or, preferably, two to about twelve carbon atoms. More preferred alkyl radicals are "lower alkenyl" radicals having two to about six carbon atoms. Examples of alkenyl radicals include ethenyl, propenyl, allyl, propenyl, butenyl and 4-methylbutenyl. The term "alkynyl" denotes linear or branched radicals having two to about twenty carbon atoms or, preferably, two to about twelve carbon atoms. More preferred alkynyl radicals are "lower alkynyl" radicals having two to about ten carbon atoms. Most preferred are lower alkynyl radicals having two to about six carbon atoms.
Examples of such radicals include propargyl, butynyl, and the like. The terms "alkenyl", "lower alkenyl", embrace radicals having "cis" and "trans" orientations, or alternatively, "E" and "Z" orientations. The term "cycloalkyl" embraces saturated carbocyclic radicals h having three to twelve carbon atoms. More preferred cycloalkyl radicals are "lower cycloalkyl" radicals having three to about eight carbon atoms. Examples of such radicals include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. The term "cycloalkenyl™ embraces partially unsaturated carbocyclic radicals having three to twelve carbon atoms. More preferred . cycloalkenyl radicals are "lower cycloalkenyl" radicals having four to about eight carbon atoms. Examples of 5 such radicals include cyclobutenyl, cyclopentenyl, cyclopentadienyl, and cyclohexenyl. The term "halo" means halogens such as fluorine, chlorine, bromine or iodine. The term "haloalkyl" embraces radicals wherein any one or more of the alkyl carbon atoms is substituted with halo as defined above. Specifically embraced are monchaloalkyl, dihaloalkyl and polyhaloalkyl radicals.
A monohaloalkyl radical, for one example, may have either an iodo, bromo, chloro or fluoro atom within the radical. Dihalo and polyhaloalkyl radicals may have two or more of the same halo atoms or a combination of different halo radicals. "Lower haloalkyl" embraces radicals having 1-6 carbon atoms. Examples of haloalkyl radicals include fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluorocethyl, difluoropropyl, dichloroethyl and dichloropropyl. The term "hydroxyalkyl" embraces linear or branched alkyl radicals having one to about ten carbon atoms any one of which may be substituted with one or more hydroxyl radicals. More preferred hydroxyalkyl radicals are "lower hydroxyalkyl" radicals having one to six carbon ) atoms and one or more hydroxyl radicals. Examples of such radicals include hydroxymethyl, hydroxyethyl, : hydroxypropyl, hydroxybutyl and hydroxyhexyl. The terms "alkoxy" and "alkyloxy" embrace linear or branched oxy- containing radicals each having alkyl portions of one to about ten carbon atoms. More preferred alkoxy radicals - are "lower alkoxy" radicals having one to six carbon ) atoms. Examples of such radicals include methoxy, ethoxy, propoxy, butoxy and tert-butoxy. The term . 5 "alkoxyalkyl" embraces alkyl radicals having one or more alkoxy radicals attached to the alkyl radical, that is, to form monoalkoxyalkyl and dialkoxyalkyl radicals. The "alkoxy" radicals may be further substituted with one or more halo atoms, such as fluoro, chloro or bromo, to provide haloalkoxy radicals. More preferred haloalkoxy radicals are "lower halocalkoxy" radicals having one to six carbon atoms and one or more halo radicals.
Examples of such radicals include fluoromethoxy, chloromethoxy, trifluoromethoxy, trifluoroethoxy, fluoroethoxy and f£luoropropoxy. The term "aryl", alone or in combination, means a carbocyclic aromatic system containing one, two or three rings wherein such rings may be attached together in a pendent manner or may be fused. The term "aryl" embraces aromatic radicals such as phenyl, naphthyl, tetrahydronaphthyl, indane and biphenyl. Aryl moieties may also be substituted at a substitutable position with one or more substituents selected independently from alkyl, alkoxyalkyl, alkylaminoalkyl, carboxyalkyl, alkoxycarbonylalkyl, aminocarbonylalkyl, alkoxy, aralkoxy, hydroxyl, amino, halo, nitro, alkylamino, acyl, cyano, carboxy, aminocarbonyl, alkoxycarbonyl and aralkoxycarbonyl. The term "heterocyclyl" embraces saturated, partially ) unsaturated and unsaturated heteroatom-containing ring- shaped radicals, where the heteroatoms may be selected from nitrogen, sulfur and oxygen. Examples of saturated heterocyclyl radicals include saturated 3 to 6-membered heteromonocylic group containing 1 to 4 nitrogen atoms
(e.g. pyrrolidinyl, imidazolidinyl, piperidino, piperazinyl, etc.); saturated 3 to 6-membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms (e.g. morpholinyl, etc.); . 5 saturated 3 to 6-membered heteromonocyclic group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms (e.g., thiazolidinyl, etc.). Examples of partially unsaturated heterocyclyl radicals include : dihydrothiophene, dihydropyran, dihydrofuran and 10 dihydrothiazole.
The term "heteroaryl" embraces unsaturated heterocyclyl radicals.
Examples of unsaturated heterocyclyl radicals, also termed "heteroaryl" radicals include unsaturated 3 to 6 membered heteromonocyclic group containing 1 to 4 15 nitrogen atoms, for example, pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazolyl (e.g., 4H-1,2,4-triazolyl, 1H- 1,2,3-triazolyl, 2H-1,2,3-triazolyl, etc.) tetrazolyl (e.g. 1lH-tetrazolyl, 2H-tetrazolyl, etc.), etc.; 20 unsaturated condensed heterocyclyl group containing 1 to nitrogen atoms, for example, indolyl, isoindolyl, indolizinyl, benzimidazolyl, quinolyl, isoquinolyl, indazolyl, benzotriazolyl, tetrazolopyridazinyl (e.g., tetrazolo[l,5-blpyridazinyl, etc.), etc.; unsaturated 3 to 6-membered heteromonocyclic group containing an oxygen atom, for example, pyranyl, furyl, etc.; unsaturated 3 to 6-membered heteromonocyclic group : containing a sulfur atom, for example, thienyl, etc.; ' unsaturated 3- to 6-membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms, for example, oxazolyl, isoxazolyl, oxadiazolyl (e.g., 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,5- oxadiazolyl, etc.) etc.; unsaturated condensed :
heterocyclyl group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms (e.g. benzoxazolyl, benzoxadiazolyl, , etc.) ; unsaturated 3 to 6-membered heteromonocyclic group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen . 5 atoms, for example, thiazolyl, thiadiazolyl (e.g.,
1,2,4- thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5-
thiadiazolyl, etc.) etc.; unsaturated condensed heterocyclyl group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms (e.g., benzothiazolyl,
benzothiadiazolyl, etc.) and the like.
The term also embraces radicals where heterocyclyl radicals are fused : with aryl radicals.
Examples of such fused bicyclic radicals include benzofuran, benzothiophene, and the like.
Said "heterocyclyl group" may have 1 to 3 substituents such as alkyl, hydroxyl, halo, alkoxy, oxo, amino and alkylamino.
The term "alkylthio" embraces radicals containing a linear or branched alkyl radical, of one to about ten carbon atoms attached to a divalent sulfur atom.
More preferred alkylthio radicals are
"lower alkylthio" radicals having alkyl radicals of one to six carbon atoms.
Examples of such lower alkylthio radicals are methylthio, ethylthio, propylthio, : butylthio and hexylthio.
The term "alkylthioalkyl™ embraces radicals containing an alkylthio radical attached through the divalent sulfur atom to an alkyl radical of one to about ten carbon atoms.
More . preferred alkylthioalkyl radicals are "lower : alkylthiocalkyl" radicals having alkyl radicals of one to ) six carbon atoms.
Examples of such lower alkylthiocalkyl radicals include methylthiomethyl.
The term "alkylsulfinyl" embraces radicals containing a linear or branched alkyl radical, of one to ten carbon atoms, attached to a divalent -S(=0)- radical.
More preferred alkylsulfinyl radicals are "lower alkylsulfinyl" : radicals having alkyl radicals of one to six carbon . atoms. Examples of such lower alkylsulfinyl radicals include methylsulfinyl, ethylsulfinyl, butylsulfinyl and - 5 hexylsulfinyl. The term "sulfonyl", whether used alone or linked to other terms such as alkylsulfonyl, denotes respectively divalent radicals -803-. "Alkylsulfonyl" : embraces alkyl radicals attached to a sulfonyl radical, where alkyl is defined as above. More preferred alkylsulfonyl radicals are "lower alkylsulfonyl” radicals having one to six carbon atoms. Examples of such lower alkylsulfonyl radicals include
E methylsul fonyl, ethylsulfonyl and propylsulfonyl. The nalkylsulfonyl" radicals may be further substituted with one or more halo atoms, such as fluoro, chloro or bromo, to provide haloalkylsulfonyl radicals. The terms ngulfamyl"”, "aminosulfonyl" and "gul fonamidyl" denote
NH202S-. The term "acyl" denotes a radical provided by the residue after removal of hydroxyl from an organic acid. Examples of such acyl radicals include alkanoyl and aroyl radicals. Examples of such lower alkanoyl radicals include formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, pivaloyl, hexanoyl, trifluoroacetyl. The term "carbonyl", whether used alone or with other terms, such as "alkoxycarbonyl", denotes -(C=0)-. The term "aroyl" embraces aryl : radicals with a carbonyl radical as defined above. . Examples of aroyl include benzoyl, naphthoyl, and the like and the aryl in said aroyl may be additionally . 30 gubstituted. The terms "carboxy" or "carboxyl", whether used alone or with other terms, such as "carboxyalkyl", denotes -COoH. The term "carboxyalkyl" embraces alkyl radicals substituted with a carboxy radical. More preferred are "lower carboxyalkyl" which embrace lower alkyl radicals as defined above, and may be additionally substituted on the alkyl radical with halo.
Examples of : such lower carboxyalkyl radicals include carboxymethyl,
. 5 carboxyethyl and carboxypropyl.
The term "alkoxycarbonyl" means a radical containing an alkoxy radical, as defined above, attached via an oxygen atom to a carbonyl radical.
More preferred are "lower alkoxycarbonyl" radicals with alkyl porions having 1 to
6 carbons.
Examples of such lower alkoxycarbonyl (ester) radicals include substituted or unsubstituted methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl and hexyloxycarbonyl.
The terms "alkylcarbonyl', "arylcarbonyl" and "aralkylcarbonyli® :
include radicals having alkyl, aryl and aralkyl : radicals, as defined above, attached to a carbonyl radical.
Examples of such radicals include substituted or unsubstituted methylcarbonyl, ethylcarbonyl, phenylcarbonyl and benzylcarbonyl.
The term "aralkyl"
embraces aryl-substituted alkyl radicals such as benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, and diphenylethyl.
The aryl in said aralkyl may be additionally substituted with halo, alkyl, alkoxy, halkoalkyl and haloalkoxy.
The terms benzyl and phenylmethyl are interchangeable.
The term "heterocyclylalkyl" embraces saturated and partially unsaturated heterocyclyl-substituted alkyl radicals, such as pyrrolidinylmethyl, and heterocaryl-substituted
) alkyl radicals, such as pyridylmethyl, quinolylmethyl,
thienylmethyl, furylethyl, and quinolylethyl.
The heteroaryl in said heteroaralkyl may be additionally substituted with halo, alkyl, alkoxy, halkoalkyl and haloalkoxy.
The term "aralkoxy" embraces aralkyl radicals attached through an oxygen atom to other radicals.
The term "aralkoxyalkyl" embraces aralkoxy . radicals attached through an oxygen atom to an alkyl radical.
The term "aralkylthio" embraces aralkyl : : 5 radicals attached to a sulfur atom.
The term "aralkylthioalkyl" embraces aralkylthio radicals attached through a sulfur atom to an alkyl radical.
The term "aminoalkyl" embraces alkyl radicals substituted with one or more amino radicals.
More preferred are
"lower aminoalkyl" radicals.
Examples of such radicals include aminomethyl, aminoethyl, and the like.
The term "alkylamino" denotes amino groups which have been substituted with one or two alkyl radicals.
Preferred are "lower N-alkylamino" radicals having alkyl portions -
having 1 to 6 carbon atoms.
Suitable lower alkylamino may be mono or dialkylamino such as N-methylamino, N- ethylamino, N,N-dimethylamino, N,N-diethylamino or the like.
The term "arylamino" denotes amino groups which have been substituted with one or two aryl radicals,
such as N-phenylamino.
The "arylamino" radicals may be further substituted on the aryl ring portion of the radical.
The term "aralkylamino" embraces aralkyl . radicals attached through an amino nitrogen atom to other radicals.
The terms "N-arylaminoalkyl" and "N-
aryl-N-alkyl-aminoalkyl" denote amino groups which have been substituted with one aryl radical or one aryl and one alkyl radical, respectively, and having the amino group attached to an alkyl radical.
Examples of such radicals include N-phenylaminomethyl and N-phenyl-N-
methylaminomethyl.
The term "aminocarbonyl" denotes an amide group of the formula -C(=O)NHp.
The term "alkylaminocarbonyl" denotes an aminocarbonyl group which hag been substituted with one or two alkyl radicals on the amino nitrogen atom. Preferred are "N- alkylaminocarbonyl" "N,N-dialkylaminocarbonyl" radicals.
More preferred are "lower N-alkylaminocarbonyl" "lower
N,N-dialkylaminocarbonyl" radicals with lower alkyl . 5 portions as defined above. The term "alkylaminoalkyl" embraces radicals having one or more alkyl radicals attached to an aminoalkyl radical. The term "aryloxyalkyl" embraces radicals having an aryl radical attached to an alkyl radical through a divalent oxygen atom. The term "arylthiocalkyl" embraces radicals having an aryl radical attached to an alkyl radical through a divalent sulfur atom.
The compounds utilized in the methods of the present invention may be present in the form of free bases or pharmaceutically acceptable acid addition salts thereof. The term "pharmaceutically-acceptable salts" embraces salts commonly used to form alkali metal salts and to form addition salts of free acids or free bases.
The nature of the salt is not critical, provided that it is pharmaceutically-acceptable. Suitable pharmaceutically-acceptable acid addition salts of compounds of the present invention may be prepared from an inorganic acid or from an organic acid. Examples of such inorganic acids are hydrochloric, hydrobromic, hydroiodic, nitric, carbonic, sulfuric and phosphoric acid. Appropriate organic acids may be selected from aliphatic, cycloaliphatic, aromatic, araliphatic, : heterocyclic, carboxylic and sulfonic classes of organic acids, example of which are formic, acetic, propionic, ’ succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, mesylic, 4-
hydroxybenzoic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic, benzenesulfonic, pantothenic, 2-hydroxyethanesulfonic, toluenesulfonic, sulfanilic, cyclohexylaminosulfonic, . 5 stearic, algenic, b-hydroxybutyric, salicylic, galactaric and galacturonic acid. Suitable pharmaceutically-acceptable base addition salts include metallic salts made from aluminum, calcium, lithium, magnesium, potassium, sodium and zinc or organic salts made from N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N- methylglucamine) and procaine. All of these salts may be prepared by conventional means from the corresponding compound by reacting, for example, the appropriate acid or base with the compound.
COMBINATIONS
The present invention is further directed to combinations comprising an aldosterone antagonist and a
NSAID. In one embodiment, the combination is a pharmaceutical composition comprising an aldosterone antagonist and a NSAID. One illustrative, nonlimiting example is a pharmaceutical composition comprising eplerenone and diclofenac. .
PHARMACEUTICAL COMPOSITIONS
The present invention comprises a pharmaceutical composition for the prevention or treatment of , cardiovascular disorders, comprising a therapeutically- effective amount of an aldosterone antagonist and NSAID : combination in association with at least one pharmaceutically-acceptable carrier, adjuvant or diluent (collectively referred to herein as "carrier" materials) and, if desired, other active ingredients. The active compounds of the present invention may be administered by any suitable route known to those skilled in the art, . preferably in the form of a pharmaceutical composition adapted to such a route, and in a dose effective for the . 5 treatment intended. The active compounds and composition may, for example, be administered orally, intravascularly, intraperitoneally, intranasally, intrabronchially, subcutaneously, intramuscularly or topically (including aerosol) .
Administration of aldosterone antagonist and
NSAID combination may take place sequentially in separate formulations, or may be accomplished by simultaneous administration in a single formulation or separate formulations. Administration may be accomplished by oral route, or by intravenous, intramuscular or subcutaneous injections. The formulation may be in the form of a bolus, or in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions. These solutions and suspensions may be prepared from sterile powders or granules having one or more pharmaceutically-acceptable carriers or diluents, or a binder such as gelatin or hydroxypropyl-methyl cellulose, together with one or more of a lubricant, preservative, surface-active or dispersing agent.
For oral administration, the pharmaceutical composition may be in the form of, for example, a tablet, capsule, suspension or liquid. The : pharmaceutical composition is preferably made in the form of a dosage unit containing a particular amount of : the active ingredient. Examples of such dosage units are tablets or capsules. These may contain, for example, an amount of each active ingredient from about 1 mg to about 1000 mg, or about 5 mg to about 500 mg, or about mg to about 250 mg, or about 25 mg to about 150 mg. A suitable daily dose for a mammal may vary widely . : depending on the condition of the patient and other factors. However, a dose of from about 0.01 to 30 mg/kg ] 5 body weight, particularly from about 1 to 15 mg/kg body weight, may be appropriate.
The active ingredients may also be administered by injection as a composition wherein, for 10 example, saline, dextrose or water may be used as a suitable carrier. A suitable daily dose of each active component is from about 0.01 to 15 mg/kg body weight injected per day in multiple doses depending on the disease being treated. A preferred daily dose would be from about 1 to 10 mg/kg body weight. Compounds indicated for prophylactic therapy will preferably be administered in a daily dose generally in a range from about 0.1 mg to about 15 mg per kilogram of body weight per day. A more preferred dosage will be a range from about 1 mg to about 15 mg per kilogram of body weight.
Most preferred is a dosage in a range from about 1 to about 10 mg per kilogram of body weight per day. A suitable dose can be administered, in multiple sub-doses per day. These sub-doses may be administered in unit dosage forms.
In one embodiment the aldosterone receptor antagonist may be present in an amount in a range from about 1 mg to about 200 mg, and the NSAID may be present in an amount in a range from about 1 mg to about 800 mg, which represents aldosterone antagonist-to-NSAID ratios . ranging from about 200:1 to about 1:800. “ In another embodiment, the aldosterone receptor antagonist may be present in an amount in a range from about 5 mg to about 400 mg, and the NSAID may be present in an amount in a range from about 1 mg to about 200 mg, which represents aldosterone antagonist- to-NSAID ratios ranging from about 400:1 to about 1:40.
In another embodiment, the aldosterone receptor antagonist may be present in an amount in a range from about 10 mg to about 200 mg, and the NSAID may be present in an amount in a range from about 5 mg to about 100 mg, which represents aldosterone antagonist-to-NSAID ratios ranging from about 40:1 to about 1:10.
In another embodiment, the aldosterone receptor antagonist may be present in an amount in a range from about 20 mg to about 100 mg, and NSAID may be present in an amount in a range from about 10 mg to about 80 mg, which represents aldosterone antagonist-to--
NSAID ratios ranging from about 10:1 to about 1:4.
The NSAID dose administered to the subject or contained in the pharmaceutical composition can vary and generally will depend on the particular NSAID used, inherent potency, bioavailability and metabolic lability of the composition and whethter it has been formulated for immediate release or extended release.
Non-limiting examples of dose ranges for specific NSAIDs are listed below:
Component | COMPOUND | ILLUSTRATIVE | ILLUSTRATIVE
Number DOSAGE FORM DOSE 2.5 mg — 650 mg
Nz [bemowspofen
EE I ca EE
N-4 diclofenac tablet/oral; 0.2mg-75 mg gel; 3% ’ solution 0.1% tablet/oral 250 mg — 500 mg 400 mg — 600 mg 200 mg 400 mg
N-8 flurbiprofen capsule/oral; 50 mg — 100 mg solution 0.03%
ibuprofen tablet/oral; 7.5 mg — 800 mg suspension; 40 mg/ml — 100 mg/5 ml
N-10 indomethacin capsule/oral; 25 mg—75 mg suppository; 25 mg - 50 mg ! injectable/injection 1 mg capsule/oral 25 mg — 200 mg
N12 ketorolc | 1 ‘ N13 | medofemamate capsule/oral [250mg tablet/oral 500 mg — 750 mg naproxen suspension 25 mg tablet/oral 250 mg — 500 mg tablet/oral (N18 [oxyphembutagome phenylbutazone I tablet/oral 150 mg —200 mg
N23 (temdsp | 1 tablet/oral 200 mg — 600 mg
N25 |zomepiac | [ tablet/oral 0.19 mg — 770 mg
One of ordinary skill in the art will be capable of using these dose ranges as a suitable starting point to administer this therapy, after which the dose may be titrated up or down, depending on the response of the subject being treated.
The dosage regimen for treating a disease condition with the combination therapy of this invention is selected in accordance with a variety of factors, including the type, age, weight, sex and medical condition of the patient, the severity of the disease, the route of administration, and the particular compound employed, and thus may vary widely. > Below, non-limiting examples of combinations of the present invention are listed wherein the - combination comprises a first amount of an aldosterone receptor antgonist and a second amount of a NSAID wherein the first amount and second amount together comprise a therapeutically-effective amount of an aldosterone receptor antagonist and a NSAID: estes | we a [Eee | we
IT RC I
Tas | seiewelseone | ©
For therapeutic purposes, the active components of this combination therapy invention are ordinarily combined with one or more adjuvants appropriate to the indicated route of administration. If administered per os, the components may be admixed with lactose, sucrose, starch powder, cellulose esters of alkanoic acids, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and ) calcium salts of phosphoric and sulfuric acids, gelatin, acacia gum, sodium alginate, polyvinylpyrrolidone, and/or polyvinyl alcohol, and then tableted or : encapsulated for convenient administration. Such capsules or tablets may contain a controlled-release formulation as may be provided in a dispersion of active compound in hydroxypropylmethyl cellulose. Formulations for parenteral administration may be in the form of agueous or non-agueous isotonic sterile injection solutions or suspensions. These solutions and suspensions may be prepared from sterile powders or ’ ~ granules having one or more of the carriers or diluents mentioned for use in the formulations for oral administration. The components may be dissolved in water, polyethylene glycol, propylene glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, and/or various buffers. Other adjuvants and modes of administration are well and widely known in the pharmaceutical art.
The present invention further comprises kits that are suitable for use in performing the methods of : treatment and/or prophylaxis described above. In one embodiment, the kit contains a first dosage form comprising one or more of the epoxy-steroidal aldosterone antagonists previously identified and a second dosage form comprising a NSAID identified in
Table 1 in quantities sufficient to carry out the methods of the present invention. Preferably, the first dosage form and the second dosage form together comprise a therapeutically effective amount of the compounds. In another embodiment, the kit further comprises written instructions stating how the contents of the kit can be used by the subject. The written instructions will be useful, for example, for the subject to obtain a therapeutic effect without inducing unwanted side- effects. In another embodiment the written instructions . comprise all or a part of the product label approved by a drug regulatory agency for the kit.
Crystalline Forms of Active Compounds
It is particularly useful to select a form of each i active compound that is easily handled, reproducible in form, easily prepared, stable and which is non- hygroscopic. By way of illustration and not limitation, several crystalline forms have been identified for the aldosterone antagonist eplerenone. These include Form H,
Form L, various crystalline solvates and amorphous eplerenone. These forms, methods to make these forms and use of these forms in preparing compositions and medicaments, are disclosed in the following publications, incorporated herein by reference:
WO 01/41535 and WO 01/42272.
Subject Populations
Certain groups are more prone to disease modulating effects of aldosterone. Members of these groups that are sensitive to aldosterone are typically also salt sensitive, wherein individuals blood pressure generally rises and falls with increased and decreased sodium consumption, respectively. While the : present invention is not to be construed as limited in practice to these groups, it is contemplated that certain subject groups may be particularly suited for therapy with an anti-inflammatory dose of an aldosterone blocker of the present invention. 300 Accordingly, subjects who can benefit from treatment ] or prophylaxis in accordance with the method of the present invention are human subjects generally exhibiting one or more of the following characteristics:
(a) the average daily intake of sodium chloride by . the subject is at least about 4 grams, particularly where this condition is satisfied over any one month : 5 interval for at least one or more monthly intervals over a given annual period.
The average daily intake of sodium by the subject preferably is at least about 6 : grams, more preferably at least about 8 grams, and still more preferably at least about 12 grams.
(b) the subject exhibits an increase in systolic blood pressure and/or diastolic blood pressure of at least about 5%, preferably at least about 7%, and more preferably at least about 10%, when daily sodium chloride intake by the subject is increased from less than about 3 g/day to at least about 10 g/day.
(¢) the activities ratio of plasma aldosterone (ng/dL) to plasma renin (ng/ml/hr) in the subject is greater than about 30, preferably greater than about 40, more preferably greater than about 50; and still more preferably greater than about 60.
(d) the subject has low plasma renin levels; for example, the morning plasma renin activity in the subject is less than about 1.0 ng/dL/hr, and/or the active renin value in the subject is less than about 15 pg/mL.
(¢) the subject suffers from or is susceptible to
* elevated systolic and/or diastolic blood pressure.
In general, the systolic blood pressure (measured, for example, by seated cuff mercury sphygmomanometer) of the subject is at least about 130 mm Hg, preferably at least about 140 mm Hg, and more preferably at least about about 150 mm Hg, and the diastolic blood pressure (measured, for example, by seated cuff mercury . sphygmomanometer) of the subject is at least about 85 mm
Hg, preferably at least about 90 mm Hg, and more . 5 preferably at least about 100 mm Hg. (f) the urinary sodium to potassium ratio (mmol /mmol) of the subject is less than about 6, preferably less than about 5.5, more preferably less than about 5, and still more preferably less than about 4.5. (g) the urinary sodium level of the subject is at least 60 mmol per day, particularly where this condition is satisfied over any one month interval for at least one or more monthly intervals over a given annual period. The urinary sodium level of the subject preferably is at least about 100 mmol per day, more preferably at least about 150 mmol per day, and still : more preferably 200 mmol per day. (h) the plasma concentration of one or more endothelins, particularly plasma immunoreactive ET-1, in the subject is elevated. Plasma concentration of ET-1 preferably is greater than about 2.0 pmol/L, more preferably greater than about 4.0 pmol/L, and still more preferably greater than about 8.0 pmol/L. (i) the subject has blood pressure that is . substantially refractory to treatment with an ACE * inhibitor; particularly a subject whose blood pressure is lowered less than about 8 mm Hg, preferably less than ’ 5 mm Hg, and more preferably less than 3 mm Hg, in response to 10 mg/day enalapril compared to the blood pressure of the subject on no antihypertensive therapy.
. (i) the subject has blood volume-expanded hypertension or blood volume-expanded borderline . hypertenision, that is, hypertension wherein increased blood volume as a result of increased sodium retension ‘ 5 contributes to blood pressure.
(k) the subject is a non-modulating individual, that ig, the individual demonstrates a blunted positive response in renal blood flow rate and/or in adrenal production of aldosterone to an elevation in sodium intake or to angiotensin II administration, particularly when the response is less than the response of individuals sampled from the general geographical population (for example, individuals sampled from the subject's country of origin or from a country of which the subject is a resident), preferably when the response ig less than 40% of the mean of the population, more preferably less than 30%, and more preferably still less than 20%.
(I) the subject has or is susceptible to renal dysfunction, particularly renal dysfunction selected from one or more members of the group consisting of reduced glomerular filtration rate, microalbuminuria, and proteinuria.
(m) the subject has or is susceptible to
95 cardiovascular disease, particularly cardiovascular disease selected from one or more members of the group
. consisting of heart failure, left ventricular diastolic dysfunction, hypertrophic cardiomyopathy, and diastolic : heart failure.
(n) the subject has or is susceptible to liver disease, particularly liver cirrhosis.
(0) the subject has or is susceptible to edema, particularly edema selected from one or more members of ) the group consisting of peripheral tissue edema, hepatic or splenic congestion, liver ascites, and respiratory or . 5 lung congestion. (p) the subject has or is susceptible to insulin resistance, particularly Type I or Type II diabetes mellitus, and/or glucose sensitivity. (gq) the subject is at least 55 years of age, preferably at least about 60 years of age, and more preferably at least about 65 years of age. (r) the subject is, in whole or in part, a member of at least one ethnic group selected from the Asian (particularly from the Japanese) ethnic group, the
American Indian ethnic group, and the Black ethnic group. (s) the subject has one or more genetic markers associated with salt sensitivity. (t) the subject is obese, preferably with greater "20 than 25% body fat, more preferably with greater than 30% body fat, and even more preferably with greater than 35% body fat. (u) the subject has one or more 1st, 27, or 3 degree relatives who are or were salt sensitive, wherein 15% degree relatives means parents or relatives sharing : one or more of the same parents, ond degree relatives means grandparents and relatives sharing one or more of ) the same grandparents, and 3™ degree relatives means great-grandparents and relatives sharing one or more of the same great-grandparents. Preferably, such individuals have four or more salt sensitive 15%, 27, or 3 degree relatives; more preferably, eight or more such relatives; even more preferably, 16 or more such relatives; and even more preferably still, 32 or more } 5 such relatives.
Unless otherwise indicated to the contrary, the values listed above preferably represent an average : value, more preferably a daily average value based on at least two measurements.
Preferably, the subject in need of treatment satisfies at least two or more of the above- characteristics, or at least three or more of the above- characteristics, or at least four or more of the above- characteristics.
Biological Evaluation
Human cardiovascular disorders are complex conditions, often initiated by vascular hypertension or a myocardial infarction (MI). In order to determine the probable effectiveness of a therapy for cardiovascular disorders, it is important to determine the potency of components in several assays. Accordingly, in Assay "A", the efficacy of the aldosterone antagonist eplerenone (epoxymexrenone) was determined in a hypertensive rat model with vascular inflammation, using angiotensin II infusion. In Assay "B" a study is * described evaluating the efficacy of the aldosterone antagonist eplerenone (epoxymexrenone) in a rat model ’ 30 using aldosterone infusion to produce hypertension with vascular inflammation. In Assay "C" a further study is described evaluating the efficacy of the aldosterone antagonist eplerenone (epoxymexrenone) in a rat model using aldosterone infusion to produce hypertension with . vascular inflammation. . 5 In addition, clinical trials can be used to evaluate aldosterone antagonist therapy in humans.
Numerous examples of such therapeutic tests have been published, including those of the RALES 003 study : described in American Journal of Cardiology 78, 902-907 (1996) or the RALES 004 study described in New England
Journal of Medicine 341, 709-717 (1999).
Assay A: In Vivo Angiotensin II Infusion Model
Protocol:
Methods: e Male Wistar rats (n=50, 10/group; BW=200 9) e 1% NaCl to drink e Experimental groups ‘ 1. Control : 2. Angiotensin II (25 ng/min, sc via alzet minipump) 3. Angiotensin II (25 ng/min, sc) + eplerenone 100 mpk . 4. Angiotensin II (25 ng/min, sc) + adrenalectomy + dexamethasone (12 pg/kg/d, sc) g 30 5. Angiotensin II (25 ng/min, sc) + adrenalectomy + dexamethasone (12 pg/kg/d, sc) + aldosterone (40 mg/kg/d, sc via alzet minipump)
e SBP measured by tail-cuff every week e 24-hours food and fluid intake and urine output . measured every day e Urine samples collected every day for determination ' 5 of urinary electrolytes. e Sacrifice by exanguination after 4 weeks. Blood was be collected in dry tubes for determination of serum electrolytes and in EDTA-containing tubes for measurement of aldosterone and corticosterone levels e Hearts were stained with hematoxylin&eosin and have been analyzed for determination of morphologic abnormalities (i.e. necrosis, vascular injury) .
Results
Blood pressure. Systolic blood pressure increased in all animals receiving angiotensin II infusion. Neither eplerenone nor adrenalectomy reduced blood pressure when compared to animals receiving vehicle. Aldosterone infusion increased blood pressure in angiotensin
I1I/salt, adrenalectomized rats. Fig. 1 demonstrates this increase in systolic blood pressure. :
Electrolyte excretion. The ratio between daily urinary
Na* excretion and urinary K' excretion (U Na*/K' ratio) was used as an index for natriuresis. Urinary Na’/K' ratio was similar in all groups before the start of the fe treatments, and increased similarly in all animals upon initiation of the high salt diet. Urinary Na'/K' ratio g 30 was not unchanged in animals receiving angiotensin IT infusion until day 17 when it was significantly increased in these animals with respect to the vehicle- infused rats. A similar effect occurred in angiotensin
II-infused animals receiving eplerenone, which demonstrated increases in urinary Na'/K’ ratio from day ; 14 of infusion. However, at no time-point did eplerenone-treated rats demonstrate higher urinary « 5 Na*/K' ratio than angiotensin II-infused rats treated with vehicle. In fact, a significant difference was only observed at day 21, when angiotensin II-infused, vehicle treated rats demonstrated higher urinary Na*/K’ ratio than eplerenone-treated animals indicating that, under these experimental conditions eplerenone did not produce a significant diuretic or natriuretic effect.
Adrenalectomized animals with or without aldosterone infusion always demonstrated higher urinary Na*/K" ratio than the adrenal-intact animals. ~ Myocardial injury. Seven out of the ten angiotensin
II/salt-treated animals developed vascular inflammatory changes in the coronary arteries. These changes were characterized by leukocyte infiltration of the perivascular space, mainly by macrophages. Fibrinoid necrosis of the media was also observed in some arteries. In some cases, when the lesions were extensive there was cardiomyocyte necrosis associated in the surrounding myocardium. Parenchymal hemorrhages were observed in these cases, consistent with findings of myocardial necrosis. These vascular inflammatory : lesions were observed in only one of the ten angiotensin
IT-infused animals receiving eplerenone, despite the ’ fact that these animals were as hypertensive as the vehicle-treated angiotensin II-infused rats. (See Fig. 2). Similarly, adrenalectomy prevented the vascular inflammatory lesions in the heart. However, aldosterone replacement restored the severe coronary and myocardial inflammation and injury observed in angiotensin-II infused, adrenal-intact, vehicle-treated rats.
Immunostaining of the hearts from angiotensin II-infused : 5 rats with a cyclooxgenase-2 specific antibody identified the presence of this enzyme in areas of inflammation around the arteries, mainly in monocyte/macrophages.
Cycloxygenase-2 staining was also observed in the vascular smooth muscle cells of the media of coronary arteries, even when there was no evidence of morphologic alterations or inflammatory aggregates in the perivascular space (Fig. 4). Eplerenone treatment, as well as adrenalectomy markedly reduced and in most cases completely prevented the expression of cycloxygenase-2 in the hearts from angiotensin II-infused rats (See
Figs. 3 and 5). Replacement of aldosterone in angiotensin-II, adrenalectomized rats restored the . presence of cycloxygenase-2 in coronary arteries.
Osteopontin (also known as early T-cell activation- 1, Eta-1) is a secreted glycoprotein with pro- inflammatory characteristics that mediates chemoattraction, activation and migration of monocytes.
Immunostaining of the hearts from angiotensin II- infused, saline-drinking rats with an osteopontin- : specific antibody identified the presence of osteopontin in the media of coronary arteries. Both eplerenone treatment and adrenalectomy prevented osteopontin expression in the hearts of angiotensin II-infused, i gsaline-drinking rats (Figs. 6 and 7). Aldosterone replacement restored osteopontin expression in adrenalectomized animals.
Assay B: In Vivo Aldosterone Infusion Model
Protocol 2:
Methods: * Male Sprague Dawley rats (n=39; BW=250 g) ® 1% NaCl to drink e Uni-nephrectomy performed during implantation of mini-pumps eo Experimental groups 1. Control 2. Aldosterone (0.75 mg/hr, sc via alzet minipump) 2. Aldosterone (0.75 mg/hr, sc via alzet minipump) + eplerenone 100 mpk, p.o 1. Aldosterone (0.75 mg /hr, sc via alzet minipump) + 0.6% KC1 in the drinking fluid e Groups 1, 2 and 3 received only 0.3% KCl in the drinking solution e SBP measured by radio-telemetry probes inserted in the abdominal aorta e Sacrifice after 4 weeks. — Hearts were harvested and divided by half through a transverse section at the mid-ventricles: The upper half was stored into formalin. The bottom part was snap-frozen in liquid nitrogen for biochemical . analysis. * Hearts were stained with hematoxylin & eosin and the collagen specific dye picro-sirius red and were analyzed for determination of interstitial collagen volume fraction and morphologic abnormalities (i.e. necrosis, vascular injury). . e Hydroxyproline concentration was measured in the frozen hearts. : : 5 ee Determination of osteopontin and COX-2 was performed by quantitative RT-PCR (Tagman). Osteopontin was also identified in the heart by immunohistochemistry.
Results
Blood pressure. Systolic blood pressure increased in all animals receiving aldosterone infusion. Eplerenone treatment significantly reduced, but did not normalize blood pressure. Fig. 21 shows these results graphically.
Myocardial injury. Saline-drinking, uni-nephrectomized rats did not have myocardial injury. Determination of interstitial collagen by histologic determination of interstitial collagen volume fraction or by biochemical determination of hydroxyproline concentration evidenced the absence of myocardial fibrosis in animals receiving aldosterone/salt treatment. However, examination of the hematoxilin-eosin-stained hearts from aldosterone/salt- treated rats evidenced severe vascular inflammatory lesions. These lesions were identical to those described in protocol 1. Administration of eplerenone completely prevented the vascular inflammatory changes in aldosterone-infused, saline-drinking, uni- nephrectomized rats (Fig. 10), even though it did not normalize blood pressure. Elevations of dietary potassium did not have significant effects in the development of aldosterone-induced injury, as these
C62 animals demonstrated similar levels of injury as the aldosterone/salt treated rats receiving vehicle.
Serum osteopontin levels were determined at 28 * 5 days, and measured for each group (NaCl 1% drinking rats, NaCl 1% drinking rats with aldosterone, and NaCl 1% drinking rats with aldosterone and eplerenone). Fig. 23 shows the marked decrease in circulating osteopontin levels in the eplerenone treated rats.
Osteopontin immunostaining was also performed in the hearts from these animals. Osteopontin was not detected in saline-drinking, uninephrectomized animals receiving no aldosterone. However, osteopontin was clearly identified in the media of coronary arteries in animals receiving aldosterone infusion. Eplerenone treatment, prevented the expression of osteopontin in the hearts from aldosterone-infused rats (Figs. 8 and 18). Increases in dietary potassium did not reduce osteopontin expression. Determination of osteopontin . mRNA by quantitative RT-PCR, demonstrated a marked (7- fold) upregulatoin of this cytokine in the hearts of aldosterone/salt-treated rats receiving vehicle (relative mRNA expression: 1.7+.2 vs 12.25x1.7,
P<.0001). This effect was prevented by eplerenone (relative mRNA expression: 2.5+.6, P<.0001 vs aldosterone/salt+vehicle group). Consistent with a role for cycloxygenase-2 in the development aldosterone- ) induced vascular inflammation in the heart, COX-2 mRNA expression was 3-fold increased in rats with aldosterone/salt+vehicle treatment (relative mRNA expression: 1.2+.12 vs 3.71.46, P<.0001). Similar to the effects on osteopontin expression, eplerenone prevented the increase in COX-2 expression in aldosterone/salt-treated rats (relative mRNA expression: . 1.8+.36, P<.01 vs aldosterone/salt+vehicle group, see
Figs. 9 and 17). In like fashion, MCP-1 expression and . 5 IL-6 expression was attenuated by eplerenone treatment . (Fig. 24).
The above data suggest that aldosterone mediates a vascular inflammatory phenotype in the heart of hypertensive rats. This phenotype is associated with up-regulation of the cytokine osteopontin and the enzyme cycloxygenase-2 in vascular smooth muscle cells in the arterial media, which may mediate the perivascular inflammation observed and the consequent ischemic/necrotic injury of coronary arteries and myocardium. Without wishing to be bound by any theory, it is believed that this is the mechanism that mediates the vascular alterations observed in diseases such as heart failure, coronary artery disease, auto-immune or viral myocarditis, periateritis nodosa, stroke, and nephrosclerosis. Fig. 11 reveals that osteopontin and cyclooxygensase-2 are expressed in similar regions of the coronary arterial wall. While theory plays no part in the instant invention, Fig. 12 shows a proposed mechanism for this model. In these examples, eplerenone treatment prevented the vascular inflammation in the heart to an extent similar to that of adrenalectomy, as demonstrated in protocol #1. The effects of eplerenone ' were largely independent of major reductions in systolic blood pressure as demonstrated in protocol #1. The lack of a diuretic or natriuretic effect of eplerenone in angiotensin II/salt hypertensive rats suggests that the protective effects of the selective aldosterone antagonist were also independent of its potential effects on epithelial tissues. In addition, the fact . that an elevated dietary potassium failed to mimic the effects of eplerenone, argue against the possibility “ 5 that eplerenone provides benefit through its potassium- sparing properties. Thus, we propose that aldosterone may have direct deleterious effects in the coronary vasculature unrelated to the effects of this hormone in : electrolyte homeostasis in epithelial tissues or its effects on blood pressure. Administration of eplerenone to humans could provide benefit by its anti-inflammatory effects in vascularized organs, including but not limited to heart, kidney, and brain, as suggested by the present experiment.
Assay C: Further In Vivo Aldosterone Infusion Study
The procedure of Assay B was expanded upon in a further study. Uninephrectomized, Sprague-Dawley rats were given 1%NaCl-0.3%KCl to drink and one of the following treatments: vehicle; aldosterone infusion; or aldosterone infusion in combination with eplerenone (100 mg/kg/day) . Aldosterone/salt treatment induced severe hypertension in rats after 30 days, which was significantly reduced by eplerenone. Myocardial tissue from animals in each treatment group was examined after 7, 14, or 30 days of treatment. Histopathologic analysis revealed vascular inflammatory lesions starting . at 14 days that extended to surrounding myocardium and ] 30 resulted in focal ischemic/necrotic changes. Lesions were preceded by the expression and progressive upregulation of proinflammatory molecules. Upregulation of proinflammatory molecules and associated vascular and myocardial damage were markedly attenuated by eplerenone treatment. These data demonstrate that eplerenone is ) effective in reducing blood pressure and providing end- organ protection against aldosterone-induced vascular , 5 inflammatory damage in the heart.
Animals :
Male Sprague-Dawley rats, weighing 230 to 250 g, (Harlan
Sprague-Dawley Industries, Indianapolis, IN) were housed din a room 12-hours light/l12-hours dark daily cycle at an ambient temperature of 22+1°C (n=96). Animals were allowed one week to adjust after arrival and had free access to TEKLAD 22/5 rodent diet (Harlan TEKLAD,
Madison, WI) and tap water until the initiation of the experiment.
Experimental Protocol
Prior to surgery the animals were individually weighed and placed in one of the following groups: (I) high salt control (vehicle/normal chow/1% NaCl & 0.3% KCl drinking water, n=31 for 3 time point groups), (II) aldosterone control (aldosterone/normal chow/1% NaCl & 0.3% KCl drinking water, n=28 for 3 time point groups), (III) 100 mg/kg/day eplerenone (aldosterone/eplerenone chow/1%NaCl & 0.3% KCl drinking water, n=30 for 3 time points).
Potassium chloride supplementation was added to the } saline solution in order to prevent the potential hypokalemia associated with aldosterone excess.
Treatment
At the time of the surgery, an Alzet 2002 osmotic minipump (Alza Corp., Palo Alto, CA) containing either vehicle (9% ethanol/87% propylene glycol/4% dH,0) or 1.0 mg/ml. d-aldosterone (Sigma Chemical, St. Louis, MO) was ] inserted subcutaneously at the nape of the neck.
Aldosterone was administered at a dose of 0.75 Og/hour. » 5 Eplerenone was incorporated into TEKLAD 22/5 rodent diet (Harlan TEKLAD, Madison, WI) at a concentration of 1mg/g of chow (calculated to deliver 100 mg/kg/day). Previous analytical work has demonstrated the stability of eplerenone in this diet, as well as the homogeneity obtained after preparation. Animals were sacrificed . from each group (n=8-13) after 7, 14, or 30 days of : treatment.
Surgical procedure
Animals to be sacrificed after 7 or 14 days of treatment were uninephrectomized and implanted with an Alzet minipump. Animals treated for 30 days were uninephrectomized, fitted for Alzet minipumps, and implanted with radio telemetry units (model# TA11PA-C40,
Data Sciences Inc., St. Paul, MN) according to the following procedure. Animals were anesthetized with 5% isoflurane (SOLVAY Animal Health Inc., Mendota Heights,
MN), which was delivered in O; using a VMS anesthesia instrument (Matrix Medical, Inc., Orchard Park, NY).
Anesthesia was maintained with 1-2% isoflurane throughout the surgical procedure. The surgery site was clipped, scrubbed with nolvasan, and sprayed with : betadine. A rostral-caudal incision was made through the skin from the base of the rib cage to the pubic ) 30 region using a #11 scalpel blade. A second incision was made through the muscles of the abdominal wall to eXpose the peritoneal cavity. The urethra, renal artery and vein of the left kidney were isolated, tied off with 4-0 silk, and the kidney excised and discarded. Organs were carefully displaced with tissue retractors in order to . expose the abdominal aorta. A 1.5 cm segment just rostral to the bifurcation of the abdominal aorta into 5 the iliac arteries was cleared of excessive connective tissue and 4-0 silk was used to make an anchor adjacent to the aorta. A microvascular clip was then placed at both ends of the cleaned region to stop excessive blood flow. Using a bent, 21 gauge needle, the abdominal aorta was penetrated. The cannula of the radio telemetry unit was inserted and stabilized in the aorta using the 4-0 silk anchor. Organs were repositioned and the telemetry unit was placed over the organs. Using a : non-interrupted suture pattern with 4-0 silk, the abdominal wall was closed, and the skin was subsequently closed using a 4-0 silk in an interrupted suture pattern. Animals were injected around the sutures with 100 pL of the anesthetic Marcaine HCl (Sanofi Winthrop
Pharmaceuticals, New York, NY) and given an injection (i.m.) of the antibiotic Mandel (Eli Lilly & Co.,
Indianapolis, IN). Post-operative care included monitoring the animals on a heating pad during recovery from anesthesia until sternal recumbency was : reestablished. Animals were monitored daily for signs of distress and infection at the surgical site. Animals displaying continued discomfort after surgery were treated with 0.1-0.5 mg/kg, s.c. Buphrenorphine (Rickett & Colman Pharmaceuticals, Inc. Richmond, VA). ’ Animals were then placed on tap water and TEKLAD 22/5 . 30 rodent diet (Harlan TEKLAD, Madison, WI).
Blood Pressure Analysis
Radiotelemetrized arterial blood pressure was calculated o with the DATAQUEST A.R.T Version 1.1-Gold software (Data
Sciences International, St. Paul, MN). Data points were collected over a 24 hour period with the collection rate set for a 10 second reading every 5 min for each animal.
The 24 hour period used was from 6:00 a.m. to 6:00 a.m.
Sacrifice
At the cessation of each experimental time point, the animals were anesthetized with pentobarbital (65 mg/kg i.p., Sigma Chemical, St. Louis MO) and weighed with a
Mettler PM6000 balance (Mettler-Toledo, Inc.,
Hightstown, NJ). The abdominal cavity was opened to expose the abdominal aorta. A 1l6-gauge needle was inserted into the abdominal aorta and the animal was exsanguinated into a 1l2cc syringe. The blood sample was transferred immediately into glass serum collection tubes (Terumo Medical Corp., Elkton, MD) for drug level analysis. The samples were placed on wet ice until sample collection was complete and centrifuged for 15 min at 3000 rev/min at 4°C.
Following exsanguination, hearts and kidneys were isolated, removed, rinsed in cold phosphate-buffered saline, and blotted dry. Kidneys were immediately bifurcated through the long axis with a razor blade and “ placed in 10% neutral buffered formalin (NBF, Richard-
Allen Scientific, Kalamazoo, MI). For the hearts, the : 30 right ventricle (RV) was cut away from the left ventricle (LV), both ventricles were weighed using a
Mettler AE163 balance (Mettler-Toledo, Inc., Hightstown,
NJ), and the RV was placed in 10% NBF. A 2 mm coronal slab of the LV apex was removed and frozen with dry ice/isopentane for analysis of gene expression and the remaining portion of the LV was placed in 10% NBF for . 5 fixation. Final wet trimming was completed after 3-4 days fixation where a second 2 mm coronal slab was removed for hydroxyproline analysis and a third 2mm slab was removed from the equatorial region for histology.
Tissue Processing & Staining
The equatorial regions of the heart were routinely . processed into paraffin with an automated tissue processor (Hypercenter XP, Shandon/Lipshaw Inc.,
Pittsburgh, PA) and embedded into fresh paraffin apical side down (Shandon Embedding Center, Shandon/Lipshaw
Inc.). Five and 10 um sections were cut from each block of tissue using a Leica RM2035 rotary microtome (Leica
Inc., Houston, Texas) and mounted on Superfrost/Plus microscope slides (Fisher Scientific, Pittsburgh, PA).
Ten um sections were stained with the collagen specific stain, Picrosirius Red F3BA (Saturated Picric Acid (Sigma Chemical, St. Louis, MO) with 0.1% (w/v) Sirius
Red F3BA (C.I. #35780, Pfaltz & Bauer, Inc. Waterbury,
CN) (6). Mounted tissues were hydrated with water.
Slides were subsequently incubated in distilled water with 0.2% (w/v) Phosphomolybdic Acid (Sigma Chemical,
St. Louis MO) for 15 min, transferred to 0.1% . Picrosirius Red F3BA stain for 110 min, placed in 95% ethanol w/ 1% acetic acid (v/v) for 1 min followed by two, l1-min incubations in 100% ethanol, and cleared in xylene for 1 min. Slides were coverslipped with #1 cover glass using Permount Histological Mounting Media (Fisher Scientific). Two slides mounted with 5 Om sections were cut for each animal. One slide was processed for H&E staining and one for Periodic Acid . Schiff (PAS) staining. The H&E and PAS were used for pathological scoring of the hearts. . 5
Histopathologic Analysis
Semi-quantification of myocardial injury was performed as described previously with minor modifications (7).
Briefly, a scale from 0 to 4 was used to score the level of myocardial injury. A score of 0 represented no damage. A score of 1 represented the presence of vascular and perivascular inflammatory lesions without cardiomyocyte injury. A score of 2 was given when one clear area of myocardial necrosis was observed.
Myocardial necrosis was defined as the presence of necrotic changes in cardiomyocytes such as nuclear © pyknosis or karyolysis, non-contracting marginal wavy fibers and hypereosinophilia of the cytoplasm, or clear : evidence of destruction of the cardiomyocyte membrane.
When two or more separate areas of necrosis were found (implicating the presence of two different infracted regions), hearts received a score of 3. A score of 4 was assigned to hearts that demonstrated extensive areas of necrosis compromising more than 50% of the left ventricle. . Image Analysis
Picrosirius Red F3BA stained slides were used to - ‘quantify interstitial collagen with a Videometric 150
Image Analysis System (Oncor Inc., Gaitherburg, MD).
Briefly, images were captured using a Nikon E Plan 10/0.25; 160/- Objective (Nikon Inc. Garden City, NY)
attached to a Nikon Optiphot microscope (Nikon Inc.). A
Toshiba 3 CCD Color Video Camera (Model#IK-T30T, Toshiba } Corp. Japan) relayed the images in RGB format from the microscope to a 386 computer with a V150 video board. . 5 The V150 video board/V1i50 software application (Oncor
Inc.) converted RGB images to HIS (Hue, Intensity,
Saturation) format for display and analysis on a Sony
Trinitron Color Video Monitor (Model#PVM-1342Q, Sony
Corp, Tokyo, Japan) at a magnification of 305x. Once the image was displayed on the image monitor; hue, intensity, and saturation of pixels to be measured were defined by a process called thresholding. The V150 application then measured only pixels which fell into : thresholding limits. The system was calibrated with a micrometer scale (EM Sciences, FT. Washington, PA 19034), which allowed data to be expressed in mm? or ’ . Om®. After each measurement, data was automatically saved in ASCII file format and transferred to Microsoft
Excel version 7.0 for final summation.
Immunohistochemistry
Five pum sections were deparaffinized in xylene (two, 5- 10 min incubations) and rehydrated by 3 min incubations in ethanol as follows: two incubations in 100% ethanol followed by two incubations in 95% alcohol and one : incubation in 70% alcohol. Once hydrated, sections were rinsed in tap water for 1 min and distilled water for 1 ‘ min. Endogenous peroxide activity was blocked by placing slides in 3.0% H;0, for 15 min followed by a 5 } 30 min rinse in distilled water. Slides were processed for antigen retrieval using citric acid, pH6.0. Slides were heated to boiling, cooled for 20 min at 25°C, and rinsed in distilled water. Slides were stained using a DAKO autostainer (DAKO Corporation, Carpinteria, CA). Prior . to staining, slides were rinsed and incubated in blocking buffer for 20 min. Blocking buffer is ” 5 described in the Vectastain ABC kit (Vector Labs,
Burlingame, CA) and contains 10 mL TNB (NEN TSA Biotin
System kit, Cat#NEL700A, NEN Life Science Products,
Boston, MA) and 3 drops of normal (corresponding to the secondary antibody) serum.
Primary antibodies used for staining include:
Osteopontin, diluted at 1:100 (Mouse monoclonal,
Cat#MPIIIbl0, Developmental Studies Hybridoma Bank, The -
University of Iowa, Iowa City, IA); ED-1 diluted at 1:500 (anti-macrophage glycoprotein, mouse monoclonal,
MAB1435, Chemicon International Inc., Temecula, CA); CD- 3 diluted at 1:300 (anti-T-cell, rabbit polyclonal- : affinity purified antibody, A0452, DAKO Corporation,
Carpineria, CA); ICAM-1 diluted at 1:100 (goat polyclonal-affinity purified, M-19:sc-1511, Santa Cruz
Biotechnology, Santa Cruz, CA); VCAM-1 diluted at 1:100 (goat polyclonal-affinity purified, C-19:sc-1504, Santa
Cruz Biotechnology). Slides were incubated with primary antibodies for 60 min, followed by biotinylated antibodies at a final concentration of 5 puL/mL for 30 min at 25°C. Staining was visualized with the
Vectastain ABC-AP kit (Vector Laboratories) and . diaminobenzidine staining (DAKO Corporation,
Carpinteria, CA). Slides were rinsed in water and . 30 counter-stained with hematoxylin for approximately 30 sec. Isotype-matched IgG (Sigma Chemical, St. Louis MO) was used as a negative control for the primary antibodies.
In situ Hybridization for Osteopontin mRNA
RNA probes were generated based on a sequence for rat : : osteopontin (GenBank accession# NM 008608-1). Briefly, a cDNA fragment of rat osteopontin was generated by RT- -
PCR using the following primers: forward primer, 5’-TGG
CAC ATT TGT CTT; reverse primer 3'AGC CCA TCC AGTC. The cDNA fragment was inserted into the PCR II plasmid using the TA cloning kit (Invitrogen Corporation, Carlsbad,
CA). Probes were labeled in 100 pL in vitro transcription reaction containing: rRNasin (2 U), DNase (0.5 U), TE Buffer (1X), GTP (10 mM), rCTP (10 mM), rATP (10 mM), x¥UTP (10 mM), (PROMEGA, Madison, WI), 5/uL (50uCi) **P-UTP (Elkin Pelmer, Boston, MA) and appropriate RNA polymerases (Spé RNA Polymerase (20
U/ul) ; T7 RNA Polymerase (15 U pL), PROMEGA) for 60 min at 37°C. Free label was removed from the reaction using
Microcon YM-50 Microconcentrators (Amicon, Bedford, MA).
Sections were deparaffinized in xylene, rehydrated in graded ethanol solutions as described above, and fixed in 4% paraformaldehyde (EMS, Ft. Washington, PA) for 10 min at 4°C. Tissues were then digested with Proteinase
K (5 mg/mL; 10 min, 37°C, Roche, Indianapolis, IN) and washed in 0.5 X SSC buffer (Saline-Sodium Citrate buffer) (10 min). Prehybridization was performed after sequential dehydration in graded series of ethanol, the , reverse process as described above for rehydration, followed by incubation in hybridization buffer (50% . formamide, 2 X SSC, 10% dextran sulfate, v/v) for 2 hours at 42°C. Hybridization was performed overnight using hybridization buffer containing tRNA (50 pg/mL,
Sigma, St. Louis, MO) and the appropriate labeled probe at 55°C. Hybridized tissues were then washed successively in 2X SSC buffer, 0.1X SSC-EDTA buffer } (0.1X ssc, i1mM EDTA), and 2X SSC buffer for 1 hour 40 min. Slides were finally dehydrated in graded series of ww 5 ethanol as described above containing NH,OAc (2 min each) and dried in a vacuum desiccator for 1.5 hours at room temperature. Tissues were exposed overnight to a phosphorus screen. Slides were coated with photographic emulsion (Kodak, Rochester, NY) and exposed at 4°C for 3-5 weeks prior to development. Developed slides were counterstained with hematoxylin and eosin.
Principles of TagMan Analysis
The fluorogenic 5'-nuclease assay (TagMan PCR) using
Applied Biosystems’ 7700 Sequence Detection System (Applied Biosystems, Foster City, CA) allowed for real time detection/quantitation of a specific gene by monitoring the increase in fluorescence of a gene- specific, dye-labeled oligonucleotide probe. Probes for target and reference genes were labeled at the 5’-end with a 6-carboxyfluorescein (6FAM) reporter dye and at the 3’-end with a 6-carboxy-N,N,N’,N’- tetramethylrhodamine (TAMRA) quencher dye. When the probe was annealed to the target gene, fluorescence of 6FAM was prevented by the close proximity of TAMRA. The exonuclease activity of Tag polymerase released the dyes from the oligonucleotide probe by displacing the probe o from the target sequence resulting in fluorescence excitation in direct proportion to the amount of target ’ 30 message present. Data analysis was performed using the
Sequence Detection System software from Applied
Biosystems.
TagMan Primers and Probes: TGFB 1, ANP, Collagen I,
Collagen IIT . Primers and probes were designed using Oligo Primer
Analysis Software, Version 5.0 (National Biosciences
Inc. (NBI)-Wojciech Rychlik, Cascade, CO). Primers were synthesized by Life Technologies (Grand Island, NY) and probes were synthesized by Applied Biosystems.
Primer/probe sets were designed from known sequences of rat genes to be analyzed. All target gene values were normalized to a reference gene, constitutively expressed cyclophilin. Primer/probe sets sequences can be found in Table 8 :
Table 8 TagMan RT-PCR Gene Marker Primer/Probe Sets
Gene Forward Primer Reverse Probe
Primer
Transform | CACCATCCATGACA | ACCTTGCTGTACT | TCAGCTCCACAG ing TGAACC “| GTGTGTCC AGAAGAACTGC growth factor beta 1 (TGFB1)
Atrial TGGGCTCCTTCTCC | AGCAGAGCCCTCA | CCATATTGGAGC natriuret | ATCAC GTTTG AAATCCCGTATA ic factor Cc (ANP)
Collagen ACCAAGGCTGCAAC | GCAGGAAGGTCAG | CCATACTCGAAC
I CTGGA CTGGAT TGGAATCCATCG
Collagen GGCTTTCAGTTCAG | GACTGTCTTGCTC | CCTGATCTTCCT
III CTATGG CATTCAC GAAGATGTCCTT
G
Cyclophil | CTTGTCCATGGCAA | GTGATCTTCTTGC | CCACAATGCTCA in ATGCTG TGGTCTTGC TGCCITCTTTCA
CC w Cyclooxeg | TCAAAGACACTCAG | CGGCACCAGACCA | CACGTCCCTGAG enase-2 GTAGA AAGACTT CACCTGCGG (COX-2) CATGATCT : Osteopont | CCAGCACACAAGCA | TCAGTCCATAAGC | CAGTCGATGTCC in GACGTT CAAGCTATCAC CTGACGGCCG
Monocyte GCAGGTCTCTGTCA | GGCTGAGACAGCA | CCTGTTGTTCAC
Chemoattxr | CGCTTCT CGTGGAT AGTTGCTGCCTG actant TAGC
Protein-1 (MCP-1)
Intercell | ACCTGCAGCCGGAA | CCCGTTTGACAGA | CCGATAGGCAGC - ular AGC CTTCACCAT GGGACACCA
Adhesion
Molecule- - 1 (ICAM- 1)
Vascular GAAGCCGGTCATGGE | GGTCACCCTTGAA | TGGCTCCTGATG
Cell TCAAGT CAGTTCTATCTC TTTACCCAATTG
Adhesion ACAGA
Molecule -1 (VCaM- 1)
Cyclophil | AGAGAAATTTGAGG | TTGTGTTTGGTCC | AAGCATACAGGT in ATGAGAACTTCAT AGCATTTG CCTGGCATCTTG
TCCAT
All oligonucleotides are written 5’ - 3’. Primers are unlabeled and all probes are labeled at the 5’ end with 6-carboxyfluorescein (6FAM) reporter dye and at the 37 end with 6-carboxy-N,N,N’ , N’-tetramethylrhodamine (TAMRA) quencher dye
RNA isolation: TGFBl, ANP, Collagen I, Collagen III
RNA was extracted from frozen (-70°C) left ventricle (LV) tissue (approximately 10-20 mg) using 1.5 mL RNA-
STAT 60 according to manufacturer’s instructions (Leedo
Medical Laboratories, Inc., Houston, Texas). Briefly, tissues were homogenized using a tissue homogenizer equipped with a 5 mm probe (Ultra-Turrax T8 Homogenizer, :
IKA Works, Inc. Wilmington, NC). Following homogenization, an egual volume of molecular grade chloroform (Sigma Chemical Co., St. Louis, Mo.) was incubated with periodic mixing for 10 min at room temperature. Samples were centrifuged at 12,0009 for 10 " 20 min and RNA was precipitated from the top layer by adding an equal volume of molecular grade isopropanol (Sigma Chemical Co.) followed by an overnight incubation at -80°C. RNA was pelleted by centrifugation at : 12,000g, washed with 75% ethanol, and solubilized in nuclease-free water (Promega, Madison, WI). RNA was diluted and analyzed spectrophotometrically for ] concentration and purity (A260/A280 = 1.9 - 2.0, with an average yield of 2-5 ug RNA). - 5
Reverse Transcription: TGFfI, ANP, Collagen I, Collagen
IIT
Double-stranded cDNA was synthesized by adding 400 ng
RNA (4ul) to a final volume of 20 ul containing 15% "10 nuclease-free water (Promega, Madison, WI), 1X RT Buffer (Life Technologies, Grand Island, NY), 10 mM DTT (Life
Technologies), 0.5 mM each of dATP, dTTP, dGTP, dCTP (PE
Biosystems, Foster City, CA), 2.5uM Oligo d(T)15 (Oligo
Therapeutics, Inc., Wilsonville, OR), 40 units RNAsin (Promega), and 200 units SuperScript II Reverse
Transcriptase (Life Technologies). The reactions were performed in thin-walled reaction tubes with caps (Applied Biosystems) to ensure accurate reaction temperatures. Reactions were performed using a GeneAmp 9600 thermal cycler (Applied Biosystems) according to the following protocol: 1 hour at 37°C, 5 min at 95°C, and 10 min at 4°C.
TagMan Analysis: TGFfl, ANP, Collagen I, Collagen III
Bach PCR reaction contained the following: 2.5 uL (50 : ng) of each cDNA added to 22.5 pL of a PCR mix : containing: 38.5% nuclease-free water (Promega), 1X PCR
Buffer II, 2 mM MgCl, 0.05 U/pL AmpliTag Gold (PCR Core
Reagent Kit, N808-0228, Applied Biosystems), 300 nM each of a forward and a reverse primer (Life Technologies), 200 nM probe (Applied Biosystems) and 200 uM each of dATP, dTTP, dGTP, and dCTP (Applied Biosystems). Single reactions were set up in MicroAmp optical tubes with ) MicroAmp optical caps (Applied Biosystems) and loaded into the 7700 Sequence Detector. The following protocol was applied to all reactions: 10 min at 95°C (polymerase activation), 40 cycles of 10 seconds at 95°C (denaturation) and 1 min at 57°C (annealing).
TagMan Primers and Probes: COX-2, Osteopontin, MCP-1,
ICAM-1, VCAM-1
All primers and probes were designed using Primer
Express software supplied with the 7700 Sequence
Detection System and synthesized by Applied Biosystems.
Standard curves using 5-fold dilutions of total RNA (from 200 ng to 320 pg) were performed to determine the efficiency of each primer/probe set in the TagMan reaction prior to the analysis of the experimental samples. Primer/probe sets were designed from known sequences of rat genes to be analyzed. All target gene : values were normalized to a reference gene, ‘constitutively expressed cyclophilin. Primer/probe set sequences can be found in Table 8.
RNA isolation: COX-2, Osteopontin, MCP-1, ICAM-1, VCAM-1
RNA was extracted from frozen (-80°C) rat heart tissue using the Totally RNA Isolation Kit (Ambion, Inc., ! Austin, TX). Tissue was crushed using a stainless steel mortar and pestle, which had been chilled to -80°C and transferred to a dounce homogenizer (Kontes, Vineland,
NJ) containing 3-10 mL cold denaturation buffer. Tissue was homogenized and transferred to a sterile, 15 mL polypropylene centrifuge tube. An equal volume of phenol :chloroform:isoamyl alcohol (25:24:1) was added, ] samples were shaken vigorously for 1 min, and incubated on ice for at least 15 min. Samples were centrifuged . 5 for 30 min at 10,000g. The aqueous phase was removed, 1/10 volume of a sodium acetate solution (3.0 M NaOAc pH 4.5) was added, samples were shaken or inverted for 10 seconds, and acid-phenol (premixed with isoamyl alcohol) :chloroform (5:1, Ambion, Inc.) was added at an volume equivalent to the starting sample volume.
Samples were shaken vigorously for 1 min, followed by a 15-min incubation on ice, and centrifuged for 30 min at 10,000g. The aqueous phase removed and placed in a clean polypropylene tube. An equal volume of isopropanol (Sigma, St. Louis, MO) was added and the samples were mixed and incubated overnight at -20°C.
The samples were centrifuged for 30 min at 10,000g, the supernatant was removed and the RNA pellet was resuspended in DNAse/RNAse-free water. Samples were frozen at -80°C for at least 2 hours, thawed on wet ice, and diluted for quantitation.
All RNA was further purified by DNase digestion to remove genomic DNA and LiCl precipitation to remove carbohydrates. Each RNA (100 pg) was incubated for 45 min at 37°C with 1 unit of DNAse (Roche Diagnostics,
Indianapolis, IN) and 10 units RNAse inhibitor (Applied , Biosystems, Foster City, CA) in a buffer containing 40 mM Tris pH 7.8, 6 mM MgCl,, 10 mM CaCl,. The DNAse and : 30 buffer were removed using the RNeasy Mini protocol for
RNA cleanup (Qiagen, Valencia, CA). The RNA was then precipitated with 7.5M LiCl/50 mM EDTA (Ambion, Inc.,
Austin, TX) in a volume equal to half the sample volume,
incubated overnight at -20°C, and centrifuged for 30 min at 13-16,000g at 4°C. All RNA was frozen for at least 2 : hours at -80°C, thawed, diluted, and analyzed spectrophotometrically for concentration and purity. ) 5
TagMan Analysis: COX-2, Osteopontin, MCP-1, ICAM-1, vCcaM-1
TagMan reactions were performed as follows. Ten pL (200 ng) of total RNA (DNAsed and LiCl precipitated) was added to 15 uL of a RT-PCR reaction mix containing: 12.5 pL of 2X One-Step PCR Master Mix without uracil-N- glycosylase (contains AmpliTag Gold DNA Polymerase, : dNTPs with dUTP, passive reference, and optimized buffer components), 0.625 pL of a 40X MultiScribe and RNAse
Inhibitor Mix, 0.625 pL of 20 uM forward primer, 0.625 pL of 20 pM reverse primer, 0.5 pL of 5 pM TagMan probe, and 0.125 pL of DNAse/RNAase-free water. Reactions were set up in duplicate in MicroAmp optical 96-well reaction plates with MicroAmp optical caps or adhesive covers (Applied Biosystems) and loaded into the 7700 Sequence
Detector. The following protocol was applied to all reactions: 30 min at 48°C (reverse transcription), 10 min at 95°C (inactivation of reverse transcriptase and polymerase activation), 40 cycles of 15 seconds at 95°C (denaturation), and 1 min at 60°C (annealing). ) Hydroxyproline Assay
Myocardial hydroxyproline concentration was measured by a colorimetric assay that quantifies the reaction between oxidized hydroxyproline, and p-
dimethylaminobenzaldehyde as described previously (4).
Briefly, tissues (180-250 mg) were dried for 18 hours at . 60°C using a Reacti-Therm heating block (Pierce,
Rockford, IL) and weighed. Dried tissues and a positive . 5 collagen control (Bovine Collagen Type I, Sigma, St.
Louis, MO) were hydrolyzed with 2 mL 6N HCl for 3 hours: at 150°C in the Reacti-Therm heating block. Acid was evaporated under nitrogen gas, samples were rehydrated in 1 mL of citrate-acetate buffer (0.7 M NaOCAc, 0.2 M citrate, 45 mM citric acid, pH 6.0) in the presence of 4 mL isopropanol, and filtered through a 0.45 Om Millex
LCR filter (Gelman Sciences, Ann Arbor, MI).
Hydroxyproline content was measured by incubating 60 pL of hydrolyzed sample or collagen standard with 350 pL citrate-acetate-isopropanol buffer (citrate-acetate buffer with 40% isopropanol, v/v) and 100 pL of 300 mM
Chloramine T (J.T. Baker, Phillipsburg, NJ) for 5 min at 25°C. Erlich’s Reagent (1.25 mL, 3.5 M p- dimethylaminobenzaldehyde in 70% perchloric acid with 80% isopropanol, v/v) was added for visualization and quantitation of hydroxyproline. Samples were incubated at 60°C for 30 min, cooled to room temperature, and absorbance was monitored at 558 nm. Hydroxyproline content was quantitated from a freshly prepared standard curve of trans-4-hydroxy-L-proline (Sigma, St. Louis,
MO). All samples and standards were performed in } duplicate.
Statistical Analysis
Data were analyzed using one-way analysis of variance (ANOVA) . Because the assumptions of normality within groups and equality of variance across groups could not be consistently met, the analysis was performed on the } rank transformed values of the raw data (nonparametric analysis). The alpha=0.05 level of significance was . 5 used for the planned comparisons between the means. The
Least Significant Differences (LSD) method was used for planned comparisons between groups. Data were analyzed using PROC TTEST in the SAS statistical software package (SAS PC, version 6.12, SAS Institute, Cary, NC). All data are reported as mean + standard error of the mean (SEM) .
Animal Exclusion
Three animals died during the experiment: rat #17 (aldosterone + salt group, found dead after 24 days of infusion), rat #64 (aldosterone + salt group, died : following surgery), and rat 5 (vehicle group, died following surgery). Additional animals were excluded if multiple parameters were found not to represent the treatment group to which they were assigned (e.g. more than 3 standard deviations from the mean for that treatment group). Three such animals were excluded from the study: rat #57 (from 7-day protocol, aldosterone + salt group), rat #97 (from l4-day protocol, aldosterone+ salt group), and rat 24 (from 30-day protocol, 100 mg/kg/day eplerenone group). These three animals demonstrated expression of inflammatory marker genes ‘ (COX-2, Osteopontin, MCP-1, ICAM-1, and VCAM-1) that were greater than 3 standard deviations from the mean for the treatment group. Rat #24 was also excluded as a result of telemetry unit dysfunction. Values generated for these animals are shown in Table 9.10-Table 9.19,
separated from the data for the other animals in the data tables.
Table 9.10 Individual data used for Table 10 ) Control: vehicle + salt
Come] 1 2 | +s [7] 8 [5] a0 5 [me [wo [wm | [Je
CE ome twee es
IR INE EEE CE CE I Ma REC [we wee [aso | | on
CA NESE EEC MEET MN CE a Ma REE
CI ME NEE = NC ICE a Ba =
INE I EE BN Nl Nl | 10 | 132 | te | wma | wie | is | 17
Ti | 50 | a50 | wee | wes | | wie | ie | 1s (12 | a50 | ase | wee | wa | | was | ies | 139
Ts [on | ev ee | wa || es | as | a
Ts [ie | 12 [ise | ts | | ise |e | 1s 5 [ies | wee | wer | me | | is [13a | 17] we [we | wes | wer | tee | | is [ama | aes
IEA NEEENN EEENN NEC CEI Ml NE EC EC > [es | eo | we | wes | | aa | 5a0 | 1am | io | en | war | des | | wen | wes | 3a 21 [ie | 11 | wes | wee | | 50 | 136 | ae “22 | ey | wee | 1a | wee | = | tas | 13 | 39 “2 | es | wes | wei | wes | oo | we | G6 [331 “2 | 2 | wea [wo | 1s | | G3 | 3a | 330] 2s | 13s | Tn | wes | 1s | | ie | 136 | 399] 6 | 12 | 11 | 17 | mee | == | wa | war] 330 -- = No data were collected due to technical difficulties.
Table 9.10 (continued)
Aldosterone + salt = |e se | ea [az | ues [mv | we ae [232 [370 [136 | av | was | nes | [es | ass 7 [a0 | vo [330 | ues | iss | ase | [es [368 5 [345 | ea | as | 160 | use | iss | | %es | ies 5 [350 11 [tan | 172 | 17a [tes | [wei | aes 50 [356 | 196 | was | 1s | 1s | tes | |e | ama 31 [35a | aon | 355 [176 | wen | Tes | | wes [47s 32 [359] 207 | zen | 150 | wwe | avo | | Ges | 350 33 [en | 230 | 16 | woe | ton | ve | | dee | dor 37 [37 222 | 176 | 205 | 220 | 15 | G70 | Ts | moa 3e [39x | 76 [17a | 21s | 215 | ee | uve | se | 203 21 [357 227 | 157 | ore | 720 | 201 | 1s [20s | aii 53 [19% | 227 | 204 | 215 | 225 | 208 | 190 | 23 | Boa 23 [200 221 | 03 | 23 | 21a | 20s [Tey | ws | 1s 5a [204 | 216 | 199 | 22a | 23 | 307 | ive [oma | mua 55 [215 | 200 | 205 | 21 | 215 | 250 | 19 | 156 | 210
El EEE EE Ee a EE Rh RE -- = No data were collected due to technical 5 difficulties.
Table 9.10 (continued)
Eplerenone + aldosterone + salt : Rat
Lo
EN
-- 6 | 133] 142 [136 152 | 126 [133 [137 1a0 [150] | -- -- 8 | 142] 146 [121 156 [131 [138 |138 [139 152] | -- |. © |1e2| 146 [139 154 | 130133 [137101151] | -- --
IE
-- =
IE
-- 17 [148 | 141 [143] 182 [149 [148 [143 [160 [274] | -- 18 | 151 | 146 [144] 187 | 152 | 149 [148 [162 [177] | -- 19 | 156] 147 [145] 192 [153 [154 [150 [166 | 277} | -- -- -- = 23 | 169 | 157 [157 [ 209 | 163 [160 [159 |180 [191 | | -- 2a | 168 | 164 [159 | 211 | 163 | 162 | 161] 180 [295] | -- 25 | 174 | 165 | 161 | 215 | 165 | 161 | 161] 182 [198 | -- -- = No data were collected due to technical difficulties. * Data from this animal were not considered for statistical analysis and not included in the final results.
Table 9.11 Individual data used for Table 11
Control: vehicle + salt : Left
Righ
Final Left Right Tibia Ventricle Venioas i Rat| Body [Ventricl|Ventricl enat Weight / Weight / ANP # |Weight |e Weight|e Weight J Tibia Neild (AU) (cm) Tibia Lengtk (g) (mg) (mg) Length (mg/cm) 0 4 iM mg/fem) 47 291 771 194 3.9 198 50 0. 48 <9 sor | eso | ass [ae] aes | slo 3. 49 0 aes | ess | see | as | ae | es 35 50 3. 267 562 175 3.8 148 46 o6 51 1. 268 636 178 3.8 167 47 11 59 0. 273 709 185 3.7 192 50 924 53 0. 269% 197 3.8 184 52 64 54 1. 245 612 189 3.8 161 50 06 55 | 0- 286 667 190 3.8 176 50 93
Se 1. 245 616 149 3.8 162 39 10
M 1. can o91 667 178 3.8 175 47 49 0.
Table 9.11 (continued) :
Aldosterone + salt
Final | Left | Right |TiPi| Left Right ) . a Ventricle | Ventricle
Rat! Body |Ventricl{Ventricl , . ANP 4 | Weight le Weightle Weight| SPg| Weight / | Weight / | 0, . o (m 5 (mn 5 th [ibia Lengtl'ibia Lengtl 9 | em) | (mg/om) | (mg/em) sg | 11. 4 266 784 183 3.8 206 48 S2 59 | 3.2 271 719 178 3.6 200 49 [} 13. 299 719 223 3.95 184 57 41 [61 | 286 | 779 | 185 [3.9] 200 [| 47 [3.6]
I I I A A A NE
274 746 168 3.8 196 44 : 63 13. 276 620 154 3.8 163 41 13 55 | 6.1 . 849 197 3.9 218 51 3 3.8 i 266 674 174 [3.7] 182 47 8
Mean] 8.1 277 736 183 3.8 194 . 48 5 0.0 1.5
SEM ooo [oe | oo I 1. -- = No data were collected due to technical difficulties. 13.32 * Data from this animal were not considered for statistical analysis and not included in the final results.
Table 9.11 (continued)
Eplerenone + aldosterone + galt
Final Left Right Tibi Left Right
R \ a Ventricle | Ventricle
Rat| Body [Ventricl Jentricle , 4 Weight / Weight / ANP # Helghe N height Helane th [ibia LengtFibia Lengt} 27)
Fe (em)| (mg/em) | (mg/em) 67 1. 306 859 216 3.9 220 55 26 1. 295 712 181 3.8 187 81 0. 286 618 154 3.7 167 42 59 2. 277 658 174 3.8 173 46 58 71 4, 295 754 192 3.8 198 51 48 281 733 171 3.8 193 45 o8 73 | 3 273 726 181 3.8 191 48 82 74 | 3. 286 190 3.8 183 50 59 75 | 0. : 700 170 3.8 184 45 95 76 | 3. 0 | 276 688 187 3.8 181 49 67
Co I VO VP OS PO I 286 714 182 3.8 188 48 77 0.0 0.
EI EE a -- = No data were collected due to technical difficulties.
Table 9.12 Individual data used for Table 12 :
Control: vehicle + salt
Left Right
Final Left Right Tibia entricleVentriclel
R Body |Ventricle Ventricle, stn|Weight / {Weight /| ANP
Weight| Weight Weight Tibia Tibia (AU) (9) (mg) (mg) (cm) Length Length 89] 322 | 665 | 179 | 3.9 | 171 | 46 [0.36] 90] 322 | soz | 208 | 3.8 | 211 | 55 |o0.89] ou] -- [ 742 | 174 | 3.8 | 195 | 46 [7.04] 93] 324 [ 747 | 303 [3.8 | 157 | 80 [3.33] 95] 303 [ 745 | 178 | 3.8 | 196 | 47 [1.08] 96] 205 | 756 | 206 | 3.9 | 19a | 53 [0.17 feay 311 | 748 | 198 | 3.8 | 195 | 52 [1.76] sed 5 | 15 | 10 [oor | a4 | 3 o.es] -- = No data were collected due to technical difficulties. nd = No data were reported due to insufficient mRNA sample.
Table 9.12 (continued)
Aldosterone + salt . | Final Left Right Tibi Left Right , } a Ventricle | Ventricle
Rat| Body |Ventricl|Ventricl Leng| Weight / Weight / ANP # |Weight |e Weightle Weight ‘yx os | (AU) . | (a) (mg) (mg) th libia Lengtlibia Lengt! 2 |(ew| (mg/em) | (mg/em) 4.5
EI a [29 | 261 | 78a | 189 [3.81 206 | 50 7.7]
A EE A A I
7.3 100} 307 912 208 3.9 234 53 4 ! 4.1 1.5 103] 3.8 17. 279 854 - 186 0 225 49 81 6.4 8.0 2.5 : Mea 6.7 270 817 189 3.8 214 50 0 0.0 1.5 nd = No data were reported due to insufficient mRNA sample. 97%] 235 | 809 [| 178 [3.9] 207 | 46 [5.96 * Data from this animal were not considered for statistical analysis and not included in the final results.
Table 9.12 (continued)
Eplerenone + aldosterone + salt
Final Left Right Tibi Left Right . . a Ventricle | Ventricle
Rat| Body |[Ventricl{Ventricl . \ ANP # |Weight |e Weightle Weight|"SRG| Weight / | Weight / | ~o, on (m y (m y th [ibia Lengtltibia Lengt}
I I |" (em | | (mg/cm) . 2.8 3.2
ES EE I PP A
6.3 6 sen | ess | ses Iso] am | ae 4.0 7] ser | cen | wo las] we | ar |]
138 25.9
I 247 833 371 3.7 225 100 0 5.5 139]
IP PR PO PY I a 3.5 140
EF FE
) 141 2.2 297 751 158 3.8 198 42 S 8.3 4.2
Mea 6.6 283 813 157 3.8 214 52 4 0.0 2.2
EI nd = No data were reported due to insufficient mRNA sample. : Table 9.13 Individual data used for Table 13
Control: vehicle + salt
Final | Left | Right |. :Pi Left Right \ . a Ventricle | Ventricle
Rat| Body |VentriclVentricl \ . ANP # | Weight |e Weighte Weight Leng) Weight / | Weight / (AD) oo (m (m th [ibia Lengtlibia Lengt] % ™ J(em)| (mg/m) | (mg/cm) 1 0.9 308 686 160 4.0 172 40 5 5 0.3 337 763 194 4.1 186 47 0 4 0.1 316 728 162 4.0 182 41 2 1.0 343 721 162 4.1 176 40 6 - 1.9 291 664 153 4.0 166 38 3 0.2 254 612 180 4.1 149 44 4 1.1 291 613 141 4.0 153 35 7 | 0.1 332 812 184 4.2 193 44 1
Mean] 0.7 314 700 167 4.1 172 41 4 0.0 0.2
EI I
Aldosterone + salt
! Co Right
Final Left Right Tibi Vem Ventricle
Rat| Body |Ventricl{Ventricl . Weight / | ANP # | Weight |e Weightle Weight| SRg| Weight / Tibia | (AU) th [ibia Lengtl] (g) (mg) (mg) (cm) (mg/cm) Length
I IP I VP PY YO I
289 934 196 234 49 59 1 I IP I . 219 726 148 3.8 191 39% 11
E53 IP I IP I 289 963 215 3.9 247 55 83 1 IP I I I A 282 942 176 3.9 242 45 20 1 I IP I 290 1030 224 3.9 264 57 83
El EE I EY 267 837 173 3.9 215 44 43
EI IE I BN I
319 962 220 3.9 247 56 14 2) oe [en | er Jao] me | we |S 263 873 187 4.0 218 47 7
El I EE 234 919 185 3.8 242 49 97 a ET VR PO OY I YO
I 272 210 192 3.9 233 49 17 0.0 3.3
EI EE ER
Table 9.13 (continued)
Eplerenone + aldosterone + salt
Final | Left | Right | + °+|_ Left Right ac Body [VentricliVentricl a ventricle Ventricle ANP # |Weight |e Weightle Weight|USRg| Weight / | Weight / | oo (g) (mg) (mg) th [ibia Lengtlibia Lengtl} 1 | 7 |(em)| (mg/cm)
EE NE EE PY iy 310 873 177 3.9 224 45 3
EF PN NE
) 343 908 . 202 4.1 233 52 5
EJ ER I PY NN
334 899 200 3.9 231 51 S
EI I a 1 299 1063 209 3.9 273 54 26 2] ae | oss | a las] se | we 361 958 187 3.9 246 48 63
El I NE EE 351 1129 242 3.9 289 62 25
EIEN FY
316 929 189 3.9 238 48 20 29] son | sos | am leo] 20s | se |'3 . | 352 805 181 4.0 206 46 2 ow as IE PP VO OY PO I 5 331 936 198 3.9 240 51 0 2.4
IE PS
* Data from this animal were not considered for statistical analysis and not included in the final : results.
Table 9.14 Individual data used for Table 14
Control: vehicle + salt
Myocardial Interstitial ] ollagen-follagen-
Rat Necrosis Collagen vdroxyproline I IIT # (0-4) Volume (pg /mg) mRNA mRNA
Fraction (%) (aU) (AU) woo L, [sw Tam aoe 48] 0.0 | 7. | 572 | 0.63 | 0.80 45] 0.0 | 3.1 | 3.35 | 1.57 | 2.00
So] 0.0 | a1 | 2.37 | 1.08 | 1.19 51 oo | 3.4 | 2.23 | 1.40 | 1.09
S200 | as | 2.48 | 0.73 | 0.52 53] oo [| 2.3 | 2.35 | 1.22 | 1.27 54] 00 [ 66 | 2.42 | 0.78 | 0.91 ss] 0.0 | sa | a.ee | 0.54 | 0.70 se] 00 | es | 521 | 0.53 | o.e1 fea 0.0 | 4.4 | 3.57 | 1.10 | 1.00 semj 0.0 | 0.5 | 0.45 | 0.15 | 0.13
Table 9.14 (continued)
Aldosterone + salt
Myocardial Interstitial } ollagen-Collagen-
Rat | , Collagen Hydroxyproline I III i Necrosis # (0-4) Volume (pg /mg) mRNA MRNA _| ~~ |Fraction (% | am | (ay 58] 0.0 [ nd | 4.48 | 0.84 | 0.65 60 | 00 | 65 | 232 | 1.97 | 1.67 61] 00 | nd | 2.14 | 1.89 | 1.67 62] 0.0 | e631 [| 2.18 | 1.36 | 1.59
[65 oo | és [2.31 | 1.05 | 1.595 65] 0.0 | 655 | "2.10 | 3.33 [ 1.58 66] 00 | a4 [ 2.22 | 1.07 | 1.30 : Mean) 0.0 [56 | 2.73 | 1.36 | 1.42 [seM{ o0.0 [ 06 [| 0.3¢ | 0.14 [ 0.12 nd = No data were reported due to insufficient mRNA ’ sample. 57] oo | 53] 3.86 J ii] 1.15 * Data from this animal were not considered for statistical analysis and not included in the final results.
Table 9.14 (continued)
Eplerenone + aldosterone + salt
Myocardial Interstitial ollagen-Collagen-
Rat Necrosis Collagen [Hydroxyproline I IIT # (0-4) Volume (ug/mg) mRNA mRNA 67] 0 | 43 | 202 [| 0.62] 0.93 68 | oo [7.2 | 4.18 | 0.92 | 0.95 eo | 0.0 | 2.5 | a.08 | 0.25 | 0.43 _ 70] o.0 [| 33 | 3.96 | 1.79 | 1.25 i 0.0 | 4.2 | 4.26 | 0.78 | 1.05 2 | 0.0 | 6.6 | s.17 | 0.85 | 1.14 (73 oo | 44 [ 1.90 | 0.29 | 0.45 7a | 0.0 | 45 | 1.55 | 0.42 | 0.64 _ 75] oo | 88 [| 2.08 | 1.28 | 1.33 (76 | oo | 69 [| 2.41 | 31.21 | 2.71
Mean| 0.0 | 5.4 | 3.06 | 0.8 | 1.09 (sem| 0.0 [| 06 [ 0.36 [ 0.15 | 0.21
Table 9.15 Individual data used for Table 15
Control: vehicle + salt . Collagen ollagen-Collagen-
Rat Myocardial Volume fydroxyprolinel I IIT # (0-4) Fraction (ng/mg) mRNA mRNA
I I NN | em | eu (8s | 0.0 | 39 | 2.20 [| 1.60 | 1.60 89] 00 | 65 | 4.51 [| 0.92 | 0.80
[90] 00 | 44 | 4.07 [| 0.58 | 0.65
[91] 00 | 63 | 2.93 | 1.28 | 1.42 (92 oo [ 31 | 400 | 0.94 [ 1.05
93] oo [ a5 | 2.89 | 1.14 [ 1.00 6a | 0.0 | 3.9 [| 32a | 1.07 | 1.02 95 | 00 | 3.2 | 3.21 | 156 | 1.00
Se | 0.0 | sa [3.46 | 0.80 | 0.56
G27] 00 | 45 | 266 | nd | nd 128] 0.0 [60 | 270 | nd | nd
Mean| 0.0 [ 4.7 | 3.26 | 1.08 | 1.01 smu] 0.0 | 04 | 0.2 | 0.10 | 0.10 nd = No data were reported due to insufficient mRNA sample.
Table 9.15 (continued)
Aldosterone + salt \ ollagen-Collagen-
Rat Myocardial Collagen ydroxyproline T ITT
Necrosis (0- Volume 4) Fraction (%) (ng/mg) TRINA mRNA (AU) (AU)
IEC ICE EPPA BER NEC BT
99] 10 | 5.4 | 2.91 | 2.31 | 1.80 100] o0.0 | 3.2 | 6.28 | 0.25 | 0.44 (100 o00 [| 5.9 | 5.63 | 1.89 | 1.39 102] oo | 4.6 | 4.83 | 2.03 [ 1.17 103) 1.0 | 3.9 | 5.64 | 1.00 | 1.24 (104 00 | 4.8 | 5.29 | 1.20 [ 1.06 105s] 00 [| 46 [| 2.76 | 1.70 [ 1.31 130] oo [ 3.4 [| 2.60 | nd [| nd 32] 30 | so | 395 | wma | na
Mean| 0.8 | 5.1 | 4.04 | 1.33 | 1.08 [sem] 03 [ 0.5 | 0.40 | 0.24 [| 0.14 nd = No data were reported due to insufficient mRNA sample. * Data from this animal were not considered for statistical analysis and not included in the final results.
Table 9.15 (continued) ’ Eplerenone + aldosterone + salt
Rat | Myocardial Collagen ydroxyproline collagen ollagen-
Necrosis (0- Volume # 4) Fraction (%) (hg/mg) mRNA MRNA
I EE ER EE _ 1 am | (av)
3] To | aa | 2.55 | 0.86 | 0.60 152] 0.0 | 62 | 5.7 | 0.86 | 1.15 3s| 1.0 | ss | 652 | 0.0 | 1.16 136] 0.0 | 3.7 | 5.35 | 1.65 | 1.24 137] 0.0 | a2 | eso | i.aa | 1.70 138] 0.0 | 3.5 | 532 | 1.44 | 1.81 55] 1.0 | 3.3 | 2.72 | 0.50 | 0.60 a0] 0.0 | 37 | 3.43 | 1.24 | 1.61 ar] 0.0 | 52 | .41 | 1.69 | 2.21 143] 00 | 60 | 503 | 3.02 | 3.77
Table 9.16 Individual data used for Table 16
Control: vehicle + salt . ollagen-follagen-
Rac | Wrossrdia || COLI yavomyproting IT | x # 4) Fraction (%) (ug/mg) WRNA mRNA (AU) (AU)
Too | =3 | 3.00 | 1.65 [ 1.43 2 | oo | aa | 2.71 | 0.90 | 0.98 a | 00 | 6.4 | 2.95 | 1.65 | 1.02 6 | 0.0 | 7.9 | 3.02 | 0.90 | 1.28 7 | oo | s.8 | 2.80 | 0.87 | 0.62 se | oo | 7.7 | 5.84 [| 1.03 | 0.54 5 | oo | 60 | 5.45 | 0.65 | 0.94
Go| oo | 7a | 7.05 | 0.2 | 0.48
Mean] 0.0 | 6.2 | 3.98 [ 1.09 | 0.91 [sem| o.0 [| os | 0.65 | 0.13 | 0.12
Aldosterone + salt } ollagen-follagen- rac | rocazdiad || Colles Lyacormyprovind I | 1m # 4) Fraction (%) (kg /mg) mRNA RNA
I RA I NN Cc) NU SI 0.0
I 15 | es [vei | 2.20 | 0.75] | 3.0 | e3 | 400 | 1.32 | 2.04 “Te os | es | 3.88 | 2.02 | i.a3 ss | as | 3.05 | 2.54 | 1.28
Mean] 2.0 | 7 [| a9 | 225 | 1.35 ou | do | oe | ear | ow] . Table 9.16 (continued)
Eplerenone + aldosterone + salt ' . ollagen-flollagen-
Rat Myocardial Collagen ydroxyproline T IT
Necrosis (0- Volume # 4) Fraction (%) (hg/mg) mRNA mRNA 21] oo | sa | sas | 1.89 | 0.95 (22 | 00 | "so | e11 | 1.54 | 0.72 23] o.0 | 65 | 5.17 | 2.65 | 1.37 25 | 00 | 7.9 | "6.40 | 1.97 | 0.85 26 | 0.0 [7.1 | 2073 | 2.98 | 1.26 27 | 0.0 | 6.3 | 2.82 | 2.65 | 1.87 28] 00 [6.1 | 2.87 | 2.90 | 1.66 25 | 0.0 | sa | 2.82 | 2.88 | 2.89 30 | 0.0 | 78 [272 | 3.35 | 5.16
Mean| 0.0 | 6.2 [| 4.10 | 2.53 | 1.53 si] oo | 05 | 053 | 0.20 | 0.23 [24x] 0.0 | 4.4 | 5.75 | 2.01 [ 0.73 * Data from this animal were not considered for statistical analysis and not included in the final results.
Table 9.17 Individual data used for Table 17
Control: vehicle + salt
Rat | COX-2 [0steoponti ICAM VCAM 47] nd | nd | nd | 31.32 [ nd | nd 48 | nd | nd | na | 0.66 | nd | nd 51 | 1.04 | 0.04 | 1.00 | 1.17 | 0.5a | nd 52 | 0.95 | 0.73 | 0.71 | 0.80 | 1.17 | 1.17] 53 | 0.87 | 1.00 | 0.82 | 1.11 | 0.82 | 0.60 ] 5a | 188 | na | na | 0.50 | na | nd 55 | 1.00 | nd | nd | 0.52 | na | ma 56 | na | 1.66 | 1.67 | 1.50 | 1.00 | 0.86
Mean} 1.06 | 1.12 | 1.07 | 0.98 | 1.02 | 0.96 [sem] 0.18 | 0.16 | 0.17 | 0.12 | 0.07 | 0.14 nd = No data was reported due to insufficient mRNA sample.
Table 9.17 (continued) ) Aldosterone + salt
COX-2 [Osteopontin] MCP1 TGF-§ ICAM VCAM : 60 | 2.01 [ 0.95 | 3.06 [| 1.31 | 1.09 [ 2.06 61} 2.95 | 1.05 | 2.36 | 1.89 | 1.61 | 2.51 66 | 2.45 | 1.32 | 2.20 | 1.21 | 1.06 | 0.27 seM| 0.20 | 0-52 | 0.17 | 0.09 | 0.10 | 0.39 57%] o0.82 | 28.64 | 5.127 [ 1.35 | 1.68 [ 5.23 * Data from this animal were not considered for statistical analysis and not included in the final results.
Table 9.17 (continued)
Eplerenone + aldosterone + salt
Rat | cox-2 TGF- 3 ICAM VCAM
Ce PE Ge | aor | am | my 6s | 2.65 | 1.24 | 1.60 | 0.81 | 0.89 | 0.58 69 | 0.60 | 0.52 | 0.85 [ 0.51 | 0.89 | 0.22 70 | na | na | nd | 1.31 | nd | na 71] 1.16 | 0.27 | 0.83 | 0.80 | 0.40 | 0.57 72 | 0.82 | 0.60 | 1.74 | 1.02 [| 1.23 | nd 75 | 0.60 | 0.96 | 0.67 | 1.51 | 0.58 | 0.53
Mean| 1.25 | 0.75 [| 1.56 | 0.99 | 0.83 | 0.56 (sem| 0.29 | 0.12 | 0.25 [| 0.12 [ 0.10 | 0.08 nd = No data were reported due to insufficient mRNA ] sample.
Table 9.18 Individual data used for Table 18
Control: vehicle + salt
Rat | COX-2 Osteoponti MCP1 TGF-8 ICAM vVCAM a _ 1 89] nd | nd [nd | 1.00 | nd | nda 90 | 1.00 | 0.94 | 0.73 | 0.84 | 1.14 | na 96 | nd | nd |" nd | 0.74 | nd | nd nd = No data were reported due to insufficient mRNA sample.
Table 9.18 (continued)
Aldosterone + salt
Se UE |e | | ee 98] nd | nd | nd [ 1.26 | nd | nd 99 | 7.39 | 8.14 | 2.42 | 1.85 | 1.16 | 0.89 (00 | 1.83 | 1.02 | 1.87 | 0.55 | 1.15 | 0.65 102] 2.59 | 4.06 | 3.5 | 1.45 | 1.5 | 0.72] 103] 6.63 | 12.04 | 3.34 | 1.18 | 1.91 | 2.23 (104| 4.18 | 2.35 | 1.91 | 1.32 | 1.19 | 1.03 : nd = No data were reported due to insufficient mRNA . sample. [57+] 23.34 | e125 | 5.88 | 1.35 | 1.84 [ 1.75
* Data from this animal were not considered for statistical analysis and not included in the final results. . 5
Table 9.18 (continued) ) Eplerenone + aldosterone + salt
Rat COX-2 [Osteoponti MCP1 TGF-8 IcaMm VCAM
[134] 1.0 | "300 | 1.37 | 0.62 | 1.36 | 0.66 : 1141] 0.99 | "0.72 | 1.89 | 1.42 | 0.98 | 0.68 143] 0.86 | 0.99 | 1.20 | 2.41 | 0.83 | 0.68 (sz | o.a9 | 0:72 | 010 | 035 | Gos | 60
Table 2.19 Individual data used for Table 19
Control: vehicle + galt
Rat COX~2 Osteoponti MCP1 TGF-# ICAM VCAM 1] 1.15 | 0.81 | 2.39 | 0.53 | 1.01 | 0.96 2 | 1.75 [ "1.46 | 1.79 | 0.52 | 2.29 | 1.93 4 | 0.96 | 0.57 | 1.00 | 1.00 | 0.99 | mud 6 |] 0.95 | 0.82 | 0.81 | 1.19 | 1.60 | 1.38 7 [Toes | 1.13 | 0.52 | 1.00 | nd | nd] [& [73.07 [1.16 | 0.55 | 1.68 | 0.55 [0.45] © | 1.00 | 1.00 [1.52 | 0.50 | 0.96 | 1.00 20] nd | nd | nd | 1.24 | nd | nd
Mean| 1.11 | 0.89 [1.22 | 1.01 | 1.23 | T.1a . nd = No data were reported due to insufficient mRNA sample.
Aldosterone + salt
Rat | COX-2 [Osteoponti TGF-8 ICAM VCAM aw _| an (31 nd | nd | nd | war | nd | mm
[12 | 4.26 | 13.13 13 | 4.81 | 11.43 (14 | na | nd | nd | 1.20 | nd | ma 15 | 1.54 | 13.78 16 | nd | nd | nd | 1.49 | nd | ma : 18.44 14.88
Mean| 4.53 | 13.27 smu | os, | 345 | 1.25 | 035 | 0.22 | 049] nd = No data were reported due to insufficient mRNA sample.
Table 9.19 (continued)
Eplerenone + aldosterone + salt
Rat COX-2 [Osteoponti MCP1 TGF-8 ICAM VCAM 26} 3.71 | 1.88 | 2.10 | 0.96 | 1.26 | 0.79 28 | 2.11 | 1.28 | 1.43 | 1.54 | 0.60 | 0.57 20 | 1.34 | 1.43 | 5.58 | 1.32 | 0.99 | 0.61 nd = No data were reported due to insufficient mRNA sample. 24%] 12.21 | 54.57 * Data from this animal were not considered for statistical analysis and not included in the final results 1S Results
Blood pressure ' Blood pressure remained normal in vehicle + salt controls throughout the experiment (Table 10).
Aldosterone + salt induced a progressive increase in blood pressure with time. In animals receiving eplerenone + aldosterone + salt, systolic blood pressure was significantly reduced at days 8-30. However, blood . pressure remained elevated compared to vehicle + salt controls. . 5
Table 10. Effects of aldosterone + salt treatment alone or in combination with eplerenone on blood pressure over time
TE EE salt n salt n aldosterone + n 3 | a22x3 [4] 13246 [8] 1261 | 9 4 [123 x3 [4] 133+ar [8] 130%2¢ | 9 [aes 1 [4] 137 +a [8] 1322s [9 6 | 130+ [4] 1485+ | 8] 139 %3x | 9 7 | 132%1 [4] iss esx [8] 143 43x [5 8 | 13231 [4] 156+4x [8] 1a2x3+F | 5 9 | 1311 [4] teat sx [8] 142 43x | 9 $10] 1272 [7] 168 ex [8] 1a2x2¢F [9 11 | 128 x2 [7] 171 ex | 8 143 x34 | 9 $12 | 1292 [7] 178 +e [8] 1a5 3x | 9 © [23] 128 x3 [7] 182r6x | 8 147 23% | 9 14] 131 +4 [7] 1826+ | 9 | 150 ax | 9 (15 | 1302 [7] 1815 [9] 14g ax | 5] (16 | 120 +2 | 7] 1876+ | 9[ 15044 (27 130%2 [7] 1957+ [9] 15a xx | 5 (18 | 13143 | 7] 1966+ [9] as7x5+F | 9 (19 | 12722 [7] 200%6x [9] 1605+ | 9 120] 126 £3 [7] 203x5¢ [9] 160%s5% [9 (21 | 127+2 | 7] 208x4¢ [9] aesxexF | 9 22 | 128 +1 [7] 2004 | 9] 167 ex | 9 (23 | 1312 | 7] 208x4x [9] a72xex | 5 24 | 132 +2 [7] 210%+3¢ | 9] 17a ex | 5] 25] 130%2 | 7] 210 %+4* [9] 176 %ex* | 5 (26 [ 131 x2 [7] 2103+ [9] aso 7#f [5
These data are expressed graphically in Figure 1.
Values are mean + SEM of values obtained every 5 min over 24-hour period. *Significantly different from vehicle + salt, p<0.05.
# Significantly different from aldosterone + salt, pP<0.05.
Body weight, Myocardial Hypertrophy and ANP
Body weights were significantly lower in animals receiving aldosterone + salt treatment at days 7, 14, and 30 compared to vehicle + salt normotensive controls (Tables 11-13). The decrease in body weight induced by aldosterone + salt treatment was significantly attenuated by administration of eplerenone at day 30 (Table 11). Significant left and right ventricular hypertrophy occurred in response to aldosterone + salt treatment. Left ventricular hypertrophy was evident after 7 days of aldosterone + salt treatment (Table 11) whereas right ventricular hypertrophy was only evident after 30 days of aldosterone + salt treatment (Table 13). Eplerenone did not impact absolute ventricular weights or ventricular weight to tibia length ratios induced by aldosterone + salt treatment (Tables 11-13).
Significant elevations in atrial natiuretic peptide (ANP) mRNA levels were also observed in animals treated with aldosterone + salt (Tables 11-13). The ANP mRNA upregulation was significantly reduced by eplerenone after 30 days of treatment but not after 14 days (Table
Table 11. Effects of aldosterone + salt treatment ‘ alone or in combination with eplerenone in . rats after 7 days of treatment
Fina| ; ft | Right | .. . Left Right . 1 . , |Tibia|[Ventricle|Ventricle
Ventri|Ventri . \ ANP
Body Lengt|Weight /| Weight /
Group |___. cle cle hy I, mRNA
Weig Weight [Weight h Tibia Tibia (AT) ht (mg) (mg) (cm) Length Length (@ | ST] | mg/m) | (mg/mm) 3.8%0
Vehicle CL es7a19 178+5 | .01 175%5 47+1 Lao + salt 0) (n=10) | (n=10) (R510 (n=10) (n=10) (n=10)
Aldoster|277+5|736+25 18347 3.810 19446 % 4553 8.72x1. one + (n=7 * .03 51%* salt ) | (n=g) | 8) | (n_gy| (8) (n=8) (n=8)
Bplereno 28714 3.8%0 ne + 2.77%0. aldoster * 714420] 18215 .01 188+5 48+1 40% # one + (n=9| (n=10) | (n=10) | (n=10| (n=10) (n=10) (n=10) salt ) )
Values are mean * SEM measured after 7 days of treatment. *Significantly different from vehicle + salt control, p<0.05. *significantly different from aldosterone + salt, p<0.05.
Eplerenone dose was 100 mg/kg/day.
ANP = atrial natiuretic peptide.
AU = arbitrary units, measured relative to cyclophilin expression.
Table 12. Effects of aldosterone + salt treatment alone or in combination with eplerenone in rats after l4ays of treatment
Left Right Left Right
Final Ventri Ventr|Tibia [Ventricle|Ventricle ANP
Body icle |Lengt|Weight /| Weight / ‘ Group | . cle , cr cr MRNA
Weigh Weight Weigh| h Tibia Tibia (AT) t (g) (2a5p) t (cm) | Length Length me) | | (mg/m) | (mg/mm) 198+1{3.8%0 vehicle [211351545405] 0 .01 | 195%a 5o43 |Lr76%0. + salt | P1200 13)| (n=13| (n=13] (n=13) | (n=13) 86 ) ) ) (n=10)
Aldoster| 270% 817£22|18945 3-820 — 041 6.70%1. * = i - - * one (n=12 (rt) me (n= (n=12) (n=12) moo)
Eplereno ne + 2836 813x222 fae 3-820 01 4+6* 5945 6.6412. : aldoster * ’ = n 22% one + | (n=11 (n=11) (n=11{ (n=11 (n=11) (n=11) (n=10) salt ) ) )
Values are mean + SEM measured after 14 days of treatment. * Significantly different from vehicle + salt, p<0.05.
Eplerenone dose was 100 mg/kg/day.
ANP = atrial natiuretic peptide.
AU = arbitrary units, measured relative to cyclophilin : expression. :
Table 13. Effects of aldosterone + salt treatment alone or in combination with eplerenone in rats after 30 days of treatment : Left [Right Left Right
Final , .
Ventr |(Ventr| _... , entricle Ventricle
Body icle | icle Tibia Weight /| Weight / ANP
Group (Weigh) i oh [Wei p |Length Tibi Tibi mRNA a. eig eig (cm) ibia ibia (AU) (a) t t Length Length ot fre 0 hers 35 rs | pros + salt |314%8 TU |167x6| TTC 172%5 41+1 TTT 5 03 3 (n=8)
Aldoste rone + |[272+11910+2|192%8|3.9+0. 20.173. salt | ox ox * 02% 233x7* 4912% 36% (n=9)
Epleren one + aldoste| 493613 198+6{3.9%0. 24049 % 5140% 9.2042. 4 rone + | 4% * 00* 4% salt (n=9) , Values are mean + SEM measured after 30 days of treatment. *Significantly different from vehicle + salt, p<0.05. : * significantly different from aldosterone + salt, p<0.05.
Eplerenone dose was 100 mg/kg/day.
ANP = atrial natiuretic peptide.
AU = arbitrary units, measured relative to cyclophilin expression. ) Myocardial Fibrosis
Interstitial collagen volume fraction and hydroxyproline levels were not statistically different at any time point among the experimental groups (Tables 14-16). A modest increase in collagen type-I message was detected in aldosterone + salt and aldosterone + eplerenone + salt treatment at 30 days, compared to vehicle + salt controls (Table 16). Collagen type III mRNA levels were not significantly increased at any time point (Tables 14-16).
Table 14. Effects of aldosterone + salt treatment alone or in combination with eplerenone on myocardial injury and fibrosis in rats after 7 days of treatment
IMyocardia vd roxXyprot - 1 Tcvr | YoroXyproCollagen-) (11 en.
Group . ° line I
Necrosis (%) III (AU) (ng/mg) (aU) “0-4 J vy 4.440 + + 0.0+0.0 .5 3.5710.4 | 1.1020. 1.0940.13
Vehicle + salt] (n=10) 5 15 (n=10) (n=10| (n=10) (n=10) = ) + + +
Aldosterone + | 0020.0 >: x0 2.73503 13650. 1.42+0.12 salt | 078) nee) | (meg) (n=8) (n=6) 5.440
Eplerenone + | .06+0. .85+0.
Ldost | 0.0x0.0 .6 3 ee 310 oe 1.094+0.21 aldosterone + | (n=10) (n=10 (n=10) (n=10) (n=10) salt ) B - ’ 20 Values are mean * SEM measured after 7 days of treatment. . Eplerenone dose was 100 mg/kg/day.
ICVF = interstitial collagen volume fraction.
Collagen-I = Collagen type I mRNA.
Collagen-III = Collagen type III mRNA.
AU=arbitrary units, measured relative to cyclophilin expression.
Table 15. Effects of aldosterone + salt treatment alone or in combination with eplerenone on . myocardial injury and fibrosis in rats after 14 days of treatment , Myocardia Hy droxXypra 1 ICVF line Collagen-|Collagen-
Group | Necrosis (%) ) I (AU) | III (aU) jo | ha/m) | _ 4.7+0 + +
Vehicle + 0.0£0.0 .4 3.26%0.2 1 1.0820. 1.01%x0.10 (n=13) b 10 (n=10) salt = (n=13 (n=13) (n=10) = ) 5.1%+0 + +
Aldosterone +} 0.8%0.3 .5 4.0420.4 1 1.3330. 1, 4g10.14 (n=12) | (n=12 0 24 (n=9) salt = N (n=12) (n=9) -
Eplerenone + 4.510 + + 14 0.50.2 3 4.4080. Lede 1.61%0.26 alaosterone + (n=11) (n=11 (neil) ps (n=11) salt ) n= n=
Values are mean * SEM measured after 14 days of treatment.
Eplerenone dose was 100 mg/kg/day.
ICVF = interstitial collagen volume fraction.
Collagen-I = collagen type I mRNA.
Collagen-III = collagen type III mRNA.
AU = arbitrary units, measured relative to cyclophilin expression.
Table 16. Effects of aldosterone + salt treatment alone or in combination with eplerenone on myocardial injury and fibrosis in rats after 30 days of treatment
Myocardia ydroxyproCollagen- 1 ICVF 1ine I Collagen-
Group | Necrosis (%) III (AU) : (pg/mg) (aU) (0-4) | | EIEIO
Vehicle + salt] 6.2+0 | 3.98+0.6 { 1.0940. 0.0%0. = .91+ (n=8) ; 0.0 p - 13 0.91+0.12
Aldosterone + | 2.0x0.4 7.9+1 | 4.39%0.6 | 2.29+0. 1 + salt (n=9) * .0 2 47% + 390.20
Eplerenone + + .10%0. +
Aldosterone + | 0.0%0.0% | 0-250 | #105051 2.5380. 1 gq, 5, salt (n=9) | ) 20
Data are mean * SEM measured after 30 days of treatment. * Significantly different from vehicle, p<0.05. # Significantly different from aldosterone + salt, . p<0.05.
Eplerenone dose was 100 mg/kg/day.
ICVF = interstitial collagen volume fraction ' Collagen-I = collagen type I mRNA.
Collagen-III = collagen type III mRNA.
AU = arbitrary units, measured relative to cyclophilin expression.
Myocardial Histopathology
Myocardial tissue damage was evaluated after 7, 14, and 30 days of treatment using a semi-quantitative scoring system. Hearts from vehicle + salt controls were histologically normal at all timepoints. No vascular or myocardial lesions were identified in hearts from rats receiving aldosterone + salt after 7 days of treatment (Table 14). In contrast, focal arterial and myocardial alterations were observed starting at 14 days of treatment (Tables 15 and 16). Qualitative changes in the arteries and myocardium were similar after 14 days and 30 days of aldosterone + salt treatment, but the frequency and severity increased with time.
Administration of eplerenone markedly attenuated myocardial injury at all time points (Tables 14-16; Fig. 44) .
Gene Expression of Inflammatory Mediators
The expression levels of multiple proinflammatory ’ molecules were assessed using quantitative Taqman PCR analysis (Tables 17-19). Expression levels of cyclooxygenase-2 (COX-2) and monocyte chemoattractant protein-1 (MCP-1) were similarly and significantly increased by aldosterone + salt treatment at all time points. Osteopontin expression was also markedly upregulated after 14 days (~6-fold) and 30 days (~13- . fold) of aldosterone + salt treatment (Tables 18-19).
Transforming growth factor beta one (TGF-Op, mRNA levels
J 5 were not upregulated at any of the time points examined.
Intracellular adhesion molecule-1 (ICAM-1) mRNA expression was upregulated at day 14 and 30 of aldosterone + salt treatment, although increases were modest (Tables 9-10). Gene expression for vascular cell adhesion molecule-1 (VCAM-1) was increased two-fold at day 30 of aldosterone + salt treatment, however this increase did not reach statistical significance (Table 19). Expression of all marker genes was significantly reduced by eplerenone compared to gene expression in animals treated with aldosterone + salt.
Table 17. Effects of aldosterone + salt treatment alone or in combination with eplerenone on the relative mRNA expression of the inflammatory markers in rats after 7 days of treatment
Osteopo
COX-~-2 atin MCP-1 TGF-£1 ICAM VCAM
Group mRNA i mRNA mRNA | mRNA | mRNA
BN Ia BP) Ec Ml Mi Mi 1.0640 | 1.1240 | 1.07+0. | 0.9840 | 1.02%0 | 0:96+0
Vehicle + .18 16 17 .12 .12 .14 salt (n=6) ) (n=5) (n=10 | (n=5) | (n=5) (n=5) ) + + aldosterone 2.22+0}11.91+0 1 2.38%0.1} 1.3520 {1.2210 | 1.55+0 .29%* .51 7* .09 .10 .39 - + salt (n=8) | (n=8) (n=8) (n=8) (n=8) (n=8)
Eplerenone +| 1-250 0.7550 1.56£0.2| 0.99%0 | 0.8330 | 0.5650 dost .27 12 5 .12 .10 .08 alaosterone | (n-g) | (n=8) (n=8) | (n=10 | (n=7) | (n=6) + salt ) .
Values are mRNA expression means in arbitrary units *
SEM after 7 days of treatment (relative to cyclophilin expression).
* Significantly different from vehicle + salt, p<0.05. # Significantly different from aldosterone + salt, p<0.05.
Eplerenone dose was 100 mg/kg/day. ) 5 COX-2=cyclooxygenase-2.
MCP-1l=monocyte chemoattractant protein-1. . TGF-Pl= transforming growth factor beta 1.
ICAM=intracellular adhesion molecule-1.
VCAM=vascular cell adhesion molecule-1.
Table 18. Effects of aldosterone + salt treatment alone or in combination with eplerenone on the relative mRNA expression of the inflammatory markers in rats after 14 days of treatment cox-2 [058SOPORY wep 1 |ger-g1| Team | vean
Group mRNA a " MRNA | mRNA | mRNA | mRNA (aU) (AU) (AT) (AU) (AU) (20) 1.0740 | 1.13+0. | 1.04%0 |1.02+0|1.12+0] 0.9740 : Vehicle + .15 08 .08 .07 .07 L111 salt (n=7) (n=7) (n=10 | (n=7) (n=5) (n=7) )
Aldosteron | 4-340. 6.56%1.3| 2.76+0.(1.27+0| 1.474+0|1.16+0 72% 7* 32% .16 L12%* .19 e + salt | (n=g) (n=8) (n=8) | (n=9) | (n=8) | (n=8)
Eplerenone 2.02+0.} 2.9440.7| 1.59+0. Least 1.1940 0-830 49x * 2 * a 10% * : .09% : aldosteron | (p-11) | (n=11) | (n=11) (n=11)| ®=11 e + salt ! )
Values are mRNA expression means in arbitrary units +
SEM after 14 days of treatment (relative to cyclophilin expression) . * Significantly different from vehicle + salt, p<0.05. # Significantly different from aldosterone + salt, p<0.05.
Eplerenone dose was 100 mg/kg/day.
COX-2=cyclooxygenase-2.
MCP-l1l=monocyte chemoattractant protein-1. ’ TGF-Bl= transforming growth factor beta 1.
ICAM=intracellular adhesion molecule-1. . VCAM=vascular cell adhesion molecule-1.
Table 19. Effects of aldosterone + salt treatment alone or in combination with eplerenone on the relative mRNA expression of the ’ 5 inflammatory markers in rats after 30 days of treatment cox-2 osteopon MCP-1 (TGF-S1| ICAM | VCAM
Group | mRNA mRNA | TRNA | mRNA | mRNA | mRNA
AU
] an | AO GD GD | GF 0.99+£0.1 +
Vehicle + 1.11%0.1 1.22%0.2(1.01+0|1.2340.(1.1440. 1 1 1 7 13 25 25 salt = = = = = (n=7) (n=7) (n=7) (n=8) | (n=6) (n=5) + + +
Aldosterone 4.53+%0.9(13.27+1.14.54+1.2{1.33+0(|1.81%0.|2.14%0. 2% 43% 5% .16 22% 49 + salt (n=6) (n=6) (n=6) | (n=9) | (n=5) (n=5)
Eplerenone + 2.28%£0.3{2.59%+0.8|2.294£0.4|1.32+011.22%0.|1.0430. aldosterone 3x # 2% # 2% * 11 15 # 14% + salt (n=9) (n=9) (n=9) | (n=9) | (n=8) (n=9)
Values are mRNA expression means * SEM after 30 days of treatment (relative to cyclophilin expression). * Significantly different from vehicle + salt, p<0.05. * significantly different from aldosterone + salt, p<0.05.
Eplerenone dose was 100 mg/kg/day.
COX-2=cyclooxygenase-2.
MCP-l=monocyte chemoattractant protein-1.
TGF-P1l= transforming growth factor beta 1.
ICAM=intracellular adhesion molecule-1.
VCAM=vascular cell adhesion molecule-1.
Immunohistochemistry
The molecular analysis of the aldosterone + salt-induced Co proinflammatory response was further characterized using immunohistochemical analysis. The majority of cells adhering to the endothelium and infiltrating the . perivascular space stained positive for a monocyte/macrophage antibody (ED-1) and negative for a
T-cell antibody (CD-3). Significant expression of osteopontin was evident in hearts from aldosterone + salt treated rats, compared with the absence of osteopontin staining in hearts from vehicle + salt controls. Osteopontin expression was primarily localized to medial cells of affected and some . 5 unaffected coronary arteries, but was also present in some macrophages in the perivascular space and areas of myocardial necrosis. No evidence of significant
Osteopontin expression was found in cardiomyocytes.
ICAM-1 staining was identified in endothelial cells and in the perivascular space; however, VCAM-1 was primarily expressed in endothelial cells. Administration of eplerenone markedly blunted the aldosterone + salt treatment induced staining in myocardial tissue for all marker proteins evaluated.
In-situ Hybridization for Osteopontin mRNA
In-situ hybridization was performed to localize osteopontin expression in myocardial tissue. The majority of osteopontin mRNA was found in the medial cells of coronary arteries (Figure 3); however, osteopontin message was also identified in perivascular cells and cells infiltrating ischemic and necrotic areas. Osteopontin mRNA was not evident in cardiomyocytes. or in unaffected interstitial areas. :
CONCLUSION
Treatment of rats with aldosterone in the presence of salt induced vascular inflammation and cardiac tissue . damage. This damage induced by aldosterone + salt treatment was preceded by an inflammatory response that _ was characterized by the upregulation of proinflammatory molecules. Eplerenone markedly attenuated this initial vascular inflammatory response and subsequent myocardial injury.
Renal Hypertensive Rat Model > 5
A combination therapy of an aldosterone inhibitor and a cyclooxygenase-2 selective inhibitor may be evaluated for blood pressure lowering activity in the renal-artery ligated hypertensive rat, a model of high renin hypertension. In this model, six days after litigation of the left renal artery, both plasma renin : activity and blood pressure are elevated significantly (J.L. Cangiano et al, J. Pharmacol. Exp. Ther., 206, 310-313 (1979)). Male Sprague-Dawley rats are instrumented with a radiotelemetry blood pressure transmitter for continuous monitoring of blood pressure.
The rats are anesthetized with a mixture of ketamine-HCl (100 mg/kg) and acepromazine maleate (2.2 mg/kg). The abdominal aorta is exposed via a midline incision.
Microvascular clamps are placed on the aorta distal to the renal arteries and the iliac bifurcation. The aorta is punctured with a 22-gauge needle and the tip of a : catheter is introduced. The catheter, which is held in place by a ligature in the psoas muscle, is connected to a radiotelemetry blood pressure transmitter (Mini-Mitter
Co., Inc., Sunriver, OR). The transmitter is placed in the peritoneal cavity and sutured to abdominal muscle upon closing of the incision. Rats are housed singly ’ above a radiotelemetry receiver and are allowed standard rat cho and water ad libitum. At least five days are allowed for recovery from surgery. Mean arterial pressure and heart rate are measured on a data recorder as is appropriate, such as a mini-computer. Data Data are sampled for 10 seconds at 200-500 Hz at 2.5 to 10 min intervals 24 hours per day. After collecting \ control data for 24 hours, the rats are anesthetized with methohexital (30 mg/kg, i.p.) and supplemented as . 5 needed. A midline abdominal incision is made, approximately 2 cm in length to expose the left kidney.
The renal artery is separated from the vein near the aorta, with care taken not to tramatize the vein. The artery is completely ligated with sterile 4-0 silk. The incision is closed by careful suturing of the muscle layer and skin. Six days later, when MAP is typically elevated by 50-70 mmHg, an aldosterone antagonist or a combination with one or more Cyclooxygenase-2 selective inhibitors are administerd by gavage each day for about 8 weeks. Single drug dosing is carried out using 20 and 200 mg/kg/day of the aldosterone inhibitor (for example, eplerenone) and 1, 3, 10, 30, and 100 mg/kg/day of the cycloogenase-2 selective inhibitor. Drug mixtures are obtained by administering a combination of a dose of 1, 3, 10, 30, or 100 mg/kg/day of the cycloogenase-2 selective inhibitor with a dose of either 20 or 200 mg/kg/day of the aldosterone inhibitor. Blood pressure lowering is monitored by the radiotelemetry system and responses with the compounds are compared to a response obtained in vehicle-treated animals. Plasma and urinary sodium and potassium levels are monitored as a measure of the effectiveness of the aldosterone blockade. Urine samples are collected overnight using metabolic cages to : isolate the samples. Plasma samples are obtained by , 30 venous catheterization. Sodium and potassium are measured by flame photometry. Cardiac fibrosis is determined by histological and chemical measurements of the excised hearts following perfusion fixation. Left and right ventricles are weighed, embedded, and sectioned. Subsequently, sections are stained with
Nn picrosirius red and the red staining collagen areas are guantitated by computerized image analysis. The apex of v 5 the heart is acid digested and the free hydroxyproline measured colorimetrically. It is expected that MAP will be significantly lowered toward normal pressures in the : test animals, treated with the combination therapy and that the condition of myocardial fibrosis will be arrested or avoided.
Several other animal models are available which are appropriate for evaluation of prevention of cardiovascular conditions including the prevention of atherosclerosis. See Stehbens, Prog. Card. Dis., XXIX, 1007-28 (1986) and Zhang et al., Science, 258, 468-71 (1992) .
An APOe mouse model for atherosclerosis has been described by Roselear et al. (Arterioscle. Thromb. Vasc.
Biol., 16, 1013-18 (1996)). The aldosterone blocker should be active in preventing atherosclerotic lesions.
The biological evaluations described herein are useful in demonstrating the efficacy of combination therapies comprising an aldosterone receptor antagonist, and a NSAID, for the treatment or prevention of a cardiovascular disorder.
Although this invention has been described with respect to specific embodiments, the details of these ’ embodiments are not to be construed as limitations. . 5
All patent documents referenced herein are incorporated by reference.
Claims (1)
- What Is Claimed Is:. 1. A combination for the treatment or prevention of a cardiovascular disorder comprising a « 5 first amount of an aldosterone receptor antagonist and a second amount of a NSAID, wherein said first amount and said second amount together comprise a therapeutically- effective amount of said aldosterone receptor antagonist and said NSAID.2. A pharmaceutical composition for the treatment or prevention of a cardiovascular disorder comprising a first amount of an aldosterone receptor antagonist, a second amount of a NSAID, and one or more pharmaceutically acceptable carrier materials, wherein said first amount and said second amount together comprise a therapeutically-effective amount of said aldosterone receptor antagonist and said NSAID.3. The pharmaceutical composition of Claim 2 wherein said aldosterone receptor antagonist is an epoxy-steroidal aldosterone receptor antagonist.4. The pharmaceutical composition of Claim 3 wherein said epoxy-steroidal aldosterone receptor antagonist has an epoxy moiety fused to the "C" ring of the steroidal nucleus of a 20-spiroxane compound.’ 5. The pharmaceutical compogition of Claim 4 wherein said 20-spiroxane compound is characterized by the presence of a 9a-,lla-substituted epoxy moiety.6. The pharmaceutical composition of Claim 2 wherein said aldosterone receptor antagonist is selected : . from the group consisting of: Eplerenone; Pregn-4-ene-7,21-dicarboxylic acid, 9,11- epoxy-17-hydroxy-3-oxo-dimethyl ester, (7a,11a,17B8) -; 3'H-cyclopropal6, 7] pregna-4,6-diene-21-carboxylic acid, 9,1l-epoxy-6,7-dihydro-17-hydroxy- 3-oxo-, vy-lactone, (68,78,11a,178)-;Pregn-4-ene-7,21-dicarboxylic acid, 9,11- epoxy-17-hydroxy-3-oxo, 7-(l-methylethyl) ester, monopotassium salt, (7«,1la,178)-;Pregn-4-ene-7,21-dicarboxylic acid, 9,11- epoxy-17-hydroxy-3-oxo-, 7-methyl ester, monopotassium salt, (7o,lle,l178)-;3'H-cyclopropal6, 7] pregna-1,4,6-triene-21- carboxylic acid, 9,1l-epoxy-6,7-dihydro-17-hydroxy-3-0oxo0-, y-lactone, (68,78,11a)-;3'H-cyclopropal[6, 7] pregna-4,6-diene-21- carboxylic acid, 9,1ll-epoxy-6,7-dihydro-17-hydroxy- 3-oxo-, methyl ester, (68,78,11la,178)-;3’H-cyclopropal6, 7] pregna-4,6-diene-21-carboxylic acid, 9,1l-epoxy-6,7-dihydro-17-hydroxy- 3-oxo-, monopotassium salt, (68,76,11l«,178)-;3’H-cyclopropalé, 7] pregna-4,6-diene-21- carboxylic acid, 9,1l-epoxy-6,7-dihydro-17-hydroxy- * 3-oxo~, <y-lactone, (68,78,11a,178)-; Pregn-4-ene-7,21-dicarboxylic acid, 9,11- epoxy-17-hydroxy-3-oxo-, y-lactone, ethyl ester, (70,112,178) -; andPregn-4-ene-7,21-dicarboxylic acid, 9,11- epoxy-17-hydroxy-3-oxo-, y-lactone, l-methylethyl ester, (7¢,1llw,17B8)-.. 5 7. The pharmaceutical composition of Claim 2 wherein said aldosterone receptor antagonist is eplerenone.8. The pharmaceutical composition of Claim 7 wherein said NSAID is selected from the group consisting of acetaminophen, benoxaprofen, carprofen, diclofenac, : diflunisal, etodolac, tenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamate, mefenamic acid, nabumetone, naproxen, oxaprozin, oxyphenbutazone, phenylbutazone, piroxicam, sulindac, suprofen, tenidap, tolmetin, zomepirac, and aspirin.9. The pharmaceutical composition of Claim 8 wherein said NSAID is selected from the group consisting of acetaminophen, benoxaprofen, carprofen, diclofenac, diflunisal, etodolac, fenoprofen, flurbiprofen, and ibuprofen.10. The pharmaceutical composition of Claim 8 wherein said NSAID is selected from the group consisting of indomethacin, ketoprofen, ketorolac, meclofenamate, mefenamic acid, nabumetone, naproxen, oxaprozin, ' oxyphenbutazone. ) 11. The pharmaceutical composition of Claim 8 wherein said NSAID is selected from the group consisting of phenylbutazone, piroxicam, sulindac, suprofen, tenidap, tolmetin, zomepirac, and aspirin.12. The pharmaceutical composition of Claim 8 w 5 wherein said NSAID and said aldosterone receptor antagonist are present in said combination in a weight ratio range from about one-to-one to about one-to-twenty of said NSAID to said aldosterone receptor antagonist.13. The pharmaceutical composition of Claim 12 wherein said weight ratio range is from about one-to- : five to about one-to-fifteen.14. The pharmaceutical composition of Claim 12 wherein said weight ratio is about one-to-ten.15. The pharmaceutical composition of Claim 2 wherein said aldosterone receptor antagonist is spironolactone.16. The pharmaceutical composition of Claim 15 wherein said NSAID is selected from the group consisting of acetaminophen, benoxaprofen, carprofen, diclofenac, diflunisal, etodolac, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamate, mefenamic acid, nabumetone, naproxen, oxaprozin, oxyphenbutazone, phenylbutazone, piroxicam, sulindac, suprofen, tenidap, tolmetin, a zomepirac, and aspirin. RE17. The pharmaceutical composition of Claim 16 wherein said NSAID and said aldosterone receptor antagonist are present in said combination in a weightLE | o | Ll ’ ® 120 oo ratio range from about one-to-one to about one-to-twenty of said NSAID to said aldosterone receptor antagonist.18. The pharmaceutical composition of Claim 17 wherein said weight ratio range is from about one-to- ) five to about one-to-fifteen. -19. The pharmaceutical composition of Claim 18 wherein said weight ratio is about one-to-ten. :"20. The pharmaceutical composition.of Claim 2 wherein said NSAID is selected from the group consisting . } of acetaminophen, benoxaprofen, carprofen, diclofenac, ‘diflunisal, etodolac, fenoprofen, flurbiprofen, - ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamate, mefenamic acid, nabumetone, naproxen, oxaprozin, oxyphenbutazone, phenylbutazone, piroxicam, sulindac, suprofen, tenidap, tolmetin, zomepirac and aspirin. : E21. A method for the prevention of a . cardiovascular disorder in a subject comprising Co administering to the subject a first amount of an aldosterone receptor antagonist and a second amount of a NSAID, wherein said first amount and said second amount together comprise an effective amount of said aldosterone receptor antagonist and said NSAID.30 . 22. The method of Claim 21 wherein the cardiovascular disorder is selected from the group consisting of hypertension, heart failure, coronary artery disease, aneurysm, arteriosclerosis, AMENDED SHEET® 121 atherosclerosis, myocardial infarction, embolism, stroke, thrombosis, angina, vascular plaque inflammation, vascular plague rupture, Kawasaki disease, calcification and inflammation. - oo23. The method of Claim 21 wherein the cardiovascular disorder is selected from the group : consisting of coronary artery disease, aneurysm, arteriosclerosis, atherosclerosis, myocardial infarction, embolism, stroke, thrombosis, angina, : , vascular plaque inflammation, vascular plague rupture, Kawasaki disease, calcification and inflammation.24. The method of Claim 21 wherein said aldosterone receptor antagonist is a spirolactone-type compound. : 25. The method of Claim 21 wherein said Co aldosterone receptor antagonist is spironolactone. :26. The method of Claim 21 wherein said NSAID is selected from the group consisting of acetaminophen, benoxaprofen, carprofen, diclofenac, diflunisal, etodolac, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamate, mefenamic acid, nabumetone, naproxen, oxaprozin, oxyphenbutazone, phenylbutazone, piroxicam, .sulindac, : suprofen, tenidap, tolmetin, zomepirac and aspirin. © 27. The method of Claim 21 wherein said NSAID © is selected from the group consisting of acetaminophen, diclofenac, fenoprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamate, nabumetone, AMENDED SHEET naproxen, oxaprozin, phenylbutazone, piroxicam, sulindac, tolmetin, and aspirin.28. The method of Claim 21 wherein said. 5 aldosterone receptor antagonist is an epoxy-steroidal aldosterone receptor antagonist.29. The method of Claim 28 wherein said epoxy-steroidal compound has an epoxy moiety fused to the “C” ring of the steroidal nucleus of a 20-spiroxane.compound . : :30. The method of Claim 29 wherein said 20- spiroxane compound is characterized by the presence of a 9-alpha,ll-beta-substituted epoxy moiety.31. The method of Claim 28 wherein said epoxy-steroidal compound is selected from the group consisting of: Eplerenone; Pregn-4-ene-7,21l-dicarboxylic acid, 9,11- epoxy-17-hydroxy-3-oxo-dimethyl ester, (70,11a,17B) -; 3'H~cyclopropa [6,7] pregna-4,6-diene-21- carboxylic acid, 9,1l-epoxy-6,7-dihydro-17-hydroxy- 3-oxo-, y-lactone, (68,78,11la,178)-; Pregn-4-ene-7,21-dicarboxylic acid, 9,11- epoxy-17-hydroxy-3-oxo, 7-(l-methylethyl) ester, monopotassium salt, (7«,lla,17B8)-; ) Pregn-4-ene-7,21l-dicarboxylic acid, 9,11- epoxy-17-hydroxy-3-oxo-, 7-methyl ester, monopotassium salt, (7«,1lo,178)-;3'H-cyclopropal6, 7]lpregna-1,4,6-triene-21- carboxylic acid, 9,1l-epoxy-6,7-dihydro-17-hydroxy- . 3-oxo-, y-lactone, (68,78,11la)-; : 3'H-cyclopropal6, 7] pregna-4,6-diene-21- ~ 5 carboxylic acid, 9,1l-epoxy-6,7-dihydro-17-hydroxy- 3-oxo-, methyl ester, .(68,78,11a,1786)-; 3’H-cyclopropalé, 7] pregna-4,6-diene-21- carboxylic acid, 9,1l-epoxy-6,7-dihydro-17-hydroxy- 3-o0xo-, monopotassium salt, (68,78,11lx,178) -; 3'H-cyclopropa [6, 7] pregna-4,6-diene-21- carboxylic acid, 9,1ll-epoxy-6,7-dihydro-17-hydroxy- 3-o0xo0-, v-lactone, (6B8,78,11x,178) -; Pregn-4-ene-7,21-dicarboxylic acid, 9,11- epoxy-17-hydroxy-3-oxo-, y-lactone, ethyl ester, (7, 11,178) -; and Pregn-4-ene-7,21-dicarboxylic acid, 9,11- epoxy-17-hydroxy-3-oxo-, y-lactone, 1l-methylethyl ester, (7«o,1la,178)-.32. The method of Claim 21 wherein said aldosterone receptor antagonist is eplerenone.33. The method of Claim 32 wherein said NSAID is selected from the group consisting of acetaminophen, Dbenoxaprofen, carprofen, diclofenac, diflunisal, etodolac, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamate, mefenamic acid, nabumetone, naproxen, oxaprozin, oxyphenbutazone, phenylbutazone, piroxicam, sulindac, } 30 suprofen, tenidap, tolmetin, zomepirac and aspirin.34. The method of Claim 21 wherein the NSAID is selected from the group consisting of acetaminophen,benoxaprofen, carprofen, diclofenac, diflunisal, etodolac, fenoprofen, f£lurbiprofen, ibuprofen,. indomethacin, ketoprofen, ketorolac, meclofenamate, mefenamic acid, nabumetone, naproxen, oxaprozin, - 5 oxyphenbutazone, phenylbutazone, piroxicam, sulindac, suprofen, tenidap, tolmetin, zomepirac and aspirin.35. The method of Claim 21 wherein said aldosterone receptor antagonist and said NSAID are administered in a sequential manner.36. The method of Claim 21 wherein said aldosterone receptor antagonist and said NSAID are administered in a substantially simultaneous manner.37. The method of Claim 32 wherein said eplerenone is administered in a daily dose range from about 0.1 mg to about 400 mg.38. The method of Claim 32 wherein said . eplerenone is administered in a daily dose range from about 1 mg to about 200 mg.39. The method of Claim 32 wherein said eplerenone is administered in a daily dose range from about 1 mg to about 100 mg.40. The method of Claim 32 wherein said eplerenone is administered in a daily dose range from about 10 mg to about 100 mg.41. The method of Claim 32 wherein said eplerenone is administered in a daily dose range from v kis ® 03/063908 : oo PCT/US03/02923 : : about 25 mg to about 100 mg. : . : © 42. The method of Claim 32 wherein said : eplerenone is administered in a daily dose selected from the group consisting of 5 mg, 10mg, 12.5 mg, 25 mg, 50 mg, 75mg, and 100 wg. . " 43, The method of Claim 32 wherein said eplerenone is administered in a daily dose selected from . the group consisting of 25 mg, 50 mg and 100 mg.44. A method for the prevention of an inflammation-related disorder in a subject comprising : administering to the subject a first amount of an Le aldosterone receptor antagonist and a second amount of a NSAID, wherein said first amount and said second amount together are sufficient to alter the expression of one or more expression products involved, directly or indirectly, in the regulation of inflammation in the subject. oo: .45. The method of Claim 44 wherein said ° inflammation-related disorder occurs in a tissue of said subject.46. The method of Claim 44 wherein said inflammation-related disorder occurs in an organ of said subject.47. The method of Claim 46 wherein said organ is the heart. AMENDED SHEET :48. The method of Claim 46 wherein said organ is the brain. }49. The method of Claim 46 wherein said organ - 5 is the kidney.50. The method of Claim 44 wherein the increased expression of one or more of said expression products is involved, directly or indirectly, in the regulation of inflammation in the subject.51. The method of Claim 44 wherein the decreased expression of FR more of said expression products is involved, directly or indirectly, in the regulation of inflammation in the subject.52. The method of Claim 44 wherein two or more of said expression products are co-expressed simultaneously.53. The method of Claim 44 wherein two or more of said expression products are co-expressed sequentially.54. The method of Claim 44 wherein said expression products are selected from the group consisting of cyclooxygenase-2, osteopontin, MCP-1, ICAM-1, VCAM-1, ANF, a.f;, Inf-y, IL-1, TNF-a, NADH/NADPH oxidase, superoxide free radicals, TXA2, b- FGF, CD44, endothelin, Angiotensin II receptor, active t-PA, inactive t-PA, PAI-1, CRP, IL-6, IL-10, IL-12, Troponin T, HSP65, amyloid, Phospholipase A2,fibrinogen, CD40/CD40L, collagen binding integrin alfsl and collagen binding integrin a2f31.55. The method of Claim 44 wherein said - 5 expression products are selected from the group consisting of cyclooxygenase-2, osteopontin, MCP-1, ICAM-1, VCAM-1, ANF, a¢B;, Inf-y, IL-1, TNF-a, NADH/NADPH oxidase, superoxide free radicals, TXA2, b- FGF, CD44, endothelin, Angiotensin II receptor, active t-PA, inactive t-PA and PAI-1. ) 56. The method of Claim 44 wherein said expression product is cyclooxygenase-2.57. The method of Claim 56 wherein said cyclooxygenase-2 ig co-expressed with one or more expression products selected from the group consisting of osteopontin, MCP-1, ICAM-1 and VCAM-1.58. The method of Claim 44 wherein said expression product is osteopontin.59. The method of Claim 58 wherein said osteopontin is co-expressed with one or more expression - products selected from the group consisting of cyclooxygenase-2, MCP-1, ICAM-1 and VCAM-1.60. The method of Claim 44 wherein said expression product is MCP-1. :61. The method of Claim 60 wherein said MCP-1 is co-expressed with one or more expression products selected from the group consisting of cyclooxygenase-2, osteopontin, ICAM-1 and VCAM-1.62. The method of Claim 44 wherein said « 5 expression product is ICAM-1.63. The method of Claim 62 wherein said ICAM- 1 is co-expressed with one or more expression products selected from the group consisting of cyclooxygenase-2, osteopontin, MCP-1 and VCAM-1.64. The method of Claim 44 wherein said expression product is VCAM-1. :65. The method of Claim 64 wherein said VCAM- 1 is co-expressed with one or more expression products - selected from the group consisting of cyclooxygenase-2, osteopontin, ICAM-1 and MCP-1.66. A kit for the treatment or prevention of a cardiovascular disorder comprising an aldosterone receptor antagonist and a NSAID.67. The kit of Claim 66 further comprising written instructions stating how the contents of said kit can be used by a subject.68. The kit of Claim 67 wherein the written : instructions further state how a subject can use the contents of said kit to obtain a therapeutic effect without inducing unwanted side-effects.PCT/US03/02923 ® 12969. The kit of Claim 67 wherein the written instructions comprise all or a part of the product label approved by a drug regulatory agency for said kit.70. Use of an aldosterone receptor antagonist and a NSAID in the manufacture of a preparation for the treatment or prevention of a cardiovascular disorder in a subject. ]71. Use of an aldosterone receptor antagonist in the manufacture of a preparation for use with a NSAID for the treatment or prevention of a cardiovascular disorder in a subject.72. Use of a NSAID in the manufacture of a preparation for use with an aldosterone receptor antagonist for the treatment or prevention of a cardiovascular disorder in a subject. : 73. Use of any one of Claims 70 to 72 wherein the cardiovascular disorder is selected from the group consisting of hypertension, heart failure, coronary artery disease, aneurysm, arteriosclerosis, : atherosclerosis, myocardial infarction, embolism, stroke, thrombosis, angina, vascular plaque inflammation, vascular plaque rupture, Kawasaki disease, calcification © and inflammation. AMENDED SHEETPCT/US03/02923 ® 13074. Use of any one of Claims 70 to 72 wherein the cardiovascular disorder is selected from the group consisting of coronary artery disease, aneurysm, arteriosclerosis, atherosclerosis, myocardial infarction, embolism, stroke, thrombosis, angina, vascular plague inflammation, vascular plaque rupture, Kawasaki disease, calcification and inflammation.75. Use of any one of Claims 70 to 72 wherein said aldosterone receptor antagonist is a spirolactone- : type compound.76. Use of any one of Claims 70 to 72 wherein said aldosterone receptor antagonist is spironolactone.77. Use of any one of Claims 70 to 72 wherein said NSAID is selected from the group consisting of acetaminophen, benoxaprofen, carprofen, diclofenac, © diflunisal, etodolac, fenoprofen, flurbiprofen, : ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamate, mefenamic acid, nabumetone, naproxen, oxaprozin, oxyphenbutazone, phenylbutazone, piroxicam, sulindac, suprofen, tenidap, tolmetin, zomepirac and aspirin.78. Use of any one of Claims 70 to 72 wherein said NSAID is selected from the group consisting of acetaminophen, diclofenac, fenoprofen, ibuprofen, AMENDED SHEET :: : : PCT/US03/02923 indomethacin, ketoprofen, ketorolac, meclofenamate, oo : nabumetone, naproxen, oxaprozin, phenylbutazone, piroxicam, sulindac, tolmetin, and aspirin. : 79. Use of any one of Claims 70 to 72 wherein said aldosterone receptor antagonist is an epoxy- steroidal aldosterone receptor antagonist.80. Use of Claim 79 wherein said epoxy- steroidal compound has an epoxy moiety fused to the "C" : ring of the steroidal nucleus of a 20-spiroxane compound.81. Use of Claim 80 wherein said 20-spiroxane compound is characterized by the presence of a 9- alpha, ll-beta-substituted epoxy moiety. :82. Use of Claim 79 wherein said epoxy- : steroidal compound is selected from the group listed in Claim 31. : : 83. Use of any one of Claims 70 to 72 wherein : said aldosterone receptor antagonist is eplerenomne.84. Use of Claim 83 wherein said NSAID is selected from the group consisting of acetaminophen, benoxaprofen, carprofen, diclofenac, diflunisal, etodolac, fenoprofen, flurbiprofen, ibuprofen, AMENDED SHEETPCTIUS03/02923 ® 132 indomethacin, ketoprofen, ketorolac, meclofenamate, mefenamic acid, nabumetone, naproxen, oxaprozin, : oxyphenbutazone, phenylbutazone, piroxicam, sulindac, suprofen, tenidap, tolmetin, zomepirac and aspirin. . : Co 85. Use of any one of Claims 70 to 72 wherein the NSAID is selected from the group consisting of acetaminophen, benoxaprofen, carprofen, diclofenac, CL diflunisal, etodolac, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, Co meclofenamate, mefenamic acid, nabumetone, naproxen, oo oxaprozin, oxyphenbutazone, phenylbutazone, piroxicam, : sulindac, suprofen, tenidap, tolmetin, zomepirac and aspirin.15 .‘86. Use of Claim 71 or Claim 72 wherein said aldosterone receptor antagonist and said NSAID are administrable in a sequential manner.87. Use of Claim 71 or Claim 72 wherein said aldosterone receptor antagonist and said NSAID are administrable in a substantially simultaneous manner.8s. Use of Claim 83 wherein said eplerencne is administered in a daily dose range from about 0.1 mg to about 400 mg. AMENDED SHEET :PCT/US03/02923 ® 13389. Use of Claim 83 wherein said eplerenone is administrable in a daily dose range from about 1 mg to ) about 200 mg. :90. Use of Claim 83 wherein said eplerenone is administrable in a daily dose range from about 1 mg to about 100 mg.91. Use of Claim 83 wherein said eplerenone is administrable in a daily dose range from about 10 mg to about 100 mg. © 92. Use of Claim 83 wherein said eplerenone is administrable in a daily dose range from about 25 mg to about 100 mg. : : 93. Use of Claim 83 wherein said eplerenone is . administrable in a daily dose selected from the group consisting of 5 mg, 10 mg, 12.5 mg, 25 mg, 50 mg, 75 mg, and 100 mg. Co94. Use of Claim 83 wherein said eplerenone is administrable in a daily dose selected from the group consisting of 25 mg, 50 mg and 100 mg.95. Use of an aldosterone receptor antagonist and a NSAID in the manufacture of a preparation for the treatment or prevention of an inflammation-related AMENDED SHEET :PCT/US03/02923® . 134 disorder in a subject, wherein said preparation is sufficient to alter the expression of one or more expression products involved, directly or indirectly, in the regulation of inflammation in the subject.96. Use of an aldosterone receptor antagonist in the manufacture of a preparation for use with a NSAID for the treatment or prevention of an inflammation- ~ related disorder in a subject, wherein said antagonist and said NSAID together are sufficient to alter the expression of one or more expression products involved, : directly or indirectly, in the regulation of inflammation in the subject.97. Use of a NSAID in the manufacture of a preparation for use with an aldosterone receptor : antagonist for the treatment or prevention of an ‘inflammation-related disorder in a subject, wherein said antagonist and said NSAID and said antagonist together are sufficient to alter the expression of one or more expression products involved, directly or indirectly, in the regulation of inflammation in the subject.98. Use of any one of Claims 95 to 97 wherein said inflammation-related disorder occurs in a tissue of said subject. AMENDED SHEET :: : PCT/US03/02923 ® 13599. Use of any one of Claims 95 to 97 wherein said inflammation-related disorder occurs in an organ of said subject. © 100. Use of Claim 99 wherein said organ is the heart.101. Use of Claim 99 wherein said organ is the brain.. 102. Use of Claim 99 wherein said organ is the kidney.103. Use of any one of Claims 95 to 97 wherein Lo 15 the increased expression of one or more of said expression products is involved, directly or indirectly, in the regulation of inflammation in the subject. . 104. Use of any one of Claims 95 to 97 wherein the decreased expression of one or more of said expression products is involved, directly or indirectly, in the regulation of inflammation in the subject. © 105. Use of any one of Claims 95 to 97 wherein two or more of said expression products are co-expressed simultaneously. AMENDED SHEET :PCT/US03/02923 ® 136106. Use of any one of Claims 95 to 97 wherein two or more of said expression products are co-expressed sequentially.107. Use of any one of Claims 95 to 97 wherein said expression products are selected from the group : consisting of cyclooxygenase-2, osteopontin, MCP-1, ICAM- 1, VCAM-1, ANF, a, B;, Inf-y, IL-1, TNF-a, NADH/NADPH oxidase, superoxide free radicals, TXA2, b-FGF, CD44, endothelin, Angiotensin II receptor, active t-PA, inactive t-PA, PAI-1, CRP, IL-6, IL-10, IL-12, Troponin ~T, HSP65, amyloid, Phospholipase AZ2, fibrinogen, CD40/CD40L, collagen binding integrin all and collagen binding integrin a2R1. :108. Use of any one of Claims 95 to 97 wherein oo said expression products are selected from the group consisting of cyclooxygenase-2, osteopontin, MCP-1, ICAM- 1, VCAM-1, ANF, a, B3;, Inf-v, IL-1, TNF-a, NADH/NADPH a oxidase, superoxide free radicals, TXA2, b-FGF, CD44, endothelin, Angiotensin II receptor, active t-PA, inactive t-PA and PAI-1.109. Use of any one of Claims 95 to 97 wherein said expression product is cyclooxygenase-2.110. Use of Claim 109 wherein said cyclooxygenase-2 is co-expressed with one or more AMENDED SHEET :PCT/US03/02923 4 127 expression products selected from the group consisting of osteopontin, MCP-1, ICAM-1 and VCAM-1.111. Use of any one of Claims 95 to 97 wherein said expression product is osteopontin. -112. Use of Claim 111 wherein said osteopontin : is co-expressed with one or more expression products selected from the group consisting of cyclooxygenase-2, MCP-1, ICAM-1 and VCAM-1.113. Use of any one of Claims 95 to 97 wherein said expression product is MCP-1.114. Use of Claim 113 wherein said MCP-1 is co. expressed with one or more expression products selected from the group consisting of cyclooxygenase-2, osteopontin, ICAM-1 and VCAM-1. - © 115. Use of any one of Claims 95 to 97 wherein said expression product. is ICAM-1.116. Use of Claim 115 wherein said ICAM-1 is : co-expressed with one or more expression products selected from the group consisting of cyclooxygenase-2, osteopontin, MCP-1 and VCAM-1. AMENDED SHEET :: | PCT/US03/02923 ® 138117. Use of any one of Claims 95 to 97 wherein 3 said expression product is vcam-1.118. Use of Claim 117 wherein said VCAM-1 is co-expressed with one or more expression products : selected from the group consisting of cyclooxygenase-2, osteopontin, ICAM-1 and MCP-1. }119. A substance or composition for use in a method for the treatment or prevention of a cardiovascular disorder in a subject, said substance or composition comprising an aldosterone receptor antagonist oo and a NSATD, and said method comprising administering to the subject a therapeutically-effective amount of said substance or compassion.120. A substance or composition for use with a NSAID in a method for the treatment or prevention of a cardiovascular disorder in a subject, said substance or composition comprising an aldosterone receptor antagonist, and said method comprising administering to the subject a therapeutically-effective amount of said : substance or composition and said NSAID. | 121. A substance or composition for use with an aldosterone receptor antagonist in a method for the treatment or prevention of a cardiovascular disorder in a subject, said substance or composition comprising a AMENDED SHEETPCT/US03/02923 ® 139 NSAID, and said method comprising administering to the subject a therapeutically-effective amount of said substance or composition and said aldosterone receptor antagonist. -122. A substance or composition for use in a : method of treatment or prevention of any one of Claims 119 to 121 wherein the cardiovascular disorder is selected from the group consisting of hypertension, heart failure, coronary artery disease, aneurysm, arteriosclerosis, atherosclerosis, myocardial infarction, embolism, stroke, thrombosis, angina, vascular plaque inflammation, vascular plaque rupture, Kawasaki disease, calcification and inflammation. oo123. A substance or composition for use in a method of treatment or prevention of any one of Claims 119 to 121 wherein the cardiovascular disorder is selected from the group consisting of coronary artery disease, aneurysm, arteriosclerosis, atherosclerosis, myocardial infarction, embolism, stroke, thrombosis, angina, vascular plaque inflammation, vascular plaque : rupture, Kawasaki disease, calcification and inflammation. ~ 124. A substance or composition for use in a method of treatment or prevention of any one of Claims AMENDED SHEET :PCT/US03/02923 ® 140 . 119 to 121 wherein said aldosterone receptor antagonist is a spirolactone-type compound. :125. A substance or composition for use in a method of treatment or prevention of any one of Claims 119 to 121 wherein said aldosterone receptor antagonist is spironolactone.126. A substance or composition for use in a method of treatment or prevention of any one of Claims . 119 to 121 wherein said NSAID is selected from the group consisting of acetaminophen, benoxaprofen, carprofen, ‘diclofenac, diflunisal, etodolac, fencoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamate, mefenamic acid, nabumetone, naproxen, oxaprozin, oxyphenbutazone, phenylbutazone, piroxicam, sulindac, suprofen, tenidap, tolmetin, zomepirac and aspirin. }127. A substance or composition for use in a method of treatment or prevention of any one of Claims 119 to 121 wherein said NSAID is selected from the group consisting of acetaminophen, diclofenac, fenoprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamate, nabumetone, naproxen, oxaprozin, phenylbutazone, piroxicam, sulindac, tolmetin, and aspirin. AMENDED SHEET: | PCT/US03/02923128. A substance or composition for use in a method of treatment or prevention of any one of Claims 119 to 121 wherein said aldosterone receptor antagonist is an epoxy- steroidal aldosterone receptor antagonist. : 129. A substance or composition for use in a method of treatment or prevention of Claim 128 wherein said epoxy-steroidal compound has: an epoxy moiety fused to the "C" ring of the steroidal nucleus of a 20- spiroxane compound.130. A substance or composition for use in a so sm method of treatment or prevention of Claim 128 wherein Sa ‘said 20-spiroxane compound is characterized by the presence of a 9-alpha, 11-beta-substituted epoxy moiety.131. A substance or composition for use in a method of treatment or prevention of Claim 128 wherein said epoxy-steroidal compound is selected from the group listed in Claim 31.132. A substance or composition for use in a method of treatment or prevention of any one of Claims 119 to 121 wherein said aldosterone receptor antagonist is eplerenone.133. A substance or composition for use in a method of treatment or prevention of Claim 132 wherein AMENDED SHEET oo PCT/US03/02923 ® 142 said NSAID is selected from the group consisting of : acetaminophen, benoxaprofen, carprofen, diclofenac, diflunisal, etodolac, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, : 5 | meclofenamate, mefenamic acid, nabumetone, naproxen, oxaprozin, oxyphenbutazone, phenylbutazone, piroxicam, a sulindac, suprofen, tenidap, tolmetin, zomepirac and aspirin.134. A substance or composition for use in a method of treatment or prevention of any one of Claims 119 to 121 wherein the NSAID is selected from the group consisting of acetaminophen, benoxaprofen, carprofen, diclofenac, diflunisal, etodolac, fenoprofen, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, meclofenamate, mefenamic acid, nabumetone, naproxen, oxaprozin, oxyphenbutazone, phenylbutazone, piroxicam, sulindac, suprofen, tenidap, tolmetin, zomepirac and aspirin. oo oo135. A substance or composition for use in a method of treatment or prevention of Claim 120 or Claim 121 wherein said aldosterone receptor antagonist and said NSAID are administered in a sequential manner. : © 136. A substance or composition for use in a method of treatment or prevention of Claim 120 or Claim 121 wherein said aldosterone receptor antagonist and said AMENDED SHEET: PCT/US03/02923 ¥ ® 143 : NSAID are administered in a substantially simultaneous manner.137. A substance or composition for use in a method of treatment or prevention of Claim 132 wherein said eplerenone is administered in a daily dose range : from about 0.1 mg to about 400 mg. SE138. A substance or composition for use in a method of treatment or prevention of Claim 132 wherein said eplerenone is administered in a daily dose range from about 1 mg to about 200 mg.139. A substance or composition for use in a method of treatment or prevention of Claim 132 wherein said eplerenone is administered in a daily dose range from about 1 mg to about 100 mg. oo 140. A substance or composition for use in a © 20 method of treatment or prevention of Claim 132 wherein : said eplerenone is administered in a daily dose range from about 10 mg to about 100 mg.141. A substance or composition for use in a method of treatment or prevention of Claim 132 wherein said eplerenone is administered in a daily dose range : from about 25 mg to about 100 mg. AMENDED SHEET :PCT/US03/02923 ® } 144 :142. A substance or composition for use in a : | method -of treatment or prevention of Claim 132 wherein said eplerenone is administered in a daily dose selected from the group consisting of 5 mg, 10 mg, 12.5 mg, 25 mg, 50 mg, 75 og, and 100 mg.143. A substance or composition for use in a method of treatment or prevention of Claim 132 wherein said eplerenone is administered in a daily dose selected from the group consisting of 25 mg, 50 mg and 100 mg. _ 144. A substance or composition for use in a : method for the treatment or prevention of an ~ inflammation-related disorder in a subject, said substance or composition comprising an aldosterone receptor antagonist and a NSAID, and said method comprising administering to the subject an effective amount of said substance or composition sufficient to alter the expression of one or more expression products involved, directly or indirectly, in the regulation of inflammation in the subject.145. A substance or composition for use with a NSAID in a method for the treatment or prevention of an inflammation-related disorder in a subject, said oo substance or composition comprising an aldosterone receptor antagonist, and said method comprising administering to the subject a first amount of said AMENDED SHEETPCT/US03/02923 ® 145 | -. : substance or composition and a second amount of said NSAID, wherein said first amount and said second amount together are sufficient to alter the expression of one or more expression products involved, directly or indirectly, in the regulation of inflammation in the oo subject.146. A substance or composition for use with an : aldosterone receptor antagonist in a method for the treatment or prevention of an inflammation-related disorder in a subject, said substance or composition . comprising a NSAID, and said method comprising administering to the subject a first amount of said substance or composition and a second amount of said aldosterone receptor antagonist, wherein said first amount and said second amount together are sufficient to alter the expression of one or more expression products involved, directly or indirectly, in the regulation of inflammation in the subject. :147. A substance or composition for use in a method of treatment or prevention of any one of Claims 144 to 146 wherein said inflammation-related disorder occurs in a tissue of said subject. : )148. A substance or composition for use in a method of treatment or prevention of any one of Claims AMENDED SHEET oo PCT/US03/02923 144 to 146 wherein said inflammation-related disorder occurs in an organ of said subject. oo : 149. A substance or composition for use in a method of treatment or prevention of Claim 148 wherein said organ is the heart.150. A substance or composition for use in a method of treatment or prevention of Claim 148 wherein : 10 said organ is the brain.151. A substance or composition for use in a method of treatment or prevention of Claim 148 wherein “said organ is the kidney.152. A substance or composition for use in a method of treatment or prevention of any one of Claims 144 to 146 wherein the increased expression of one or more of said expression products is involved, directly or ‘20 . indirectly, in the regulation of inflammation in the subject.153. A substance or composition for use in a ‘method of treatment or prevention of any one of Claims 144 to 146 wherein the decreased expression of one or more of said expression products is involved, directly or indirectly, in the regulation of inflammation in the subject. AMENDED SHEETPCT/US03/02923 J | 147154. A substance or composition for use in a method of treatment or prevention of any one of Claims 144 to 146 wherein two or more of said expression - products are co-expressed simultaneously. :155. A substance or composition for use in a : method of treatment or prevention of any one of Claims : 144 to 146 wherein two or more of said expression products are co-expressed sequentially.156. A substance or composition for use in a method of treatment or prevention of any one of Claims 144 to 146 wherein said expression products are selected from the group consisting of cyclooxygenase-2, osteopontin, MCP-1, ICAM-1, VCAM-1, ANF, a,B;, Inf-y, IL- 1, TNF-a, NADH/NADPH oxidase, superoxide free radicals, oo - TXA2, b-FGF, CD44, endothelin, Angiotensin II receptor, active t-PA, inactive t-PA, PAI-1, CRP, IL-6, IL-10,.IL- .12, Troponin T, HSP65, amyloid, Phospholipase AZ, fibrinogen, CD40/CD40L, collagen binding integrin alR1 and collagen binding integrin a2f1.157. A substance or composition for use in a method of treatment or prevention of any one of Claims 144 to 146 wherein said expression products are selected from the group consisting of cyclooxygenase-2, osteopontin, MCP-1, ICAM-1, VCAM-1, ANF, a B,, Inf-vy, IL- 1, TNF-a, NADH/NADPH oxidase, superoxide free radicals, AMENDED SHEETPCT/US03/02923 ® 148 . TXA2, Db-FGF, CD44, endothelin, Angiotensin II receptor, ~ active t-PA, inactive t-PA and PAI-1.158. A substance or composition for use in a method of treatment or prevention of any one of Claims oo 144 to 146 wherein said expression product is cyclooxygenase-2.159. A substance or composition for use in a =~ method of treatment ox prevention of Claim 158 wherein said cyclooxygenase-2 1s co-expressed with one or more expression products selected from the group consisting of osteopontin, MCP-1, ICAM-1 and VCAM-1.160. A substance or composition for use in a method of treatment or prevention of any one of Claims 144 to 146 wherein said expression product is osteopontin.lel. A substance or composition for use in a method of treatment or prevention of Claim 160 wherein: : said osteopontin is co-expressed with one or more expression products selected from the group consisting of : cyclooxygenase-2, MCP-1, ICAM-1 and VCAM-1.162. A substance or composition for use in a method of treatment or prevention of any one of Claims 144 to 146 wherein said expression product is MCP-1. AMENDED SHEET; : PCT/US03/02923 Q 149163. A substance or composition for use in a method of treatment or prevention of Claim 162 wherein : said MCP-1 is co-expressed with one or more expression products selected from the group consisting of cyclooxygenase-2, osteopontin, ICAM-1 and VCAM-1.164. A substance or composition for use in a method of treatment or prevention of any one of Claims oo 144 to 146 wherein said expression product is ICAM-1. F : : ~ 165. A substance or composition for use in a : method of treatment or prevention of Claim 164 wherein : said ICAM-1 is co-expressed with one or more expression products selected from the group consisting of cyclooxygenase-2, osteopontin, MCP-1 and VCAM-1. : 166. A substance or composition for use in a : method of treatment or prevention of any one of Claims : "144 to 146 wherein said expression product is VCAM-1. ‘167. A substance or composition for use in a method of treatment or prevention of Claim 166 wherein said VCAM-1 is co-expressed with one or more expression products selected from the group consisting of cyclooxygenase-2, osteopontin, ICAM-1 and MCP-1.168. A combination of Claim 1, substantially as hereinbefore described and illustrated. AMENDED SHEETPCT/US03/02923 t Q 150169. A composition of any one of Claims 2 to 20, substantially as hereinbefore described and oo illustrated.170. A method of any one of Claims 21 to 65, substantially as hereinbefore described and illustrated.171. A kit of any one of Claims 66 to 69, : substantially as hereinbefore described and illustrated. oo172. Use of any one of Claims 70 to 118, substantially as hereinbefore described and illustrated. oo173. A substance or composition for use in a method of treatment or prevention of any one of Claims 119 to 167, substantially as hereinbefore described and illustrated.174. A new combination, a new composition, a new non-therapeutic method of treatment, a new kit, a new use of an aldosterone receptor antagonist and/or a NSAID, or a substance or composition for a new use in a method of treatment or prevention, substantially as hereinbefore described. AMENDED SHEET
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35300802P | 2002-01-30 | 2002-01-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200405829B true ZA200405829B (en) | 2005-10-21 |
Family
ID=27663163
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200405829A ZA200405829B (en) | 2002-01-30 | 2004-07-21 | Aldosterone antagonist and non-steroidal anti-inflammatory agent combination therapy to prevent or treat cardiovascular disorders. |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1469884A1 (en) |
JP (1) | JP2005521665A (en) |
KR (1) | KR20040078683A (en) |
CN (1) | CN1625412A (en) |
BR (1) | BR0307342A (en) |
CA (1) | CA2473797A1 (en) |
MX (1) | MXPA04007128A (en) |
PL (1) | PL371436A1 (en) |
WO (1) | WO2003063908A1 (en) |
ZA (1) | ZA200405829B (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20050084572A (en) * | 2002-09-25 | 2005-08-26 | 포비스 메디-테크 인코포레이티드 | Derivatives comprising sterols and/or stanols and specific classes of anti-inflammatory agents and use thereof in treating or preventing cardiovascular disease |
US8487128B2 (en) * | 2002-11-26 | 2013-07-16 | Chs Pharma, Inc. | Protection of normal cells |
US8258181B2 (en) | 2005-03-23 | 2012-09-04 | Florida Atlantic University | Treatment or prevention of cancer and precancerous disorders |
WO2014160702A1 (en) | 2013-03-25 | 2014-10-02 | Chs Pharma, Inc. | Retinopathy treatment |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5550124A (en) * | 1991-12-10 | 1996-08-27 | University Of Southern California | Use of peripheral-type benzodiazpine sites for treatment of CNS trauma or disease |
JPH10500669A (en) * | 1994-04-12 | 1998-01-20 | アルザ・コーポレーション | Screening method for cytokine inhibitors |
AU4777896A (en) * | 1995-02-10 | 1996-08-27 | G.D. Searle & Co. | Use of low dose amount of spironolactone for treatment of cardiovascular disease |
AU5687199A (en) * | 1998-08-24 | 2000-03-14 | Global Vascular Concepts, Inc. | Use of anti-angiogenic agents for inhibiting vessel wall injury |
UA74141C2 (en) * | 1998-12-09 | 2005-11-15 | Дж.Д. Сірл Енд Ко. | Oral pharmaceutical compositions comprising micronized eplerenone (variants), method for its production and method for treating aldosterone-mediated states (variants) |
ES2269442T3 (en) * | 2000-07-27 | 2007-04-01 | Pharmacia Corporation | ALDOSTERONE ANTAGONIST COMBINATION THERAPY AND CYCLLOXYGENASA-2 INHIBITOR TO PREVENT OR TREAT CARDIOVASCULAR DISORDERS RELATED TO INFLAMMATION. |
-
2003
- 2003-01-30 PL PL03371436A patent/PL371436A1/en not_active Application Discontinuation
- 2003-01-30 WO PCT/US2003/002923 patent/WO2003063908A1/en not_active Application Discontinuation
- 2003-01-30 EP EP03706012A patent/EP1469884A1/en not_active Withdrawn
- 2003-01-30 JP JP2003563597A patent/JP2005521665A/en not_active Withdrawn
- 2003-01-30 CN CNA038030330A patent/CN1625412A/en active Pending
- 2003-01-30 KR KR10-2004-7011785A patent/KR20040078683A/en not_active Application Discontinuation
- 2003-01-30 MX MXPA04007128A patent/MXPA04007128A/en not_active Application Discontinuation
- 2003-01-30 CA CA002473797A patent/CA2473797A1/en not_active Abandoned
- 2003-01-30 BR BR0307342-4A patent/BR0307342A/en not_active IP Right Cessation
-
2004
- 2004-07-21 ZA ZA200405829A patent/ZA200405829B/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2005521665A (en) | 2005-07-21 |
CA2473797A1 (en) | 2003-08-07 |
EP1469884A1 (en) | 2004-10-27 |
KR20040078683A (en) | 2004-09-10 |
CN1625412A (en) | 2005-06-08 |
WO2003063908A1 (en) | 2003-08-07 |
BR0307342A (en) | 2004-12-21 |
PL371436A1 (en) | 2005-06-13 |
MXPA04007128A (en) | 2005-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20030162759A1 (en) | Aldosterone blocker therapy to prevent or treat inflammation-related disorders | |
US6716829B2 (en) | Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders | |
EP1303308B1 (en) | Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders | |
CN101621995A (en) | Mineralcorticoid receptor antagonists for the treatment of endometriosis | |
US20040067918A1 (en) | Combination of an aldosterone receptor antagonist and nicotinic acid or a nicotinic acid derivative | |
ZA200405829B (en) | Aldosterone antagonist and non-steroidal anti-inflammatory agent combination therapy to prevent or treat cardiovascular disorders. | |
US20040037806A1 (en) | Aldosterone blocker therapy to prevent or treat inflammation-related disorders | |
AU2003207773A1 (en) | Aldosterone antagonist and non-steroidal anti-inflammatory agent combination therapy to prevent or treat cardiovascular disorders | |
US20030219401A1 (en) | Combination of an aldosterone receptor antagonist and a bile acid sequestering agent | |
JP2005519918A (en) | Combination treatment of aldosterone receptor antagonists and α-adrenergic modulators for preventing or treating pathogenic conditions | |
EP1485132A2 (en) | Combination of an aldosterone receptor antagonist and a fibric acid derivative |